Jaywj personal page - To The Moon

Jaywj

Jaywj

No personal profile

21Follow

0Followers

0Topic

0Badge

2021-06-29

Like n comment

Tech stock rally sends S&P and Nasdaq to record highs

2021-07-08

Like and comment

Why Apple Stock Climbed to a New High Today

2021-06-12

Well well

15 momentum stocks expected to show the best sales growth over the next two years, including Carvana, Tesla and Palantir

2021-07-08

Yes

Is China set to cut RRR soon? What are the implications?

2021-06-28

Like and comment

With cloud and AI, IBM broadens 5G deals with Verizon and Telefonica

2021-06-28

Good

This Small-Cap Stock Can Pivot Between Old and New Energy

2021-06-15

Like + comment

ARK: Cathie Wood And The Exquisite Art Of Tail Gunning

2022-01-27

Huat ah

2022-01-27

Great ariticle, would you like to share it?

@TigerEvents:Join Tiger Ski Championship, Win a Bonus of Up to USD 2022

2021-07-08

Yes

Gold prices steamrolling toward $2,000: Goldman Sachs

2021-06-29

Well

CVRx Pursues $100 Million U.S. IPO Plan

2021-06-29

Wow

CVRx Pursues $100 Million U.S. IPO Plan

2021-06-15

Huats

Apple Plans Faster Watch, Future Temperature and Glucose Sensors

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582021834657737","uuid":"3582021834657737","gmtCreate":1618927810538,"gmtModify":1621520234697,"name":"Jaywj","pinyin":"jaywj","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":21,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.13","exceedPercentage":"80.01%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.86%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.22%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9090777410,"gmtCreate":1643274632493,"gmtModify":1676533793807,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Huat ah","listText":"Huat ah","text":"Huat ah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090777410","isVote":1,"tweetType":1,"viewCount":339,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9090772831,"gmtCreate":1643274454927,"gmtModify":1676533793736,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090772831","repostId":"9004448317","repostType":1,"repost":{"id":9004448317,"gmtCreate":1642676525258,"gmtModify":1676533734534,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"Join Tiger Ski Championship, Win a Bonus of Up to USD 2022","htmlText":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: <a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/happy-new-year/#/\" target=\"_blank\">Click to Join the Game</a>","listText":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: <a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/happy-new-year/#/\" target=\"_blank\">Click to Join the Game</a>","text":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: Click to Join the Game","images":[{"img":"https://static.tigerbbs.com/a7b44fa056439fb4010fa55e163d27c3","width":"750","height":"1726"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004448317","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149287253,"gmtCreate":1625730806872,"gmtModify":1703747287326,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149287253","repostId":"2149154533","repostType":4,"repost":{"id":"2149154533","kind":"news","pubTimestamp":1625727047,"share":"https://ttm.financial/m/news/2149154533?lang=&edition=fundamental","pubTime":"2021-07-08 14:50","market":"us","language":"en","title":"Gold prices steamrolling toward $2,000: Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2149154533","media":"Yahoo Finance","summary":"Gold prices are finally catching a long-awaited bid as inflation fears have subsided, and Goldman Sa","content":"<p>Gold prices are finally catching a long-awaited bid as inflation fears have subsided, and Goldman Sachs analyst Mikhail Sprogis said the upside move is only just beginning.</p>\n<p>Sprogis reiterated his $2,000 an ounce price target on gold prices in a new research note this week, voicing optimism amid the backup in Treasury yields and easing inflation concerns.</p>\n<p>\"As a result of the liquidation, gold is now again pricing a Goldilocks scenario of moderate inflation and continued global recovery and is thus trading at a large discount to the current real rate. We estimate that the current gold price is consistent with a real rate of 0.1% vs. the -0.87% that is currently priced by the market. In our base case that the global recovery continues uninterrupted and inflation remains subdued, we expect this discount to persist and see just modest upside to gold, driven by only a small increase in real rates and a continued improvement in EM wealth,\" Sprogis contends.</p>\n<p>Sprogis' price target assumes an 11% gain in gold prices from current levels.</p>\n<p>To say the gold trade has been dead in the water may be an understatement, as investors have rotated into value stocks in a bid to drive returns during a sharp economic recovery. More recently, gold has fallen by the wayside as traders buy up big-cap tech stocks such as Apple and Amazon.</p>\n<p>While gold prices have tacked on 2% in the past week, they remain 11% lower from the July 2020 record high of more than $2,036 an ounce. Silver prices have remained mostly steady during the same timespan. Copper prices have rallied nearly 50% due to the metal's role in rebuilding the industrial economy post-pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://s.yimg.com/os/creatr-uploaded-images/2021-07/f717e2c0-df44-11eb-bd79-77f05c0df7f7\" tg-width=\"3000\" tg-height=\"2021\" referrerpolicy=\"no-referrer\"><span>A worker scoops gold shots at Japanese jewellery brand, Ginza Tanaka's original equipment manufacturer (OEM) factory in the Chiba prefecture, east of Tokyo. REUTERS/Yuriko Nakao (JAPAN BUSINESS IMAGES OF THE DAY)Yuriko Nakao / reuters</span></p>\n<p>\"Over the past several months, gold has been strongly correlated with the \"inflation fear factor. Prices therefore corrected sharply after the hawkish Fed surprise which our economists interpret as the Fed taking a more backward-looking interpretation of average inflation targeting,\" said Sprogis. \"This not only reversed the inflation trade but also removed the market's pricing of inflation tail risks.\"</p>\n<p>Now it looks to be game (at least in the short-term) on for not only gold prices, but for correlated equities.</p>\n<p>Shares of gold miner Barrick Gold are up 1.5% in the last week, slightly outperforming the S&amp;P 500. The SPDR Gold Shares ET is up about 1.8%.</p>\n<p>\"In a scenario where the global economic recovery does not play out as expected or inflation begins to move materially above expectations, we see material upside to gold given its undervaluation and low allocation from the investment community. Therefore, we think that gold may be a good strategic purchase here for portfolio managers looking to hedge against tail risks of macro volatility,\" added Sprogis.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gold prices steamrolling toward $2,000: Goldman Sachs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGold prices steamrolling toward $2,000: Goldman Sachs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 14:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gold-prices-steamrolling-toward-2000-goldman-sachs-170547546.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gold prices are finally catching a long-awaited bid as inflation fears have subsided, and Goldman Sachs analyst Mikhail Sprogis said the upside move is only just beginning.\nSprogis reiterated his $2,...</p>\n\n<a href=\"https://finance.yahoo.com/news/gold-prices-steamrolling-toward-2000-goldman-sachs-170547546.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FCX":"麦克莫兰铜金","GS":"高盛","GOLD":"巴里克黄金","GSD.SI":"GLD SG$"},"source_url":"https://finance.yahoo.com/news/gold-prices-steamrolling-toward-2000-goldman-sachs-170547546.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149154533","content_text":"Gold prices are finally catching a long-awaited bid as inflation fears have subsided, and Goldman Sachs analyst Mikhail Sprogis said the upside move is only just beginning.\nSprogis reiterated his $2,000 an ounce price target on gold prices in a new research note this week, voicing optimism amid the backup in Treasury yields and easing inflation concerns.\n\"As a result of the liquidation, gold is now again pricing a Goldilocks scenario of moderate inflation and continued global recovery and is thus trading at a large discount to the current real rate. We estimate that the current gold price is consistent with a real rate of 0.1% vs. the -0.87% that is currently priced by the market. In our base case that the global recovery continues uninterrupted and inflation remains subdued, we expect this discount to persist and see just modest upside to gold, driven by only a small increase in real rates and a continued improvement in EM wealth,\" Sprogis contends.\nSprogis' price target assumes an 11% gain in gold prices from current levels.\nTo say the gold trade has been dead in the water may be an understatement, as investors have rotated into value stocks in a bid to drive returns during a sharp economic recovery. More recently, gold has fallen by the wayside as traders buy up big-cap tech stocks such as Apple and Amazon.\nWhile gold prices have tacked on 2% in the past week, they remain 11% lower from the July 2020 record high of more than $2,036 an ounce. Silver prices have remained mostly steady during the same timespan. Copper prices have rallied nearly 50% due to the metal's role in rebuilding the industrial economy post-pandemic.\nA worker scoops gold shots at Japanese jewellery brand, Ginza Tanaka's original equipment manufacturer (OEM) factory in the Chiba prefecture, east of Tokyo. REUTERS/Yuriko Nakao (JAPAN BUSINESS IMAGES OF THE DAY)Yuriko Nakao / reuters\n\"Over the past several months, gold has been strongly correlated with the \"inflation fear factor. Prices therefore corrected sharply after the hawkish Fed surprise which our economists interpret as the Fed taking a more backward-looking interpretation of average inflation targeting,\" said Sprogis. \"This not only reversed the inflation trade but also removed the market's pricing of inflation tail risks.\"\nNow it looks to be game (at least in the short-term) on for not only gold prices, but for correlated equities.\nShares of gold miner Barrick Gold are up 1.5% in the last week, slightly outperforming the S&P 500. The SPDR Gold Shares ET is up about 1.8%.\n\"In a scenario where the global economic recovery does not play out as expected or inflation begins to move materially above expectations, we see material upside to gold given its undervaluation and low allocation from the investment community. Therefore, we think that gold may be a good strategic purchase here for portfolio managers looking to hedge against tail risks of macro volatility,\" added Sprogis.","news_type":1},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149287632,"gmtCreate":1625730785426,"gmtModify":1703747287164,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149287632","repostId":"1100970955","repostType":4,"repost":{"id":"1100970955","kind":"news","pubTimestamp":1625730236,"share":"https://ttm.financial/m/news/1100970955?lang=&edition=fundamental","pubTime":"2021-07-08 15:43","market":"sh","language":"en","title":"Is China set to cut RRR soon? What are the implications?","url":"https://stock-news.laohu8.com/highlight/detail?id=1100970955","media":"Yahoo Finance","summary":"By Kevin Yao\nBEIJING, July 8 (Reuters) - The Chinese government on Wednesday pledged to use timely c","content":"<p>By Kevin Yao</p>\n<p>BEIJING, July 8 (Reuters) - The Chinese government on Wednesday pledged to use timely cuts in the amount of cash that banks must hold as reserves to support the slowing economy, raising expectations about an imminent move to ease policy.</p>\n<p>Such reductions in the reserve requirement ratio (RRR) will help underpin the economy, especially small firms, the cabinet said, taking investors by surprise as most had bet on a gradual tightening of policy.</p>\n<p>All eyes are now on the People's Bank of China (PBOC), which has been gradually scaling back pandemic-driven stimulus to curb debt risks, while maintaining targeted support for small firms.</p>\n<p>An RRR cut would be the first since April 2020 when the economy was jolted by the COVID-19 pandemic.</p>\n<p>IS AN RRR CUT COMING?</p>\n<p>Likely but not guaranteed.</p>\n<p>The PBOC usually follows guidance from the cabinet, which oversees the world's second-largest economy and charts the fundamental course of China's policies.</p>\n<p>In most cases in the past, the PBOC has followed the cabinet's calls for RRR cuts, but not every time. For example, there was no policy move after the cabinet flagged a cut in June 2020.</p>\n<p>Growth in China's economy is slowing, probably to 7-8% in April-June from a record 18.3% expansion in the first quarter, which was heavily skewed by the recoil effect from the sharp slump in activity in early 2020. The current slowdown could deepen due to rising commodity prices.</p>\n<p>Small firms in downstream industries could bear the brunt of rising raw material prices, as they struggle to pass on increased costs to consumers.</p>\n<p>WHEN AND IN WHAT FORM?</p>\n<p>Not certain.</p>\n<p>Most analysts expect a targeted RRR cut for small banks, given that the cabinet emphasised the need to support small firms, but a cut for all lenders cannot be ruled out.</p>\n<p>Analysts at Nomura expect a universal 50-basis point cut in the coming weeks.</p>\n<p>Wen Bin, an economist at Mingsheng Bank, expects a cut towards the end of September, if consumer inflation softens in the coming months.</p>\n<p>An RRR cut could inject permanent funds into the banking system, enabling banks to expand loan books and lower financing costs. Other policy channels such as the medium-term lending facility (MLF) will pump out short- to medium-term funds.</p>\n<p>The PBOC has used MLF loans more frequently in recent years than RRR cuts.</p>\n<p>Expected RRR cuts will help to ease liquidity pressure caused by the maturing of over 4 trillion yuan ($617.2 billion)in MLF loans and net government bond issuance totalling 4.5 trillion yuan in the second half of this year.</p>\n<p>HOW MUCH ROOM FOR FURTHER CUTS?</p>\n<p>There is still room but not as big as before.</p>\n<p>The RRR cut in April 2020 marked the tenth such reduction since early 2018, when the PBOC started an easing cycle, which accelerated significantly from early 2020 after the COVID-19 pandemic paralysed economic activity.</p>\n<p>In May 2020, the PBOC said the average RRR for Chinese financial institutions had fallen by a total of 520 basis points from early 2018 to 9.4%.</p>\n<p>WILL AN RRR CUT CHANGE POLICY COURSE?</p>\n<p>The central bank has been trying to cool credit growth to help rein in debt and financial risks, and that fundamental policy may not change.</p>\n<p>Chinese leaders have pledged to avoid sharp policy turns as the economic recovery is not yet broad-based and balanced.</p>\n<p>The PBOC has kept its benchmark lending rate, the loan prime rate (LPR), unchanged for 14 months.</p>\n<p>The economy is widely expected to grow more than 8% this year, against the government's modest growth target of over 6%, suggesting there is no big pressure to step up easing.</p>\n<p>On the fiscal front, local governments are likely to speed up bond issuance to channel more funds into key projects, helping to stimulate growth.</p>\n<p>An expected RRR cut, along with efforts to guide market interest rates lower, will likely be a policy fine-tuning operation to soothe downward pressure on the economy.</p>\n<p>A former central bank official said earlier this week that Beijing should also guide market interest rates lower to support economic growth and ease funding pressures on local governments, ($1 = 6.4808 Chinese yuan renminbi) (Reporting by Kevin Yao Editing by Shri Navaratnam)</p>","source":"yahoofinance_sg","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is China set to cut RRR soon? What are the implications?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs China set to cut RRR soon? What are the implications?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 15:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/explainer-china-set-cut-rrr-073327973.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Kevin Yao\nBEIJING, July 8 (Reuters) - The Chinese government on Wednesday pledged to use timely cuts in the amount of cash that banks must hold as reserves to support the slowing economy, raising ...</p>\n\n<a href=\"https://finance.yahoo.com/news/explainer-china-set-cut-rrr-073327973.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/explainer-china-set-cut-rrr-073327973.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100970955","content_text":"By Kevin Yao\nBEIJING, July 8 (Reuters) - The Chinese government on Wednesday pledged to use timely cuts in the amount of cash that banks must hold as reserves to support the slowing economy, raising expectations about an imminent move to ease policy.\nSuch reductions in the reserve requirement ratio (RRR) will help underpin the economy, especially small firms, the cabinet said, taking investors by surprise as most had bet on a gradual tightening of policy.\nAll eyes are now on the People's Bank of China (PBOC), which has been gradually scaling back pandemic-driven stimulus to curb debt risks, while maintaining targeted support for small firms.\nAn RRR cut would be the first since April 2020 when the economy was jolted by the COVID-19 pandemic.\nIS AN RRR CUT COMING?\nLikely but not guaranteed.\nThe PBOC usually follows guidance from the cabinet, which oversees the world's second-largest economy and charts the fundamental course of China's policies.\nIn most cases in the past, the PBOC has followed the cabinet's calls for RRR cuts, but not every time. For example, there was no policy move after the cabinet flagged a cut in June 2020.\nGrowth in China's economy is slowing, probably to 7-8% in April-June from a record 18.3% expansion in the first quarter, which was heavily skewed by the recoil effect from the sharp slump in activity in early 2020. The current slowdown could deepen due to rising commodity prices.\nSmall firms in downstream industries could bear the brunt of rising raw material prices, as they struggle to pass on increased costs to consumers.\nWHEN AND IN WHAT FORM?\nNot certain.\nMost analysts expect a targeted RRR cut for small banks, given that the cabinet emphasised the need to support small firms, but a cut for all lenders cannot be ruled out.\nAnalysts at Nomura expect a universal 50-basis point cut in the coming weeks.\nWen Bin, an economist at Mingsheng Bank, expects a cut towards the end of September, if consumer inflation softens in the coming months.\nAn RRR cut could inject permanent funds into the banking system, enabling banks to expand loan books and lower financing costs. Other policy channels such as the medium-term lending facility (MLF) will pump out short- to medium-term funds.\nThe PBOC has used MLF loans more frequently in recent years than RRR cuts.\nExpected RRR cuts will help to ease liquidity pressure caused by the maturing of over 4 trillion yuan ($617.2 billion)in MLF loans and net government bond issuance totalling 4.5 trillion yuan in the second half of this year.\nHOW MUCH ROOM FOR FURTHER CUTS?\nThere is still room but not as big as before.\nThe RRR cut in April 2020 marked the tenth such reduction since early 2018, when the PBOC started an easing cycle, which accelerated significantly from early 2020 after the COVID-19 pandemic paralysed economic activity.\nIn May 2020, the PBOC said the average RRR for Chinese financial institutions had fallen by a total of 520 basis points from early 2018 to 9.4%.\nWILL AN RRR CUT CHANGE POLICY COURSE?\nThe central bank has been trying to cool credit growth to help rein in debt and financial risks, and that fundamental policy may not change.\nChinese leaders have pledged to avoid sharp policy turns as the economic recovery is not yet broad-based and balanced.\nThe PBOC has kept its benchmark lending rate, the loan prime rate (LPR), unchanged for 14 months.\nThe economy is widely expected to grow more than 8% this year, against the government's modest growth target of over 6%, suggesting there is no big pressure to step up easing.\nOn the fiscal front, local governments are likely to speed up bond issuance to channel more funds into key projects, helping to stimulate growth.\nAn expected RRR cut, along with efforts to guide market interest rates lower, will likely be a policy fine-tuning operation to soothe downward pressure on the economy.\nA former central bank official said earlier this week that Beijing should also guide market interest rates lower to support economic growth and ease funding pressures on local governments, ($1 = 6.4808 Chinese yuan renminbi) (Reporting by Kevin Yao Editing by Shri Navaratnam)","news_type":1},"isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149284466,"gmtCreate":1625730748455,"gmtModify":1703747285868,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/149284466","repostId":"1140881081","repostType":4,"repost":{"id":"1140881081","kind":"news","pubTimestamp":1625714447,"share":"https://ttm.financial/m/news/1140881081?lang=&edition=fundamental","pubTime":"2021-07-08 11:20","market":"hk","language":"en","title":"Why Apple Stock Climbed to a New High Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1140881081","media":"The motley fool","summary":"Shares of $Apple$rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.JPMorgan analyst Samik Chatterjee reiterated his overweight rating on Apple's stock yesterday and boosted his share price forecast from $165 to $170. His new estimate implies potential gains to investors of roughly 18% in the coming year.Chatterjee noted that Apple underperformed theS&P 500and$Nasdaq$in the first half of 202","content":"<p>What happened</p>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/AAPL\">Apple</a></b>(NASDAQ:AAPL)rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.</p>\n<p>So what</p>\n<p>JPMorgan analyst Samik Chatterjee reiterated his overweight rating on Apple's stock yesterday and boosted his share price forecast from $165 to $170. His new estimate implies potential gains to investors of roughly 18% in the coming year.</p>\n<p>Chatterjee noted that Apple underperformed the<b>S&amp;P 500</b>and<b><a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a></b>in the first half of 2021. Yet he expects thetechtitan to post strong sales of both current and future models of the iPhone. Thus, Chatterjee posits that Apple's shares could generate strong gains for shareholders in the second half of the year ahead of the launch of the iPhone 13.</p>\n<p>Now what</p>\n<p>The recent rally in Apple's stock price suggests many investors agree with Chatterjee's bullish outlook. They're likely correct to do so. Robust iPhone volumes tend to also drive sales of Apple's high-margin services and fast-growing wearables revenue. So, if it does deliver blowout iPhone sales figures, Apple could enjoy an earnings bonanza later this year. This potential profit windfall, combined with Apple's bountiful share repurchases and steadily growing dividend, gives shareholders multiple ways to win.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Apple Stock Climbed to a New High Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Apple Stock Climbed to a New High Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/07/why-apple-stock-climbed-to-a-new-high-today/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Apple(NASDAQ:AAPL)rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/07/why-apple-stock-climbed-to-a-new-high-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","NGD":"New Gold","03086":"华夏纳指","AAPL":"苹果"},"source_url":"https://www.fool.com/investing/2021/07/07/why-apple-stock-climbed-to-a-new-high-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140881081","content_text":"What happened\nShares of Apple(NASDAQ:AAPL)rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.\nSo what\nJPMorgan analyst Samik Chatterjee reiterated his overweight rating on Apple's stock yesterday and boosted his share price forecast from $165 to $170. His new estimate implies potential gains to investors of roughly 18% in the coming year.\nChatterjee noted that Apple underperformed theS&P 500andNasdaqin the first half of 2021. Yet he expects thetechtitan to post strong sales of both current and future models of the iPhone. Thus, Chatterjee posits that Apple's shares could generate strong gains for shareholders in the second half of the year ahead of the launch of the iPhone 13.\nNow what\nThe recent rally in Apple's stock price suggests many investors agree with Chatterjee's bullish outlook. They're likely correct to do so. Robust iPhone volumes tend to also drive sales of Apple's high-margin services and fast-growing wearables revenue. So, if it does deliver blowout iPhone sales figures, Apple could enjoy an earnings bonanza later this year. This potential profit windfall, combined with Apple's bountiful share repurchases and steadily growing dividend, gives shareholders multiple ways to win.","news_type":1},"isVote":1,"tweetType":1,"viewCount":509,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159979095,"gmtCreate":1624938744317,"gmtModify":1703848408211,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Well","listText":"Well","text":"Well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159979095","repostId":"1124906464","repostType":4,"repost":{"id":"1124906464","kind":"news","pubTimestamp":1624936236,"share":"https://ttm.financial/m/news/1124906464?lang=&edition=fundamental","pubTime":"2021-06-29 11:10","market":"us","language":"en","title":"CVRx Pursues $100 Million U.S. IPO Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1124906464","media":"seekingalpha","summary":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commerc","content":"<p>Summary</p>\n<ul>\n <li>CVRx has filed to raise $100 million in a U.S. IPO of its common stock.</li>\n <li>The firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.</li>\n <li>CVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.</li>\n <li>Looking for more investing ideas like this one? Get them exclusively at IPO Edge.</li>\n</ul>\n<p>CVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.</p>\n<p>The firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.</p>\n<p>CVRX was negatively affected by the COVID-19 pandemic but has rebounded.</p>\n<p>However, the IPO appears pricey, so I'll watch it from the sidelines.</p>\n<p><b>Company and Technology</b></p>\n<p>Minneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.</p>\n<p>Management is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.</p>\n<p>CVRx has received at least $330 million in equity investment from investors including Johnson &amp; Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.</p>\n<p><b>Customer Acquisition and Market</b></p>\n<p>The firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.</p>\n<p>The firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>155.9%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>160.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>97.6%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>0.3</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.0</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>According to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.</p>\n<p>This represents a forecast CAGR of 13.1% from 2016 to 2022.</p>\n<p>The main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.</p>\n<p>Also, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.</p>\n<p><b>Financial Performance</b></p>\n<p>CVRx’s recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Rebounding topline revenue growth</p></li>\n <li><p>Increasing gross profit but uneven gross margin</p></li>\n <li><p>Growing operating losses</p></li>\n <li><p>Increasing cash used in operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Total Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Total Revenue</p></td>\n   <td><p>% Variance vs. Prior</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ 2,860,000</p></td>\n   <td><p>66.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ 6,053,000</p></td>\n   <td><p>-3.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ 6,257,000</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Gross Profit (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Gross Profit (Loss)</p></td>\n   <td><p>% Variance vs. Prior</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ 1,993,000</p></td>\n   <td><p>55.0%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ 4,613,000</p></td>\n   <td><p>0.9%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ 4,574,000</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Gross Margin</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Gross Margin</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>69.69%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>76.21%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>73.10%</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Operating Profit (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Operating Profit (Loss)</p></td>\n   <td><p>Operating Margin</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (4,217,000)</p></td>\n   <td><p>-147.4%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (11,514,000)</p></td>\n   <td><p>-190.2%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (10,194,000)</p></td>\n   <td><p>-162.9%</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Net Income (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Net Income (Loss)</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (8,627,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (14,109,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (14,633,000)</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Cash Flow From Operations</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Cash Flow From Operations</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (5,038,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (16,096,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (12,785,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>(Glossary Of Terms)</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>As of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).</p>\n<p><b>IPO Details</b></p>\n<p>CVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.</p>\n<p>No existing shareholders have indicated an interest to purchase shares at the IPO price.</p>\n<p>Assuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.</p>\n<p>Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.</p>\n<p>Management says it will use the net proceeds from the IPO as follows:</p>\n<blockquote>\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n</blockquote>\n<p>Management’s presentation of the company roadshow isavailable here.</p>\n<p>Listed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Measure [TTM]</b></p></td>\n   <td><p><b>Amount</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Market Capitalization at IPO</p></td>\n   <td><p>$296,717,728</p></td>\n  </tr>\n  <tr>\n   <td><p>Enterprise Value</p></td>\n   <td><p>$170,592,728</p></td>\n  </tr>\n  <tr>\n   <td><p>Price / Sales</p></td>\n   <td><p>41.24</p></td>\n  </tr>\n  <tr>\n   <td><p>EV / Revenue</p></td>\n   <td><p>23.71</p></td>\n  </tr>\n  <tr>\n   <td><p>EV / EBITDA</p></td>\n   <td><p>-13.70</p></td>\n  </tr>\n  <tr>\n   <td><p>Earnings Per Share</p></td>\n   <td><p>-$0.97</p></td>\n  </tr>\n  <tr>\n   <td><p>Float To Outstanding Shares Ratio</p></td>\n   <td><p>33.70%</p></td>\n  </tr>\n  <tr>\n   <td><p>Proposed IPO Midpoint Price per Share</p></td>\n   <td><p>$16.00</p></td>\n  </tr>\n  <tr>\n   <td><p>Net Free Cash Flow</p></td>\n   <td><p>-$16,946,000</p></td>\n  </tr>\n  <tr>\n   <td><p>Free Cash Flow Yield Per Share</p></td>\n   <td><p>-5.71%</p></td>\n  </tr>\n  <tr>\n   <td><p>Revenue Growth Rate</p></td>\n   <td><p>66.47%</p></td>\n  </tr>\n  <tr>\n   <td><p>(Glossary Of Terms)</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p><b>Commentary</b></p>\n<p>CVRx is seeking public investment capital for its continued commercialization efforts.</p>\n<p>The company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.</p>\n<p>Revenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.</p>\n<p>Free cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&amp;A efficiency rate has since increased to 0.3x in Q1 2021.</p>\n<p>The market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.</p>\n<p>JPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.</p>\n<p>As for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.</p>\n<p>While CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.</p>\n<p>Expected IPO Pricing Date: June 29, 2021</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVRx Pursues $100 Million U.S. IPO Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVRx Pursues $100 Million U.S. IPO Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 11:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVRX":"CVRx, Inc."},"source_url":"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1124906464","content_text":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.\nLooking for more investing ideas like this one? Get them exclusively at IPO Edge.\n\nCVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.\nThe firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.\nCVRX was negatively affected by the COVID-19 pandemic but has rebounded.\nHowever, the IPO appears pricey, so I'll watch it from the sidelines.\nCompany and Technology\nMinneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.\nManagement is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.\nCVRx has received at least $330 million in equity investment from investors including Johnson & Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.\nCustomer Acquisition and Market\nThe firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.\nThe firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.\nSelling, G&A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nThree Mos. Ended March 31, 2021\n155.9%\n\n\n2020\n160.5%\n\n\n2019\n97.6%\n\n\n\n(Source)\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nThree Mos. Ended March 31, 2021\n0.3\n\n\n2020\n0.0\n\n\n\n(Source)\nAccording to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.\nThis represents a forecast CAGR of 13.1% from 2016 to 2022.\nThe main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.\nAlso, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.\nFinancial Performance\nCVRx’s recent financial results can be summarized as follows:\n\nRebounding topline revenue growth\nIncreasing gross profit but uneven gross margin\nGrowing operating losses\nIncreasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 2,860,000\n66.5%\n\n\n2020\n$ 6,053,000\n-3.3%\n\n\n2019\n$ 6,257,000\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 1,993,000\n55.0%\n\n\n2020\n$ 4,613,000\n0.9%\n\n\n2019\n$ 4,574,000\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nThree Mos. Ended March 31, 2021\n69.69%\n\n\n2020\n76.21%\n\n\n2019\n73.10%\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nThree Mos. Ended March 31, 2021\n$ (4,217,000)\n-147.4%\n\n\n2020\n$ (11,514,000)\n-190.2%\n\n\n2019\n$ (10,194,000)\n-162.9%\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nThree Mos. Ended March 31, 2021\n$ (8,627,000)\n\n\n2020\n$ (14,109,000)\n\n\n2019\n$ (14,633,000)\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nThree Mos. Ended March 31, 2021\n$ (5,038,000)\n\n\n2020\n$ (16,096,000)\n\n\n2019\n$ (12,785,000)\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nAs of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.\nFree cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).\nIPO Details\nCVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.\nNo existing shareholders have indicated an interest to purchase shares at the IPO price.\nAssuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.\nExcluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.\nManagement says it will use the net proceeds from the IPO as follows:\n\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n\nManagement’s presentation of the company roadshow isavailable here.\nListed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$296,717,728\n\n\nEnterprise Value\n$170,592,728\n\n\nPrice / Sales\n41.24\n\n\nEV / Revenue\n23.71\n\n\nEV / EBITDA\n-13.70\n\n\nEarnings Per Share\n-$0.97\n\n\nFloat To Outstanding Shares Ratio\n33.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$16,946,000\n\n\nFree Cash Flow Yield Per Share\n-5.71%\n\n\nRevenue Growth Rate\n66.47%\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nCommentary\nCVRx is seeking public investment capital for its continued commercialization efforts.\nThe company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.\nRevenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.\nFree cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).\nSelling, G&A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&A efficiency rate has since increased to 0.3x in Q1 2021.\nThe market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.\nJPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.\nAs for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.\nWhile CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.\nExpected IPO Pricing Date: June 29, 2021","news_type":1},"isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159947813,"gmtCreate":1624938641132,"gmtModify":1703848406268,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159947813","repostId":"1124906464","repostType":4,"repost":{"id":"1124906464","kind":"news","pubTimestamp":1624936236,"share":"https://ttm.financial/m/news/1124906464?lang=&edition=fundamental","pubTime":"2021-06-29 11:10","market":"us","language":"en","title":"CVRx Pursues $100 Million U.S. IPO Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1124906464","media":"seekingalpha","summary":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commerc","content":"<p>Summary</p>\n<ul>\n <li>CVRx has filed to raise $100 million in a U.S. IPO of its common stock.</li>\n <li>The firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.</li>\n <li>CVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.</li>\n <li>Looking for more investing ideas like this one? Get them exclusively at IPO Edge.</li>\n</ul>\n<p>CVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.</p>\n<p>The firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.</p>\n<p>CVRX was negatively affected by the COVID-19 pandemic but has rebounded.</p>\n<p>However, the IPO appears pricey, so I'll watch it from the sidelines.</p>\n<p><b>Company and Technology</b></p>\n<p>Minneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.</p>\n<p>Management is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.</p>\n<p>CVRx has received at least $330 million in equity investment from investors including Johnson &amp; Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.</p>\n<p><b>Customer Acquisition and Market</b></p>\n<p>The firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.</p>\n<p>The firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>155.9%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>160.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>97.6%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>0.3</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.0</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>According to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.</p>\n<p>This represents a forecast CAGR of 13.1% from 2016 to 2022.</p>\n<p>The main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.</p>\n<p>Also, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.</p>\n<p><b>Financial Performance</b></p>\n<p>CVRx’s recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Rebounding topline revenue growth</p></li>\n <li><p>Increasing gross profit but uneven gross margin</p></li>\n <li><p>Growing operating losses</p></li>\n <li><p>Increasing cash used in operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Total Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Total Revenue</p></td>\n   <td><p>% Variance vs. Prior</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ 2,860,000</p></td>\n   <td><p>66.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ 6,053,000</p></td>\n   <td><p>-3.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ 6,257,000</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Gross Profit (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Gross Profit (Loss)</p></td>\n   <td><p>% Variance vs. Prior</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ 1,993,000</p></td>\n   <td><p>55.0%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ 4,613,000</p></td>\n   <td><p>0.9%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ 4,574,000</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Gross Margin</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Gross Margin</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>69.69%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>76.21%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>73.10%</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Operating Profit (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Operating Profit (Loss)</p></td>\n   <td><p>Operating Margin</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (4,217,000)</p></td>\n   <td><p>-147.4%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (11,514,000)</p></td>\n   <td><p>-190.2%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (10,194,000)</p></td>\n   <td><p>-162.9%</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Net Income (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Net Income (Loss)</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (8,627,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (14,109,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (14,633,000)</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Cash Flow From Operations</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Cash Flow From Operations</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (5,038,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (16,096,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (12,785,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>(Glossary Of Terms)</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>As of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).</p>\n<p><b>IPO Details</b></p>\n<p>CVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.</p>\n<p>No existing shareholders have indicated an interest to purchase shares at the IPO price.</p>\n<p>Assuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.</p>\n<p>Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.</p>\n<p>Management says it will use the net proceeds from the IPO as follows:</p>\n<blockquote>\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n</blockquote>\n<p>Management’s presentation of the company roadshow isavailable here.</p>\n<p>Listed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Measure [TTM]</b></p></td>\n   <td><p><b>Amount</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Market Capitalization at IPO</p></td>\n   <td><p>$296,717,728</p></td>\n  </tr>\n  <tr>\n   <td><p>Enterprise Value</p></td>\n   <td><p>$170,592,728</p></td>\n  </tr>\n  <tr>\n   <td><p>Price / Sales</p></td>\n   <td><p>41.24</p></td>\n  </tr>\n  <tr>\n   <td><p>EV / Revenue</p></td>\n   <td><p>23.71</p></td>\n  </tr>\n  <tr>\n   <td><p>EV / EBITDA</p></td>\n   <td><p>-13.70</p></td>\n  </tr>\n  <tr>\n   <td><p>Earnings Per Share</p></td>\n   <td><p>-$0.97</p></td>\n  </tr>\n  <tr>\n   <td><p>Float To Outstanding Shares Ratio</p></td>\n   <td><p>33.70%</p></td>\n  </tr>\n  <tr>\n   <td><p>Proposed IPO Midpoint Price per Share</p></td>\n   <td><p>$16.00</p></td>\n  </tr>\n  <tr>\n   <td><p>Net Free Cash Flow</p></td>\n   <td><p>-$16,946,000</p></td>\n  </tr>\n  <tr>\n   <td><p>Free Cash Flow Yield Per Share</p></td>\n   <td><p>-5.71%</p></td>\n  </tr>\n  <tr>\n   <td><p>Revenue Growth Rate</p></td>\n   <td><p>66.47%</p></td>\n  </tr>\n  <tr>\n   <td><p>(Glossary Of Terms)</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p><b>Commentary</b></p>\n<p>CVRx is seeking public investment capital for its continued commercialization efforts.</p>\n<p>The company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.</p>\n<p>Revenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.</p>\n<p>Free cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&amp;A efficiency rate has since increased to 0.3x in Q1 2021.</p>\n<p>The market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.</p>\n<p>JPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.</p>\n<p>As for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.</p>\n<p>While CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.</p>\n<p>Expected IPO Pricing Date: June 29, 2021</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVRx Pursues $100 Million U.S. IPO Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVRx Pursues $100 Million U.S. IPO Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 11:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVRX":"CVRx, Inc."},"source_url":"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1124906464","content_text":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.\nLooking for more investing ideas like this one? Get them exclusively at IPO Edge.\n\nCVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.\nThe firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.\nCVRX was negatively affected by the COVID-19 pandemic but has rebounded.\nHowever, the IPO appears pricey, so I'll watch it from the sidelines.\nCompany and Technology\nMinneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.\nManagement is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.\nCVRx has received at least $330 million in equity investment from investors including Johnson & Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.\nCustomer Acquisition and Market\nThe firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.\nThe firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.\nSelling, G&A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nThree Mos. Ended March 31, 2021\n155.9%\n\n\n2020\n160.5%\n\n\n2019\n97.6%\n\n\n\n(Source)\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nThree Mos. Ended March 31, 2021\n0.3\n\n\n2020\n0.0\n\n\n\n(Source)\nAccording to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.\nThis represents a forecast CAGR of 13.1% from 2016 to 2022.\nThe main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.\nAlso, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.\nFinancial Performance\nCVRx’s recent financial results can be summarized as follows:\n\nRebounding topline revenue growth\nIncreasing gross profit but uneven gross margin\nGrowing operating losses\nIncreasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 2,860,000\n66.5%\n\n\n2020\n$ 6,053,000\n-3.3%\n\n\n2019\n$ 6,257,000\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 1,993,000\n55.0%\n\n\n2020\n$ 4,613,000\n0.9%\n\n\n2019\n$ 4,574,000\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nThree Mos. Ended March 31, 2021\n69.69%\n\n\n2020\n76.21%\n\n\n2019\n73.10%\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nThree Mos. Ended March 31, 2021\n$ (4,217,000)\n-147.4%\n\n\n2020\n$ (11,514,000)\n-190.2%\n\n\n2019\n$ (10,194,000)\n-162.9%\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nThree Mos. Ended March 31, 2021\n$ (8,627,000)\n\n\n2020\n$ (14,109,000)\n\n\n2019\n$ (14,633,000)\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nThree Mos. Ended March 31, 2021\n$ (5,038,000)\n\n\n2020\n$ (16,096,000)\n\n\n2019\n$ (12,785,000)\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nAs of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.\nFree cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).\nIPO Details\nCVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.\nNo existing shareholders have indicated an interest to purchase shares at the IPO price.\nAssuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.\nExcluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.\nManagement says it will use the net proceeds from the IPO as follows:\n\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n\nManagement’s presentation of the company roadshow isavailable here.\nListed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$296,717,728\n\n\nEnterprise Value\n$170,592,728\n\n\nPrice / Sales\n41.24\n\n\nEV / Revenue\n23.71\n\n\nEV / EBITDA\n-13.70\n\n\nEarnings Per Share\n-$0.97\n\n\nFloat To Outstanding Shares Ratio\n33.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$16,946,000\n\n\nFree Cash Flow Yield Per Share\n-5.71%\n\n\nRevenue Growth Rate\n66.47%\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nCommentary\nCVRx is seeking public investment capital for its continued commercialization efforts.\nThe company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.\nRevenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.\nFree cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).\nSelling, G&A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&A efficiency rate has since increased to 0.3x in Q1 2021.\nThe market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.\nJPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.\nAs for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.\nWhile CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.\nExpected IPO Pricing Date: June 29, 2021","news_type":1},"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159944514,"gmtCreate":1624938589238,"gmtModify":1703848405619,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Like n comment&nbsp;","listText":"Like n comment&nbsp;","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/159944514","repostId":"2147837316","repostType":4,"repost":{"id":"2147837316","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624921533,"share":"https://ttm.financial/m/news/2147837316?lang=&edition=fundamental","pubTime":"2021-06-29 07:05","market":"us","language":"en","title":"Tech stock rally sends S&P and Nasdaq to record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2147837316","media":"Reuters","summary":" - The Nasdaq and S&P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.Big tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&P 500 and the Nasdaq.The S&P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.In contrast, cycl","content":"<p>(Reuters) - The Nasdaq and S&amp;P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.</p>\n<p>Big tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&amp;P 500 and the Nasdaq.</p>\n<p>The S&amp;P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.</p>\n<p>In contrast, cyclical sectors dropped sharply amid fears over a spike in COVID-19 cases across Asia. Financials and energy posted the biggest sectoral loss on S&amp;P 500, down by 0.81% and 3.33%, respectively.</p>\n<p>“It’s end of the quarter and investors may want to take some profits and rotate out of energy and stick with tech,” said Sam Stovall, chief investment strategist at CFRA Research in New York.</p>\n<p>Stovall expects stocks should continue their near-term climb as investors await the new earnings season, in which year-over-year earnings growth of S&amp;P 500 companies is expected to top 60%.</p>\n<p>The Dow Jones Industrial Average fell 150.57 points, or 0.44%, to close at 34,283.27. The S&amp;P 500 pared earlier losses and advanced from Friday’s record high by gaining 9.91 points, or 0.23%, to 4,290.61. The Nasdaq Composite added 140.12 points, or 0.98%, to 14,500.51.</p>\n<p>Both the S&amp;P 500 and the Nasdaq hit a series of record highs last week. the tech-heavy Nasdaq’s 5% gain in June is outpacing its peers as investors pile back in to tech-oriented growth stocks on diminishing worries about runaway inflation.</p>\n<p>“We believe with the Fed putting a realistic goal post, investors now have much more of a risk-on mentality going into the second half of the year. A lot of these tech names have underperformed, while fundamentals were very robust going into the June quarter,” said Wedbush Securities analyst Daniel Ives, who expects the Nasdaq to hit 16,000 by year-end.</p>\n<p>Facebook jumped over 4% as a U.S. judge granted the company’s motion to dismiss a Federal Trade Commission lawsuit. The social media giant finished Monday with over $1 trillion in market capitalization.</p>\n<p>On the Nasdaq 100, the largest gainer was Nvidia Corp, which rose 5.0% after major chip makers Broadcom Inc, Marvell and Taiwan-based MediaTek endorsed its $40 billion deal to buy UK chip designer Arm.</p>\n<p>With the S&amp;P 500 up almost 14% as the first half of 2021 draws to a close, activity in some areas of the market indicates concern over potential volatility, with some investors suggesting the market may be overdue for a significant pullback.</p>\n<p>On the economic front, investor attention will be focused on consumer confidence data, a private jobs report and a crucial monthly employment report due later this week. Quarterly results from Micron Technology Inc and Walgreens Boots Alliance are also slated for this week.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 36 new 52-week highs and no new lows; the Nasdaq Composite recorded 100 new highs and 31 new lows.</p>\n<p>Volume on U.S. exchanges was 9.55 billion shares, compared with the 11.17 billion average for the full session over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tech stock rally sends S&P and Nasdaq to record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTech stock rally sends S&P and Nasdaq to record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-29 07:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) - The Nasdaq and S&amp;P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.</p>\n<p>Big tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&amp;P 500 and the Nasdaq.</p>\n<p>The S&amp;P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.</p>\n<p>In contrast, cyclical sectors dropped sharply amid fears over a spike in COVID-19 cases across Asia. Financials and energy posted the biggest sectoral loss on S&amp;P 500, down by 0.81% and 3.33%, respectively.</p>\n<p>“It’s end of the quarter and investors may want to take some profits and rotate out of energy and stick with tech,” said Sam Stovall, chief investment strategist at CFRA Research in New York.</p>\n<p>Stovall expects stocks should continue their near-term climb as investors await the new earnings season, in which year-over-year earnings growth of S&amp;P 500 companies is expected to top 60%.</p>\n<p>The Dow Jones Industrial Average fell 150.57 points, or 0.44%, to close at 34,283.27. The S&amp;P 500 pared earlier losses and advanced from Friday’s record high by gaining 9.91 points, or 0.23%, to 4,290.61. The Nasdaq Composite added 140.12 points, or 0.98%, to 14,500.51.</p>\n<p>Both the S&amp;P 500 and the Nasdaq hit a series of record highs last week. the tech-heavy Nasdaq’s 5% gain in June is outpacing its peers as investors pile back in to tech-oriented growth stocks on diminishing worries about runaway inflation.</p>\n<p>“We believe with the Fed putting a realistic goal post, investors now have much more of a risk-on mentality going into the second half of the year. A lot of these tech names have underperformed, while fundamentals were very robust going into the June quarter,” said Wedbush Securities analyst Daniel Ives, who expects the Nasdaq to hit 16,000 by year-end.</p>\n<p>Facebook jumped over 4% as a U.S. judge granted the company’s motion to dismiss a Federal Trade Commission lawsuit. The social media giant finished Monday with over $1 trillion in market capitalization.</p>\n<p>On the Nasdaq 100, the largest gainer was Nvidia Corp, which rose 5.0% after major chip makers Broadcom Inc, Marvell and Taiwan-based MediaTek endorsed its $40 billion deal to buy UK chip designer Arm.</p>\n<p>With the S&amp;P 500 up almost 14% as the first half of 2021 draws to a close, activity in some areas of the market indicates concern over potential volatility, with some investors suggesting the market may be overdue for a significant pullback.</p>\n<p>On the economic front, investor attention will be focused on consumer confidence data, a private jobs report and a crucial monthly employment report due later this week. Quarterly results from Micron Technology Inc and Walgreens Boots Alliance are also slated for this week.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 36 new 52-week highs and no new lows; the Nasdaq Composite recorded 100 new highs and 31 new lows.</p>\n<p>Volume on U.S. exchanges was 9.55 billion shares, compared with the 11.17 billion average for the full session over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF",".SPX":"S&P 500 Index","PSQ":"纳指反向ETF","WBA":"沃尔格林联合博姿",".DJI":"道琼斯","QLD":"纳指两倍做多ETF","MU":"美光科技","TWTR":"Twitter","TQQQ":"纳指三倍做多ETF","NVDA":"英伟达","NFLX":"奈飞","SQQQ":"纳指三倍做空ETF","NDAQ":"纳斯达克OMX交易所"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147837316","content_text":"(Reuters) - The Nasdaq and S&P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.\nBig tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&P 500 and the Nasdaq.\nThe S&P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.\nIn contrast, cyclical sectors dropped sharply amid fears over a spike in COVID-19 cases across Asia. Financials and energy posted the biggest sectoral loss on S&P 500, down by 0.81% and 3.33%, respectively.\n“It’s end of the quarter and investors may want to take some profits and rotate out of energy and stick with tech,” said Sam Stovall, chief investment strategist at CFRA Research in New York.\nStovall expects stocks should continue their near-term climb as investors await the new earnings season, in which year-over-year earnings growth of S&P 500 companies is expected to top 60%.\nThe Dow Jones Industrial Average fell 150.57 points, or 0.44%, to close at 34,283.27. The S&P 500 pared earlier losses and advanced from Friday’s record high by gaining 9.91 points, or 0.23%, to 4,290.61. The Nasdaq Composite added 140.12 points, or 0.98%, to 14,500.51.\nBoth the S&P 500 and the Nasdaq hit a series of record highs last week. the tech-heavy Nasdaq’s 5% gain in June is outpacing its peers as investors pile back in to tech-oriented growth stocks on diminishing worries about runaway inflation.\n“We believe with the Fed putting a realistic goal post, investors now have much more of a risk-on mentality going into the second half of the year. A lot of these tech names have underperformed, while fundamentals were very robust going into the June quarter,” said Wedbush Securities analyst Daniel Ives, who expects the Nasdaq to hit 16,000 by year-end.\nFacebook jumped over 4% as a U.S. judge granted the company’s motion to dismiss a Federal Trade Commission lawsuit. The social media giant finished Monday with over $1 trillion in market capitalization.\nOn the Nasdaq 100, the largest gainer was Nvidia Corp, which rose 5.0% after major chip makers Broadcom Inc, Marvell and Taiwan-based MediaTek endorsed its $40 billion deal to buy UK chip designer Arm.\nWith the S&P 500 up almost 14% as the first half of 2021 draws to a close, activity in some areas of the market indicates concern over potential volatility, with some investors suggesting the market may be overdue for a significant pullback.\nOn the economic front, investor attention will be focused on consumer confidence data, a private jobs report and a crucial monthly employment report due later this week. Quarterly results from Micron Technology Inc and Walgreens Boots Alliance are also slated for this week.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored decliners.\nThe S&P 500 posted 36 new 52-week highs and no new lows; the Nasdaq Composite recorded 100 new highs and 31 new lows.\nVolume on U.S. exchanges was 9.55 billion shares, compared with the 11.17 billion average for the full session over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127791491,"gmtCreate":1624868018013,"gmtModify":1703846581916,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127791491","repostId":"2146854378","repostType":4,"repost":{"id":"2146854378","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624865895,"share":"https://ttm.financial/m/news/2146854378?lang=&edition=fundamental","pubTime":"2021-06-28 15:38","market":"us","language":"en","title":"With cloud and AI, IBM broadens 5G deals with Verizon and Telefonica","url":"https://stock-news.laohu8.com/highlight/detail?id=2146854378","media":"Reuters","summary":"BARCELONA, June 28 (Reuters) - IBM will offer telecom operators Verizon and Telefonica new services ","content":"<p>BARCELONA, June 28 (Reuters) - <a href=\"https://laohu8.com/S/IBM\">IBM</a> will offer telecom operators Verizon and Telefonica new services ranging from running 5G over a cloud platform to using artificial intelligence, the U.S. technology company said on Monday.</p>\n<p>Big technology players such as Microsoft and Amazon&nbsp;are vying for a share of 5G revenue by offering telecom operators next-generation software tools.</p>\n<p>IBM, using technology it obtained from buying software firm Red Hat, will offer the telecom operators cloud services to run their networks and assist them in selling products tailored to customers. No financial terms were disclosed about the tie-ups, which broadened IBM's existing partnerships with the two firms.</p>\n<p>A cloud platform uses software instead of physical equipment to perform network functions, helping telecom operators build 5G networks faster, reduce costs and sell customised services.</p>\n<p>\"It's a disruptive time in this particular market segment, telcos are trying to position themselves as the destination for services like augmented reality, machine learning and AI,\" Darell Jordan-Smith, vice president of Redhat, told Reuters.</p>\n<p>On the AI front, IBM and Spain's Telefonica have created a virtual assistant that they say will remove friction points, such as long wait times, by automating the handling of frequently asked questions and tasks like billing.</p>\n<p>\"We see this as an existential moment for telco operators with 5G: architecturally, they're looking to gain more control on their platforms and rethink their network as a digital world rather than a structured physical model,\" said Steve Canepa, IBM's general manager for communications business.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>With cloud and AI, IBM broadens 5G deals with Verizon and Telefonica</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWith cloud and AI, IBM broadens 5G deals with Verizon and Telefonica\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-28 15:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BARCELONA, June 28 (Reuters) - <a href=\"https://laohu8.com/S/IBM\">IBM</a> will offer telecom operators Verizon and Telefonica new services ranging from running 5G over a cloud platform to using artificial intelligence, the U.S. technology company said on Monday.</p>\n<p>Big technology players such as Microsoft and Amazon&nbsp;are vying for a share of 5G revenue by offering telecom operators next-generation software tools.</p>\n<p>IBM, using technology it obtained from buying software firm Red Hat, will offer the telecom operators cloud services to run their networks and assist them in selling products tailored to customers. No financial terms were disclosed about the tie-ups, which broadened IBM's existing partnerships with the two firms.</p>\n<p>A cloud platform uses software instead of physical equipment to perform network functions, helping telecom operators build 5G networks faster, reduce costs and sell customised services.</p>\n<p>\"It's a disruptive time in this particular market segment, telcos are trying to position themselves as the destination for services like augmented reality, machine learning and AI,\" Darell Jordan-Smith, vice president of Redhat, told Reuters.</p>\n<p>On the AI front, IBM and Spain's Telefonica have created a virtual assistant that they say will remove friction points, such as long wait times, by automating the handling of frequently asked questions and tasks like billing.</p>\n<p>\"We see this as an existential moment for telco operators with 5G: architecturally, they're looking to gain more control on their platforms and rethink their network as a digital world rather than a structured physical model,\" said Steve Canepa, IBM's general manager for communications business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VZ":"威瑞森","MSFT":"微软","AMZN":"亚马逊","IBM":"IBM"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146854378","content_text":"BARCELONA, June 28 (Reuters) - IBM will offer telecom operators Verizon and Telefonica new services ranging from running 5G over a cloud platform to using artificial intelligence, the U.S. technology company said on Monday.\nBig technology players such as Microsoft and Amazon are vying for a share of 5G revenue by offering telecom operators next-generation software tools.\nIBM, using technology it obtained from buying software firm Red Hat, will offer the telecom operators cloud services to run their networks and assist them in selling products tailored to customers. No financial terms were disclosed about the tie-ups, which broadened IBM's existing partnerships with the two firms.\nA cloud platform uses software instead of physical equipment to perform network functions, helping telecom operators build 5G networks faster, reduce costs and sell customised services.\n\"It's a disruptive time in this particular market segment, telcos are trying to position themselves as the destination for services like augmented reality, machine learning and AI,\" Darell Jordan-Smith, vice president of Redhat, told Reuters.\nOn the AI front, IBM and Spain's Telefonica have created a virtual assistant that they say will remove friction points, such as long wait times, by automating the handling of frequently asked questions and tasks like billing.\n\"We see this as an existential moment for telco operators with 5G: architecturally, they're looking to gain more control on their platforms and rethink their network as a digital world rather than a structured physical model,\" said Steve Canepa, IBM's general manager for communications business.","news_type":1},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127793510,"gmtCreate":1624867974030,"gmtModify":1703846582241,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127793510","repostId":"1142078063","repostType":4,"repost":{"id":"1142078063","kind":"news","pubTimestamp":1624866368,"share":"https://ttm.financial/m/news/1142078063?lang=&edition=fundamental","pubTime":"2021-06-28 15:46","market":"us","language":"en","title":"This Small-Cap Stock Can Pivot Between Old and New Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142078063","media":"Barrons","summary":"The energy transition is on its way, but for most companies the tangible results won’t show up for y","content":"<p>The energy transition is on its way, but for most companies the tangible results won’t show up for years. At Chart Industries, the action is happening now, and the company’s stock isn’t fully reflecting that yet.</p>\n<p>Chart (ticker: GTLS) makes cryogenic tanks and other equipment to freeze gases and make them easier to isolate and transport. Its products operate behind the scenes in a variety of industries, keeping soda bubbly and delivering oxygen to patients suffering from Covid-19. For now, Chart makes most of its money providing&nbsp;equipment to industrial-gas companies or fossil-fuel energy markets. But its stock offers a way to play both the rebound in traditional energy and the transition to new forms of it.</p>\n<p>“In the case of Big Oil, the energy transition will take 30 years,” says Raymond James analyst Pavel Molchanov. “For Chart, it’s happening in real time.” He has an Outperform rating on the shares and a $165 price target—18% above a recent price of $140.</p>\n<p>Chart is based in the small city of Ball Ground, Ga., but operates all over the globe. Its results have fluctuated with the fortunes of the natural-gas and chemical industries in recent years. Chart mostly persevered through the pandemic, growing earnings to $2.73 a share from $2.52 the previous year, on a slight decline in sales, to $1.2 billion. The company, however, has a record backlog of orders and is entering a much faster growth period, one that more than justifies its valuation of about 26 times next year’s expected earnings.</p>\n<p><img src=\"https://static.tigerbbs.com/333b9c8b2fde68b6acdb0557454fe1e7\" tg-width=\"950\" tg-height=\"625\"></p>\n<p>Chart specializes in taking volatile gases and processing them so they can be contained and transported. That can mean pumping them through heat exchangers, freezing and storing them in cryogenic tanks, and transporting them through insulated pipes. These technologies are used to turn natural gas into liquid form to be transported through pipes or overseas.</p>\n<p>The company has benefited as the shale-drilling revolution and new laws helped the U.S. become a major exporter of natural gas. But the technology that makes it possible to capture natural gas is also useful for capturing and taming other gases.</p>\n<p>“We’re molecule-agnostic,” Chart CEO Jillian Evanko tells&nbsp;<i>Barron’s</i>.</p>\n<p><img src=\"https://static.tigerbbs.com/6651e519519516c310bcc85214b99134\" tg-width=\"956\" tg-height=\"643\"></p>\n<p>Chart’s systems help pump nitrogen into pressurized containers to make nitro cold brew coffee, carbon dioxide into greenhouses to make cannabis plants grow faster, and ozone into water systems to keep them clean. Even more promising are its renewable-energy divisions, like hydrogen and carbon capture. Its specialty products division is the main reason that Chart is expected to grow earnings per share by 44% this year and 33% next year, with an expected long-term growth rate of 25%, according to FactSet. Specialty products now make up 20% of the company’s revenue, but analysts see them growing to nearly half of sales by 2025.</p>\n<p>Hydrogen, an alternative fuel that can produce electricity and power vehicles, is a big opportunity. Chart has been making equipment to process and transport hydrogen for decades, mostly for use in aerospace, but it is now becoming a key part of the supply chain for hydrogen use in alternative energy.</p>\n<p>Along with equipment for processing, storage, and transportation, Chart helps build the hydrogen fueling stations themselves, which are quickly spreading throughout Europe and starting to show up in the U.S. Its hydrogen orders grew to $71 million in the first quarter this year from $4 million in the first quarter of 2020, and it expects hydrogen and helium sales to rise to at least $99 million this year from $22 million in 2020. The company thinks the potential hydrogen market opportunity is worth $2.4 billion over the next three to five years.</p>\n<p>That pitch is drawing investors who are excited by hydrogen but wary of some companies in the sector that have potential but no profits.</p>\n<p>“If you play hydrogen through Chart, then you are already getting profits from those sales, because hydrogen is one of our most profitable elements as a business,” Evanko says.</p>\n<p>Steven Klopukh, a portfolio manager at Thornburg Investment Management, owns Chart in two funds he runs. “It’s a really good infrastructure play on the hydrogen economy,” he says. He sees a clear path for earnings to hit $8 a share a year and for the stock to reach $180 off the strength of its renewable energy products.</p>\n<p>Klopukh also sees promise in carbon capture and storage, a process that takes carbon emitted from drilling sites or factories and processes it for reuse or underground storage.</p>\n<p>Carbon capture is “the next big thing” in the energy transition businesses, predicts Evercore analyst James West. Among the companies betting big on carbon capture are&nbsp;Exxon Mobil(XOM), which is already one of Chart’s customers.</p>\n<p>Chart has projected that its slice of the carbon capture market is worth $800 million in the next three to five years. “It’s a year behind hydrogen, as far as what we’re seeing in the market,” CEO Evanko says.</p>\n<p>Government policies and investment could become another catalyst for Chart, particularly in areas like carbon capture. The company would almost certainly benefit from the infrastructure proposal just endorsed by President Joe Biden. “We still would expect to see significant growth without the infrastructure bill in the U.S., because there are multiple macro tailwinds in place,” Evanko says. “But it would definitely be an accelerant.”</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Small-Cap Stock Can Pivot Between Old and New Energy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Small-Cap Stock Can Pivot Between Old and New Energy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 15:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/chart-industries-stock-natural-gas-hydrogen-51624662014?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The energy transition is on its way, but for most companies the tangible results won’t show up for years. At Chart Industries, the action is happening now, and the company’s stock isn’t fully ...</p>\n\n<a href=\"https://www.barrons.com/articles/chart-industries-stock-natural-gas-hydrogen-51624662014?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GTLS":"查特工业"},"source_url":"https://www.barrons.com/articles/chart-industries-stock-natural-gas-hydrogen-51624662014?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142078063","content_text":"The energy transition is on its way, but for most companies the tangible results won’t show up for years. At Chart Industries, the action is happening now, and the company’s stock isn’t fully reflecting that yet.\nChart (ticker: GTLS) makes cryogenic tanks and other equipment to freeze gases and make them easier to isolate and transport. Its products operate behind the scenes in a variety of industries, keeping soda bubbly and delivering oxygen to patients suffering from Covid-19. For now, Chart makes most of its money providing equipment to industrial-gas companies or fossil-fuel energy markets. But its stock offers a way to play both the rebound in traditional energy and the transition to new forms of it.\n“In the case of Big Oil, the energy transition will take 30 years,” says Raymond James analyst Pavel Molchanov. “For Chart, it’s happening in real time.” He has an Outperform rating on the shares and a $165 price target—18% above a recent price of $140.\nChart is based in the small city of Ball Ground, Ga., but operates all over the globe. Its results have fluctuated with the fortunes of the natural-gas and chemical industries in recent years. Chart mostly persevered through the pandemic, growing earnings to $2.73 a share from $2.52 the previous year, on a slight decline in sales, to $1.2 billion. The company, however, has a record backlog of orders and is entering a much faster growth period, one that more than justifies its valuation of about 26 times next year’s expected earnings.\n\nChart specializes in taking volatile gases and processing them so they can be contained and transported. That can mean pumping them through heat exchangers, freezing and storing them in cryogenic tanks, and transporting them through insulated pipes. These technologies are used to turn natural gas into liquid form to be transported through pipes or overseas.\nThe company has benefited as the shale-drilling revolution and new laws helped the U.S. become a major exporter of natural gas. But the technology that makes it possible to capture natural gas is also useful for capturing and taming other gases.\n“We’re molecule-agnostic,” Chart CEO Jillian Evanko tells Barron’s.\n\nChart’s systems help pump nitrogen into pressurized containers to make nitro cold brew coffee, carbon dioxide into greenhouses to make cannabis plants grow faster, and ozone into water systems to keep them clean. Even more promising are its renewable-energy divisions, like hydrogen and carbon capture. Its specialty products division is the main reason that Chart is expected to grow earnings per share by 44% this year and 33% next year, with an expected long-term growth rate of 25%, according to FactSet. Specialty products now make up 20% of the company’s revenue, but analysts see them growing to nearly half of sales by 2025.\nHydrogen, an alternative fuel that can produce electricity and power vehicles, is a big opportunity. Chart has been making equipment to process and transport hydrogen for decades, mostly for use in aerospace, but it is now becoming a key part of the supply chain for hydrogen use in alternative energy.\nAlong with equipment for processing, storage, and transportation, Chart helps build the hydrogen fueling stations themselves, which are quickly spreading throughout Europe and starting to show up in the U.S. Its hydrogen orders grew to $71 million in the first quarter this year from $4 million in the first quarter of 2020, and it expects hydrogen and helium sales to rise to at least $99 million this year from $22 million in 2020. The company thinks the potential hydrogen market opportunity is worth $2.4 billion over the next three to five years.\nThat pitch is drawing investors who are excited by hydrogen but wary of some companies in the sector that have potential but no profits.\n“If you play hydrogen through Chart, then you are already getting profits from those sales, because hydrogen is one of our most profitable elements as a business,” Evanko says.\nSteven Klopukh, a portfolio manager at Thornburg Investment Management, owns Chart in two funds he runs. “It’s a really good infrastructure play on the hydrogen economy,” he says. He sees a clear path for earnings to hit $8 a share a year and for the stock to reach $180 off the strength of its renewable energy products.\nKlopukh also sees promise in carbon capture and storage, a process that takes carbon emitted from drilling sites or factories and processes it for reuse or underground storage.\nCarbon capture is “the next big thing” in the energy transition businesses, predicts Evercore analyst James West. Among the companies betting big on carbon capture are Exxon Mobil(XOM), which is already one of Chart’s customers.\nChart has projected that its slice of the carbon capture market is worth $800 million in the next three to five years. “It’s a year behind hydrogen, as far as what we’re seeing in the market,” CEO Evanko says.\nGovernment policies and investment could become another catalyst for Chart, particularly in areas like carbon capture. The company would almost certainly benefit from the infrastructure proposal just endorsed by President Joe Biden. “We still would expect to see significant growth without the infrastructure bill in the U.S., because there are multiple macro tailwinds in place,” Evanko says. “But it would definitely be an accelerant.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187046338,"gmtCreate":1623732173124,"gmtModify":1704209868307,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Huats&nbsp;","listText":"Huats&nbsp;","text":"Huats","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187046338","repostId":"1109511555","repostType":4,"repost":{"id":"1109511555","kind":"news","pubTimestamp":1623727571,"share":"https://ttm.financial/m/news/1109511555?lang=&edition=fundamental","pubTime":"2021-06-15 11:26","market":"us","language":"en","title":"Apple Plans Faster Watch, Future Temperature and Glucose Sensors","url":"https://stock-news.laohu8.com/highlight/detail?id=1109511555","media":"Bloomberg","summary":"Updated screens and performance this year, new functions later. New entry-level and extreme sports models planned for 2022. A customer tries on an Apple watch at a store in Palo Alto, California. Photographer: Nina Riggio/Bloomberg. Apple Inc. is working on new Apple Watch models and health features, spanning display and speed upgrades, an extreme sports edition and body temperature and blood sugar sensors.The Cupertino, California-based tech giant is planning to refresh the line this year -- wi","content":"<ul>\n <li>Updated screens and performance this year, new functions later</li>\n <li>New entry-level and extreme sports models planned for 2022</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e86dd58655f96500dda750d2b1350121\" tg-width=\"2000\" tg-height=\"1333\"><span>A customer tries on an Apple watch at a store in Palo Alto, California. Photographer: Nina Riggio/Bloomberg</span></p>\n<p>Apple Inc.&nbsp;is working on new Apple Watch models and health features, spanning display and speed upgrades, an extreme sports edition and body temperature and blood sugar sensors.</p>\n<p>The Cupertino, California-based tech giant is planning to refresh the line this year -- with a model likely dubbed the Apple Watch Series 7 -- by adding a faster processor, improved wireless connectivity and an updated screen, according to people with knowledge of the plans. Next year the company plans to update the main Apple Watch alongside a successor for the lower-end Apple Watch SE and a new version targeting extreme sports athletes.</p>\n<p>Apple had previously aimed to put a body temperature sensor in this year’s model, but that is now more likely to be included in the 2022 update. The blood-sugar sensor, which would help diabetics monitor their glucose levels, is unlikely to be ready for commercial launch for several more years.</p>\n<p>For this year’s model, Apple has tested thinner display borders and a new lamination technique that brings the display closer to the front cover. The new Watch is likely to be slightly thicker overall, but not in a way that’s noticeable to the user.</p>\n<p>The model will include updated ultra-wideband functionality, the same underlying technology in the Apple AirTag item finder. At its developer conference in early June, Apple previewed the upcoming watchOS 8 software update that will let the device unlock door and hotel rooms.</p>\n<p>The extreme sports model, described by some inside Apple as either an “explorer” or “adventure” edition, was in development for release as early as this year, but it is now more likely to launch in 2022. That new model would help Apple compete with rugged offerings from players like&nbsp;Garmin Ltd.&nbsp;and&nbsp;Casio Computer Co.</p>\n<p>An Apple spokeswoman declined to comment. The company’s plans remain fluid and could change, the people said.</p>\n<p>Luxshare Precision Industry Co.&nbsp;is the primary assembler for the main Apple Watch, while&nbsp;Hon Hai Precision Industry Co., or Foxconn, shares some of those orders in addition to splitting assembly of the Apple Watch SE with Taiwan’s&nbsp;Compal Electronics Inc.</p>\n<p>Measuring body temperature became an essential part of Covid-19 detection, prompting a&nbsp;surge&nbsp;in demand for gadgets such as the&nbsp;Withings Thermo. Some companies offer small digital thermometers that plug into a smartphone’s charging port. Adding the functionality into its watch would help Apple match other smartwatches and fitness bands, including products from&nbsp;Alphabet Inc.-owned&nbsp;Fitbit.</p>\n<p>Blood sugar monitoring has been long in the works at Apple and would be a feature thus far unrivaled by competitors. Apple and others currently rely on apps that let users input their glucose levels manually, while medical device companies like&nbsp;Dexcom Inc.&nbsp;offer blood sugar monitors that share data with the Apple Watch. Users typically need to prick their finger to draw blood for an accurate glucose test, but Apple is aiming for a non-invasive solution that can analyze blood through the skin.</p>\n<p>Since going on sale in 2015, the Apple Watch has grown into a key part of Apple’s product portfolio. Along with the iPhone and iPad, it fills out the company’s hardware ecosystem and helped Apple’s broader wearables, home and accessories category generate more than $30 billion last fiscal year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Plans Faster Watch, Future Temperature and Glucose Sensors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Plans Faster Watch, Future Temperature and Glucose Sensors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 11:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-14/apple-plans-faster-watch-future-temperature-and-glucose-sensors><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Updated screens and performance this year, new functions later\nNew entry-level and extreme sports models planned for 2022\n\nA customer tries on an Apple watch at a store in Palo Alto, California. ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-14/apple-plans-faster-watch-future-temperature-and-glucose-sensors\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-14/apple-plans-faster-watch-future-temperature-and-glucose-sensors","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109511555","content_text":"Updated screens and performance this year, new functions later\nNew entry-level and extreme sports models planned for 2022\n\nA customer tries on an Apple watch at a store in Palo Alto, California. Photographer: Nina Riggio/Bloomberg\nApple Inc. is working on new Apple Watch models and health features, spanning display and speed upgrades, an extreme sports edition and body temperature and blood sugar sensors.\nThe Cupertino, California-based tech giant is planning to refresh the line this year -- with a model likely dubbed the Apple Watch Series 7 -- by adding a faster processor, improved wireless connectivity and an updated screen, according to people with knowledge of the plans. Next year the company plans to update the main Apple Watch alongside a successor for the lower-end Apple Watch SE and a new version targeting extreme sports athletes.\nApple had previously aimed to put a body temperature sensor in this year’s model, but that is now more likely to be included in the 2022 update. The blood-sugar sensor, which would help diabetics monitor their glucose levels, is unlikely to be ready for commercial launch for several more years.\nFor this year’s model, Apple has tested thinner display borders and a new lamination technique that brings the display closer to the front cover. The new Watch is likely to be slightly thicker overall, but not in a way that’s noticeable to the user.\nThe model will include updated ultra-wideband functionality, the same underlying technology in the Apple AirTag item finder. At its developer conference in early June, Apple previewed the upcoming watchOS 8 software update that will let the device unlock door and hotel rooms.\nThe extreme sports model, described by some inside Apple as either an “explorer” or “adventure” edition, was in development for release as early as this year, but it is now more likely to launch in 2022. That new model would help Apple compete with rugged offerings from players like Garmin Ltd. and Casio Computer Co.\nAn Apple spokeswoman declined to comment. The company’s plans remain fluid and could change, the people said.\nLuxshare Precision Industry Co. is the primary assembler for the main Apple Watch, while Hon Hai Precision Industry Co., or Foxconn, shares some of those orders in addition to splitting assembly of the Apple Watch SE with Taiwan’s Compal Electronics Inc.\nMeasuring body temperature became an essential part of Covid-19 detection, prompting a surge in demand for gadgets such as the Withings Thermo. Some companies offer small digital thermometers that plug into a smartphone’s charging port. Adding the functionality into its watch would help Apple match other smartwatches and fitness bands, including products from Alphabet Inc.-owned Fitbit.\nBlood sugar monitoring has been long in the works at Apple and would be a feature thus far unrivaled by competitors. Apple and others currently rely on apps that let users input their glucose levels manually, while medical device companies like Dexcom Inc. offer blood sugar monitors that share data with the Apple Watch. Users typically need to prick their finger to draw blood for an accurate glucose test, but Apple is aiming for a non-invasive solution that can analyze blood through the skin.\nSince going on sale in 2015, the Apple Watch has grown into a key part of Apple’s product portfolio. Along with the iPhone and iPad, it fills out the company’s hardware ecosystem and helped Apple’s broader wearables, home and accessories category generate more than $30 billion last fiscal year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187041668,"gmtCreate":1623732067154,"gmtModify":1704209865887,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Like + comment","listText":"Like + comment","text":"Like + comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187041668","repostId":"1164323104","repostType":4,"repost":{"id":"1164323104","kind":"news","pubTimestamp":1623726988,"share":"https://ttm.financial/m/news/1164323104?lang=&edition=fundamental","pubTime":"2021-06-15 11:16","market":"us","language":"en","title":"ARK: Cathie Wood And The Exquisite Art Of Tail Gunning","url":"https://stock-news.laohu8.com/highlight/detail?id=1164323104","media":"seekingalpha","summary":"Summary\n\nARK Active ETFs are worth the management fee.\nStructured Lookback is introduced.\nTails are ","content":"<p><b>Summary</b></p>\n<ul>\n <li>ARK Active ETFs are worth the management fee.</li>\n <li>Structured Lookback is introduced.</li>\n <li>Tails are shown to have a logical structure and consistent patterns.</li>\n <li>The concepts of Simultaneity and Sequentiality are introduced.</li>\n <li>CO/OC directional differences are important indicators that are much more useful than two-dimensional measures like standard deviation.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b1271b2416859ceba7776d3cb65f490c\" tg-width=\"768\" tg-height=\"512\"><span>phongphan5922/iStock via Getty Images</span></p>\n<p><b>The Legend of Cathie Wood and Ark Active</b></p>\n<blockquote>\n Beatrix Kiddo: I am proficient in Tiger Crane style and more than proficient in the exquisite art of the samurai sword.\n</blockquote>\n<blockquote>\n <b>Kill Bill Vol 2 - The Cruel Tutelage of Pai Mei</b>\n</blockquote>\n<p>There is no question that Cathie Wood will be elected to the Stock Picker Hall of Fame on the first year of eligibility. The last person achieving that honor was Peter Lynch.</p>\n<p>Ark Active ETFs weren't really on my radar until after&nbsp;Trading Edge&nbsp;was published on June 1. At some point, I planned to make that article more about equity groups instead of ETFs, specifically biotech. Eventually the plan changed because that seemed premature.</p>\n<p>Another reason for my lack of attention is that I usually look for issues with at least 1500 days of price history and the four horsemen of Ark Active passed that milestone less than 200 trade days ago.</p>\n<p>Some commentators have mentioned recent negative return issues with&nbsp;ARKG, noting that the natives are getting restless. The first argument has some merit and touches on technical details that will affect the entire market. But, call me a romantic, I'm OK with cutting ARK a little slack here.</p>\n<p><b>Tail Gunning</b></p>\n<p><b>Tail</b>&nbsp;is a statistical term related to&nbsp;<b>data distribution</b>. When data points are plotted, a&nbsp;<b>bell shaped curve</b>&nbsp;forms and the unusual results on either side of the curve are the tails. If the distribution is consistent with the ideal bell pattern, it is considered normal. Results of many coin flips produce a<b>normal distribution</b>, stock returns do not.</p>\n<p>This implies that&nbsp;<b>probabilities</b>&nbsp;based on normal distributions are accurate while non-normal distribution probabilities are not. This is a serious problem for the academic discipline of Finance as not understanding probabilities suggests that it cannot offer a practical methodology to mitigate&nbsp;<b>risk</b>.</p>\n<p>In this article, I will try to show that Ark Active returns are highly dependent on exploiting extreme tail activity. Hence the term&nbsp;<b>tail gunning</b>. Surprisingly, tail activity is more structured than one might initially think, so this may have some theoretical importance.</p>\n<p>ARK Active has been quite good over many years at staying on the wild side.</p>\n<p><b>The Legend of Data Manipulation</b></p>\n<p>Modern stock exchanges and casinos both appeared in the first part of the 17th century, not long after the modern rules of chess were established. Academic disciplines relevant to understanding these innovations such as calculus, linear algebra, statistics, quantum mechanics etc. slowly developed over the next 400 years.</p>\n<p>The revolutionary implications of data science have not yet been fully appreciated. Practical skill in data manipulation more than compensates for lack of formal academic knowledge in any of the other disciplines. A goal of my work is to demonstrate the soundness of this view.</p>\n<p>A trained practitioner of statistical finance won't approach the stock return problem through data manipulation. No doubt, data manipulation is my hammer, so everything else looks like a nail.</p>\n<p>Major weaknesses in the academic understanding of stuff in general include:</p>\n<ul>\n <li>Time</li>\n <li>High dimensionality</li>\n</ul>\n<p>Volatility is a function of time, claims by some financial sages that they understand volatility are prima facie absurd. Academic deficiencies can be exploited by competent users of computer power.</p>\n<p>In this article, I'll discuss how to set up and analyze market data, with attention given to the superb performance of the ARK Active ETFs.</p>\n<p><b>Price History Data</b></p>\n<p><img src=\"https://static.tigerbbs.com/d90c98591d40fa964b5d072099898d37\" tg-width=\"466\" tg-height=\"296\" referrerpolicy=\"no-referrer\"></p>\n<p>The analysis presented here, only considers the date, open and close. Financial statisticians generally consider daily open, high, and low numbers to be noise. Essentially, that is an admission of the limitations of their analytical framework.</p>\n<p>Looking at one stock at a time is wrong on many different levels. It is absolutely critical to examine groups of stocks.</p>\n<p>A mechanism is needed to produce historical daily prices for many different stocks. Prices must be adjusted for dividends and splits. The data should be stored in Excel csv workbooks where the workbook and worksheet names are the stock symbol.</p>\n<p>Databases are inappropriate for historical price analysis. Rebuilding the data at least daily from scratch is quick and eliminates many possible points of failure.</p>\n<p>It is best to solve the data problem by paying for a reliable delivery method like Norgate. Everyone who does this type of work, initially spends a lot of time figuring out how to get prices for free. I did that for about 15 years. It is good to build up the skill and understanding, but eventually the cost of inefficient use of time is substantial.</p>\n<p><b>Data Transformation - Natural Log Returns</b></p>\n<p><img src=\"https://static.tigerbbs.com/fe2b70f7a667237e2fde7818ec22248f\" tg-width=\"515\" tg-height=\"239\" referrerpolicy=\"no-referrer\"></p>\n<p>The per share price of a stock has absolutely no rational analytical relevance, assuming the investor has at least enough money to buy one share.</p>\n<p>The human mind can deal with a limited number of things at once, and with stock groups, price is too much detail. Data transformation is a methodology to remove that complexity. Here, daily prices are transformed to a return stream. That makes it easy to analyze even large groups of equities.</p>\n<p>Natural logs are the correct way to store a return stream, unless you are in a contest to find an inferior solution.</p>\n<p>The simple calculations below need to be done for each date for each stock in the group being analyzed. It only takes a few minutes on an 8th generation i7 Windows PC to do this for hundreds of stocks containing thousands of days of price history.</p>\n<p>Using 3/16 in the table above as an example:</p>\n<ul>\n <li><b>CC</b>(Close to Close) = natural log of 3/16 Close / 3/15 Close = nl(394.62/395.12) = -0.0013.</li>\n <li><b>CO</b>(Close to Open) = natural log of 3/16 Open / 3/15 Close = nl(395.77/395.12) = 0.0017.</li>\n <li><b>OC</b>(Open to Close) = natural log of 3/16 Close / 3/16 Open = nl(394.62/395.77) = -0.0029.</li>\n</ul>\n<p>The bCC/bCO/bOC columns are binary answers to the question of whether the excursion was positive (1 = positive 0 = not positive). It is quite useful to answer questions before they are asked. This same technique is used to encode strategies into a return stream.</p>\n<p>I specialize in low level stuff. For example, with the binary codes:</p>\n<ul>\n <li>If bCO = 1 and bOC = 1 Then bCC = 1</li>\n <li>If bCO = 0 and bOC = 0 Then bCC = 0</li>\n <li>otherwise, you have to check bCC.</li>\n</ul>\n<p>Probably, most people wouldn't spend months analyzing the implications of that. I'm making good progress but still not finished. xSig, discussed below is related to that analysis. The issue is that if bCC = 4, bCO = 2, and bOC = 1 to create an Octal number; 3 and 4 can't happen.</p>\n<p><b>1,400-Day Structured Lookback</b></p>\n<p><img src=\"https://static.tigerbbs.com/6a9152d4c32880ea9b67cfcfba92a528\" tg-width=\"640\" tg-height=\"451\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/816a4f84749432ed63cad49e9629fea1\" tg-width=\"640\" tg-height=\"440\" referrerpolicy=\"no-referrer\"><b>CC1400 = CO1400 + OC1400</b></p>\n<p><b>$CC1400 = $CO1400 * $OC1400</b></p>\n<p>In my&nbsp;Trading Edge article, CC1400 was called tCC.</p>\n<p><b>CO/OC Imbalance</b></p>\n<p>The CO state is clearly dominant over OC. Trading Edge even suggested this may be a permanent market feature. It is somewhat heretical to even whisper of such things. If someone refutes that, I promise not to get mad.</p>\n<p>Trading Edge considered the 3x Bulls to be the most obvious way to exploit the CO edge. ARK Active smokes the leveraged financially engineered abominations.</p>\n<p><b>Structured Lookback Design</b></p>\n<p><img src=\"https://static.tigerbbs.com/3619120948d5766322b4336d698d190f\" tg-width=\"428\" tg-height=\"275\" referrerpolicy=\"no-referrer\"></p>\n<p>I introduced date yrmolation as a concept in my&nbsp;Kabbalah articlein January. Perhaps structured lookback is a better term, if only because it has more vowels. The idea is to provide a logical methodology for creating segments of sequential time.</p>\n<p>The day is the standard market unit of time. The traditional day/week/month/year construct does not get us closer to a suitable lookback solution, and mostly just confuses the issue. Generally, one doesn't solve a problem by adding needless complexity.</p>\n<p>Every total time frame of&nbsp;<b>n days</b>, is broken into 3 consecutive periods. The first period is 1/7 the total period, the second 2/7, and the third 4/7. I worked on this backwards of course, so:</p>\n<ul>\n <li>x[1] = 200</li>\n <li>x[2] = x[1] * 2 = 400</li>\n <li>x[3] = x[1] * 4 = 800</li>\n <li>x[0] = Total days = 200 + 400 + 800 = 1400</li>\n</ul>\n<p>Another time concept is iteration. The study is labeled 200i0. i0 means iteration 0. An i1 study implies the 1400 days before 11/13/15.</p>\n<p><b>xSig logic.</b>There are three hex codes after the x. The bit values go:</p>\n<ul>\n <li>8 = xx1400</li>\n <li>4 = xx200</li>\n <li>2 = xx400</li>\n <li>1 = xx800</li>\n</ul>\n<p>xFF2 appears most often in the table. This means:</p>\n<ul>\n <li>First/F - All structured CC periods have positive returns.</li>\n <li>Second/F - All Structured CO periods have positive returns.</li>\n <li>Third/2 - All OC periods except OC400 have losses.</li>\n</ul>\n<p><b>Win Rate</b></p>\n<p>This is another critically important metric that virtually nobody looks at. In the table, the differences between CO and OC win rates are stunning.</p>\n<p><b>400-Day Segment Detail</b></p>\n<p><img src=\"https://static.tigerbbs.com/7299f454e25cd1b7c76e9270ba0d7555\" tg-width=\"640\" tg-height=\"318\" referrerpolicy=\"no-referrer\"></p>\n<p>The 400-day segment showed the best numbers for OC so it is worth looking at. All four of the time segments display simultaneously on an HD monitor; the challenge writing about them is mostly how to cut up the information for the article format. The win percentages for OC are notably higher than those seen on the 1400 day study. ARKW performs respectably here, both CO and OC, but even in the best OC environment, with the most favorable ETF, CO is not worse.</p>\n<p><b>ARKG</b></p>\n<p>ARKG performs better CO than any of the 3x Bulls CC or CO. ARK win rates are all at least 62% CO, much better than the bulls. Win rates OC are much worse. Obviously, with the strategy of playing CO, ideally we want to see all positive returns during CO and all the negative returns during OC.</p>\n<p><b>Performance Graphs</b></p>\n<blockquote>\n <img src=\"https://static.tigerbbs.com/62164faed041f049e43de95eae97d7f8\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\">Sam: I never walk into a place I don't know how to walk out of.\n</blockquote>\n<blockquote>\n <b>Ronin</b>\n</blockquote>\n<p>I can see how the recent sharp excursion down to about the 38.2 fib line might freak out some of the CC players, especially those who bought near the top. Personally, I'm afraid of parabolic heights, so it is difficult for me to visualize the thought process of the players who were buying at triple digits. Guess that is why I'll never be rich.</p>\n<p>After detailed poring over the entrails and consulting entities whose names are best left unspoken, I think holding any of the ARK Active puppies CO is worth serious consideration.</p>\n<p>I was really impressed by ARK's stock selection results and watched a recent interview of Cathie, where she was confident of the funds performing at the historical pace. Needless to say, I've been curious if she knows about the CO/OC imbalance where a CO player could theoretically beat buy and hold by about a factor of 10.</p>\n<p><b>Finding Biotech Tail</b></p>\n<p>Virtually all Biotechs are part of the tail when considered with the stock universe, so all one needs is a list of suitable candidates.</p>\n<p>Biotech and Semiconductors are the two industries with the most favorable positive CO vs OC characteristics based on my research. Energy is also quite good, but I haven't looked at that sector closely. Small caps are also consistently favorable.</p>\n<p>Biotech is a bit more persistent and obvious. An ETF performs at some sort of median to the characteristics of the group it is composed of, but ETF numbers pretty much precisely reflect the characteristics of the entire group.</p>\n<p>81 biotech stocks with average daily volume greater than 300K, and current price greater than $10 were assembled. The top stocks in CC, CO, and OC will be shown below:</p>\n<p><b>Top Biotech CC</b><img src=\"https://static.tigerbbs.com/d841bf3f146ef20a3b33e5907560506f\" tg-width=\"640\" tg-height=\"398\" referrerpolicy=\"no-referrer\"><b>Top BioTech CO</b><img src=\"https://static.tigerbbs.com/75d42024dd22967d2389f0bff6f5051b\" tg-width=\"640\" tg-height=\"359\" referrerpolicy=\"no-referrer\"><b>Top Biotech OC and Median</b></p>\n<p><img src=\"https://static.tigerbbs.com/71d670bb51438ece3d1e0ea1af330418\" tg-width=\"640\" tg-height=\"339\" referrerpolicy=\"no-referrer\"></p>\n<p>These are just overwhelming numbers arguing for CO. A random pick in this universe is much more likely to be profitable CO than anywhere else and that profit is much more likely to exceed CC. The win rates are lower than seen in most sectors. In general, this type of analysis is a fertile avenue for research.</p>\n<p><b>CO/OC or Standard Deviation</b></p>\n<p>The tendency of stocks to move in opposite directions CO and OC can be measured as has been shown here. These movements appear to be quite persistent and consistent in direction over time. The investor gains important and usable information by studying these structures, as opposed to standard deviation.</p>\n<p>Standard deviation only measures CC and ignores violent movements during the day. A year is usually considered the proper standard deviation sample, mostly because any other length is equally worthless.</p>\n<p><b>Recent Action</b></p>\n<p>CO has not been a great performer lately. I've been noting that on my website since at least March I think. The more interesting thing is watching things unfold with a decent toolset and trying to figure out what is happening.</p>\n<p><b>252-Day Structured Lookback</b></p>\n<p><img src=\"https://static.tigerbbs.com/8d0b19158fd2c03a403a0b4e050337e5\" tg-width=\"640\" tg-height=\"277\" referrerpolicy=\"no-referrer\"></p>\n<p>I'll stick with natural log results only in this pass. A natural log of 0.69 is doubling your money. 0.72 for ARKG is CV$1 2.06. All of the puppies at least tripled CO except for ARKW. Not bad for a year. Note the CO win rate.</p>\n<p>xSig is weaker than long term as xFF is no longer showing. As time ranges get longer, xFF gets more common.</p>\n<p><img src=\"https://static.tigerbbs.com/56d55c932d2bf44bdbc6453973b0deca\" tg-width=\"640\" tg-height=\"259\" referrerpolicy=\"no-referrer\"></p>\n<p>I guess the CC players got annoyed that things were better at this end point than 6/11/21. CO win rates are about the best I've ever seen.</p>\n<p><img src=\"https://static.tigerbbs.com/8545852036c8982dbfe9b43f7a5cbadb\" tg-width=\"640\" tg-height=\"259\" referrerpolicy=\"no-referrer\"></p>\n<p>Win rates seriously dropped from the 144 day segment. The Biotech correction started February 9th.</p>\n<p><img src=\"https://static.tigerbbs.com/b8a78565860d28888443a05446a954fc\" tg-width=\"640\" tg-height=\"282\" referrerpolicy=\"no-referrer\"></p>\n<p>The ARKG pattern starts with a double top. LABU and XBI made a single top, with a nice dark cloud cover candle that worked out for a change. In some parallel universes, they always work.</p>\n<p><img src=\"https://static.tigerbbs.com/05104399c4fdd23a584cf50f2b0c17f1\" tg-width=\"640\" tg-height=\"282\" referrerpolicy=\"no-referrer\"></p>\n<p>The black candles show the day traders getting slapped. No big deal for CO players. I'm happy I wasn't playing these guys during this period; no question I would have botched things up.</p>\n<p><img src=\"https://static.tigerbbs.com/6ae737de17a78652910a1d3026bcb38c\" tg-width=\"640\" tg-height=\"259\" referrerpolicy=\"no-referrer\"></p>\n<p>The 36-day shows weakness coming into CO and a little strength in OC at least for ARKG. Note the two winning percentages are the same. This is less trivial than it appears as that situation also exists in the Biotechs.</p>\n<p><img src=\"https://static.tigerbbs.com/149ae96de3fe3e9bae8c62f9d00080d3\" tg-width=\"640\" tg-height=\"432\" referrerpolicy=\"no-referrer\"></p>\n<p><img src=\"https://static.tigerbbs.com/0dcc46d54a59d3ac1078bb04cdefaac4\" tg-width=\"640\" tg-height=\"282\" referrerpolicy=\"no-referrer\"></p>\n<p>The recent low at 72.87 was not only the important ludicrously long term 38.2 fib line but the 52 week moving average, and on the other side of the chasm there is obvious support around 72. I don't see how that can be arranged to spell sell. Note the pop we are seeing off the low is coming on OC strength.</p>\n<p>The plain meaning of the weekly chart is bullish: Heat sensitive longs from the congestion period, put stops in below the 52 week SMA that were triggered during the week of May 10. That is shown by the head fake and bottoming tail. Even a retest of the low would probably not be too bad, but hopefully that won't part of the near term conversation. The poke above the 13-week SMA is encouraging, a move above 93 doesn't seem excessively optimistic.</p>\n<p>Is The 252-Day Structured Lookback Kosher?</p>\n<p>252 market days is as close to an exact calendar year as you can get. 252 / 7 = 36. Therefore we can say that a market year is divided into 7 periods of 36 days. In this scheme, every day is the end of a year.</p>\n<p>With<b>Gematria</b>, the number 36 is 2 * 18. 18 = Life. 36 is comprised of the letters Lamed Vav, which correspond to the<b>TzadikimNistarim</b>, the 36 hidden righteous ones who support the world in every generation.</p>\n<p>Somehow, that gives me a little confidence that the structured lookback solution isn't completely ridiculous. It is definitely kosher.</p>\n<p>Simultaneity and Sequentiality</p>\n<blockquote>\n Adm Mark Turso USN Ret: You were given a Ferrari and your people treated it like a lawnmower.\n</blockquote>\n<blockquote>\n <b>The Bourne Legacy</b>\n</blockquote>\n<p>Earlier, I mentioned the binary codes bCC, bCO, and bOC. These probably have to be understood to understand the CO/OC imbalance. They are useful in understanding the forces of simultaneity and sequentiality which propel stock prices.</p>\n<p><img src=\"https://static.tigerbbs.com/6c17ed7424c6e637ad896c0fbaed4baf\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\"></p>\n<p>The ARK Ferraris are included with the lawn mowers.</p>\n<p>XBI and IBB are weird with their different returns, which is not easily exploitable.</p>\n<p>Buy The Dip Or Pop - CCn1 or CCp1<img src=\"https://static.tigerbbs.com/6ca6dcb7e38682509246a811e20b4b50\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\">The Specter Clock</p>\n<p>CCn1 means CC negative returns of the Specter stock from the previous day are analyzed. The Specter stock is SPY. The specter functions something like a clock and provides high dimensional order to the group.</p>\n<p>This happened 105 times in the last 252 days - note end of top line. The bulk of CC profits occurred after this happened. The CC median win rate is 60 instead of 55. Note that this state accounts for more than 100% of OC profits.</p>\n<p><b>CCp1</b></p>\n<p><img src=\"https://static.tigerbbs.com/7c139fe7edf8287f22fb4902d489ee01\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\">CC is usually positive of course and it was for 147 of the 252 days. It has been best to buy the pop CO and then get out OC.</p>\n<p>These might be good examples of sequentiality, or not.</p>\n<p>SPY is Positive or Negative CO Today - COp0 or COn0</p>\n<p><img src=\"https://static.tigerbbs.com/2e4b10f70d9011fe586ed6d10f3dff28\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\"></p>\n<p>This is an example of simultaneity. If SPY is up OC 90% of the sector ETFs will go up.</p>\n<p>Simultaneity has weakened during the last segment and probably a little before that as well.</p>\n<p><img src=\"https://static.tigerbbs.com/49fd6dcb993413dabcf4039ed0937c37\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\">There definitely isn't the same kind of breadth as in the good old days. That seems at least mildly negative.</p>\n<p><b>COn0</b></p>\n<p><img src=\"https://static.tigerbbs.com/a1da4b68139194cb3c20cbdddbfcddd5\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\">This shows that COn0 weakness in SPY is less of a factor than COp0. Note that if CO is negative, there are better chances for OC to be positive.</p>\n<p><img src=\"https://static.tigerbbs.com/14ca38d49389a36c6f2b1c69036409fa\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\"></p>\n<p>The 36-day view shows the sectors having consensus on SPY down moves rather than up moves lately. There has been no lack of buyers OC.</p>\n<p>Essentially, this type of analysis adds a concrete framework that shows a pretty subtle picture of market state. It confirms a vague feeling many have noticed that things are changing.</p>\n<p>I doubt that mechanical CO playing is ready for prime time just yet. Certainly the CC/CO binary results above need to be better understood. Mostly, I think the analytical framework presented here is quite powerful and worth continued development.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARK: Cathie Wood And The Exquisite Art Of Tail Gunning</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARK: Cathie Wood And The Exquisite Art Of Tail Gunning\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 11:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4434708-ark-cathie-wood-and-tail-gunning><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nARK Active ETFs are worth the management fee.\nStructured Lookback is introduced.\nTails are shown to have a logical structure and consistent patterns.\nThe concepts of Simultaneity and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4434708-ark-cathie-wood-and-tail-gunning\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKR":"Ark Restaurants Corp","ARKQ":"ARK Autonomous Technology & Robotics ETF","ARKF":"ARK Fintech Innovation ETF","ARKG":"ARK Genomic Revolution ETF","ARKO":"ARKO Corp","ARKK":"ARK Innovation ETF"},"source_url":"https://seekingalpha.com/article/4434708-ark-cathie-wood-and-tail-gunning","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164323104","content_text":"Summary\n\nARK Active ETFs are worth the management fee.\nStructured Lookback is introduced.\nTails are shown to have a logical structure and consistent patterns.\nThe concepts of Simultaneity and Sequentiality are introduced.\nCO/OC directional differences are important indicators that are much more useful than two-dimensional measures like standard deviation.\n\nphongphan5922/iStock via Getty Images\nThe Legend of Cathie Wood and Ark Active\n\n Beatrix Kiddo: I am proficient in Tiger Crane style and more than proficient in the exquisite art of the samurai sword.\n\n\nKill Bill Vol 2 - The Cruel Tutelage of Pai Mei\n\nThere is no question that Cathie Wood will be elected to the Stock Picker Hall of Fame on the first year of eligibility. The last person achieving that honor was Peter Lynch.\nArk Active ETFs weren't really on my radar until after Trading Edge was published on June 1. At some point, I planned to make that article more about equity groups instead of ETFs, specifically biotech. Eventually the plan changed because that seemed premature.\nAnother reason for my lack of attention is that I usually look for issues with at least 1500 days of price history and the four horsemen of Ark Active passed that milestone less than 200 trade days ago.\nSome commentators have mentioned recent negative return issues with ARKG, noting that the natives are getting restless. The first argument has some merit and touches on technical details that will affect the entire market. But, call me a romantic, I'm OK with cutting ARK a little slack here.\nTail Gunning\nTail is a statistical term related to data distribution. When data points are plotted, a bell shaped curve forms and the unusual results on either side of the curve are the tails. If the distribution is consistent with the ideal bell pattern, it is considered normal. Results of many coin flips produce anormal distribution, stock returns do not.\nThis implies that probabilities based on normal distributions are accurate while non-normal distribution probabilities are not. This is a serious problem for the academic discipline of Finance as not understanding probabilities suggests that it cannot offer a practical methodology to mitigate risk.\nIn this article, I will try to show that Ark Active returns are highly dependent on exploiting extreme tail activity. Hence the term tail gunning. Surprisingly, tail activity is more structured than one might initially think, so this may have some theoretical importance.\nARK Active has been quite good over many years at staying on the wild side.\nThe Legend of Data Manipulation\nModern stock exchanges and casinos both appeared in the first part of the 17th century, not long after the modern rules of chess were established. Academic disciplines relevant to understanding these innovations such as calculus, linear algebra, statistics, quantum mechanics etc. slowly developed over the next 400 years.\nThe revolutionary implications of data science have not yet been fully appreciated. Practical skill in data manipulation more than compensates for lack of formal academic knowledge in any of the other disciplines. A goal of my work is to demonstrate the soundness of this view.\nA trained practitioner of statistical finance won't approach the stock return problem through data manipulation. No doubt, data manipulation is my hammer, so everything else looks like a nail.\nMajor weaknesses in the academic understanding of stuff in general include:\n\nTime\nHigh dimensionality\n\nVolatility is a function of time, claims by some financial sages that they understand volatility are prima facie absurd. Academic deficiencies can be exploited by competent users of computer power.\nIn this article, I'll discuss how to set up and analyze market data, with attention given to the superb performance of the ARK Active ETFs.\nPrice History Data\n\nThe analysis presented here, only considers the date, open and close. Financial statisticians generally consider daily open, high, and low numbers to be noise. Essentially, that is an admission of the limitations of their analytical framework.\nLooking at one stock at a time is wrong on many different levels. It is absolutely critical to examine groups of stocks.\nA mechanism is needed to produce historical daily prices for many different stocks. Prices must be adjusted for dividends and splits. The data should be stored in Excel csv workbooks where the workbook and worksheet names are the stock symbol.\nDatabases are inappropriate for historical price analysis. Rebuilding the data at least daily from scratch is quick and eliminates many possible points of failure.\nIt is best to solve the data problem by paying for a reliable delivery method like Norgate. Everyone who does this type of work, initially spends a lot of time figuring out how to get prices for free. I did that for about 15 years. It is good to build up the skill and understanding, but eventually the cost of inefficient use of time is substantial.\nData Transformation - Natural Log Returns\n\nThe per share price of a stock has absolutely no rational analytical relevance, assuming the investor has at least enough money to buy one share.\nThe human mind can deal with a limited number of things at once, and with stock groups, price is too much detail. Data transformation is a methodology to remove that complexity. Here, daily prices are transformed to a return stream. That makes it easy to analyze even large groups of equities.\nNatural logs are the correct way to store a return stream, unless you are in a contest to find an inferior solution.\nThe simple calculations below need to be done for each date for each stock in the group being analyzed. It only takes a few minutes on an 8th generation i7 Windows PC to do this for hundreds of stocks containing thousands of days of price history.\nUsing 3/16 in the table above as an example:\n\nCC(Close to Close) = natural log of 3/16 Close / 3/15 Close = nl(394.62/395.12) = -0.0013.\nCO(Close to Open) = natural log of 3/16 Open / 3/15 Close = nl(395.77/395.12) = 0.0017.\nOC(Open to Close) = natural log of 3/16 Close / 3/16 Open = nl(394.62/395.77) = -0.0029.\n\nThe bCC/bCO/bOC columns are binary answers to the question of whether the excursion was positive (1 = positive 0 = not positive). It is quite useful to answer questions before they are asked. This same technique is used to encode strategies into a return stream.\nI specialize in low level stuff. For example, with the binary codes:\n\nIf bCO = 1 and bOC = 1 Then bCC = 1\nIf bCO = 0 and bOC = 0 Then bCC = 0\notherwise, you have to check bCC.\n\nProbably, most people wouldn't spend months analyzing the implications of that. I'm making good progress but still not finished. xSig, discussed below is related to that analysis. The issue is that if bCC = 4, bCO = 2, and bOC = 1 to create an Octal number; 3 and 4 can't happen.\n1,400-Day Structured Lookback\nCC1400 = CO1400 + OC1400\n$CC1400 = $CO1400 * $OC1400\nIn my Trading Edge article, CC1400 was called tCC.\nCO/OC Imbalance\nThe CO state is clearly dominant over OC. Trading Edge even suggested this may be a permanent market feature. It is somewhat heretical to even whisper of such things. If someone refutes that, I promise not to get mad.\nTrading Edge considered the 3x Bulls to be the most obvious way to exploit the CO edge. ARK Active smokes the leveraged financially engineered abominations.\nStructured Lookback Design\n\nI introduced date yrmolation as a concept in my Kabbalah articlein January. Perhaps structured lookback is a better term, if only because it has more vowels. The idea is to provide a logical methodology for creating segments of sequential time.\nThe day is the standard market unit of time. The traditional day/week/month/year construct does not get us closer to a suitable lookback solution, and mostly just confuses the issue. Generally, one doesn't solve a problem by adding needless complexity.\nEvery total time frame of n days, is broken into 3 consecutive periods. The first period is 1/7 the total period, the second 2/7, and the third 4/7. I worked on this backwards of course, so:\n\nx[1] = 200\nx[2] = x[1] * 2 = 400\nx[3] = x[1] * 4 = 800\nx[0] = Total days = 200 + 400 + 800 = 1400\n\nAnother time concept is iteration. The study is labeled 200i0. i0 means iteration 0. An i1 study implies the 1400 days before 11/13/15.\nxSig logic.There are three hex codes after the x. The bit values go:\n\n8 = xx1400\n4 = xx200\n2 = xx400\n1 = xx800\n\nxFF2 appears most often in the table. This means:\n\nFirst/F - All structured CC periods have positive returns.\nSecond/F - All Structured CO periods have positive returns.\nThird/2 - All OC periods except OC400 have losses.\n\nWin Rate\nThis is another critically important metric that virtually nobody looks at. In the table, the differences between CO and OC win rates are stunning.\n400-Day Segment Detail\n\nThe 400-day segment showed the best numbers for OC so it is worth looking at. All four of the time segments display simultaneously on an HD monitor; the challenge writing about them is mostly how to cut up the information for the article format. The win percentages for OC are notably higher than those seen on the 1400 day study. ARKW performs respectably here, both CO and OC, but even in the best OC environment, with the most favorable ETF, CO is not worse.\nARKG\nARKG performs better CO than any of the 3x Bulls CC or CO. ARK win rates are all at least 62% CO, much better than the bulls. Win rates OC are much worse. Obviously, with the strategy of playing CO, ideally we want to see all positive returns during CO and all the negative returns during OC.\nPerformance Graphs\n\nSam: I never walk into a place I don't know how to walk out of.\n\n\nRonin\n\nI can see how the recent sharp excursion down to about the 38.2 fib line might freak out some of the CC players, especially those who bought near the top. Personally, I'm afraid of parabolic heights, so it is difficult for me to visualize the thought process of the players who were buying at triple digits. Guess that is why I'll never be rich.\nAfter detailed poring over the entrails and consulting entities whose names are best left unspoken, I think holding any of the ARK Active puppies CO is worth serious consideration.\nI was really impressed by ARK's stock selection results and watched a recent interview of Cathie, where she was confident of the funds performing at the historical pace. Needless to say, I've been curious if she knows about the CO/OC imbalance where a CO player could theoretically beat buy and hold by about a factor of 10.\nFinding Biotech Tail\nVirtually all Biotechs are part of the tail when considered with the stock universe, so all one needs is a list of suitable candidates.\nBiotech and Semiconductors are the two industries with the most favorable positive CO vs OC characteristics based on my research. Energy is also quite good, but I haven't looked at that sector closely. Small caps are also consistently favorable.\nBiotech is a bit more persistent and obvious. An ETF performs at some sort of median to the characteristics of the group it is composed of, but ETF numbers pretty much precisely reflect the characteristics of the entire group.\n81 biotech stocks with average daily volume greater than 300K, and current price greater than $10 were assembled. The top stocks in CC, CO, and OC will be shown below:\nTop Biotech CCTop BioTech COTop Biotech OC and Median\n\nThese are just overwhelming numbers arguing for CO. A random pick in this universe is much more likely to be profitable CO than anywhere else and that profit is much more likely to exceed CC. The win rates are lower than seen in most sectors. In general, this type of analysis is a fertile avenue for research.\nCO/OC or Standard Deviation\nThe tendency of stocks to move in opposite directions CO and OC can be measured as has been shown here. These movements appear to be quite persistent and consistent in direction over time. The investor gains important and usable information by studying these structures, as opposed to standard deviation.\nStandard deviation only measures CC and ignores violent movements during the day. A year is usually considered the proper standard deviation sample, mostly because any other length is equally worthless.\nRecent Action\nCO has not been a great performer lately. I've been noting that on my website since at least March I think. The more interesting thing is watching things unfold with a decent toolset and trying to figure out what is happening.\n252-Day Structured Lookback\n\nI'll stick with natural log results only in this pass. A natural log of 0.69 is doubling your money. 0.72 for ARKG is CV$1 2.06. All of the puppies at least tripled CO except for ARKW. Not bad for a year. Note the CO win rate.\nxSig is weaker than long term as xFF is no longer showing. As time ranges get longer, xFF gets more common.\n\nI guess the CC players got annoyed that things were better at this end point than 6/11/21. CO win rates are about the best I've ever seen.\n\nWin rates seriously dropped from the 144 day segment. The Biotech correction started February 9th.\n\nThe ARKG pattern starts with a double top. LABU and XBI made a single top, with a nice dark cloud cover candle that worked out for a change. In some parallel universes, they always work.\n\nThe black candles show the day traders getting slapped. No big deal for CO players. I'm happy I wasn't playing these guys during this period; no question I would have botched things up.\n\nThe 36-day shows weakness coming into CO and a little strength in OC at least for ARKG. Note the two winning percentages are the same. This is less trivial than it appears as that situation also exists in the Biotechs.\n\n\nThe recent low at 72.87 was not only the important ludicrously long term 38.2 fib line but the 52 week moving average, and on the other side of the chasm there is obvious support around 72. I don't see how that can be arranged to spell sell. Note the pop we are seeing off the low is coming on OC strength.\nThe plain meaning of the weekly chart is bullish: Heat sensitive longs from the congestion period, put stops in below the 52 week SMA that were triggered during the week of May 10. That is shown by the head fake and bottoming tail. Even a retest of the low would probably not be too bad, but hopefully that won't part of the near term conversation. The poke above the 13-week SMA is encouraging, a move above 93 doesn't seem excessively optimistic.\nIs The 252-Day Structured Lookback Kosher?\n252 market days is as close to an exact calendar year as you can get. 252 / 7 = 36. Therefore we can say that a market year is divided into 7 periods of 36 days. In this scheme, every day is the end of a year.\nWithGematria, the number 36 is 2 * 18. 18 = Life. 36 is comprised of the letters Lamed Vav, which correspond to theTzadikimNistarim, the 36 hidden righteous ones who support the world in every generation.\nSomehow, that gives me a little confidence that the structured lookback solution isn't completely ridiculous. It is definitely kosher.\nSimultaneity and Sequentiality\n\n Adm Mark Turso USN Ret: You were given a Ferrari and your people treated it like a lawnmower.\n\n\nThe Bourne Legacy\n\nEarlier, I mentioned the binary codes bCC, bCO, and bOC. These probably have to be understood to understand the CO/OC imbalance. They are useful in understanding the forces of simultaneity and sequentiality which propel stock prices.\n\nThe ARK Ferraris are included with the lawn mowers.\nXBI and IBB are weird with their different returns, which is not easily exploitable.\nBuy The Dip Or Pop - CCn1 or CCp1The Specter Clock\nCCn1 means CC negative returns of the Specter stock from the previous day are analyzed. The Specter stock is SPY. The specter functions something like a clock and provides high dimensional order to the group.\nThis happened 105 times in the last 252 days - note end of top line. The bulk of CC profits occurred after this happened. The CC median win rate is 60 instead of 55. Note that this state accounts for more than 100% of OC profits.\nCCp1\nCC is usually positive of course and it was for 147 of the 252 days. It has been best to buy the pop CO and then get out OC.\nThese might be good examples of sequentiality, or not.\nSPY is Positive or Negative CO Today - COp0 or COn0\n\nThis is an example of simultaneity. If SPY is up OC 90% of the sector ETFs will go up.\nSimultaneity has weakened during the last segment and probably a little before that as well.\nThere definitely isn't the same kind of breadth as in the good old days. That seems at least mildly negative.\nCOn0\nThis shows that COn0 weakness in SPY is less of a factor than COp0. Note that if CO is negative, there are better chances for OC to be positive.\n\nThe 36-day view shows the sectors having consensus on SPY down moves rather than up moves lately. There has been no lack of buyers OC.\nEssentially, this type of analysis adds a concrete framework that shows a pretty subtle picture of market state. It confirms a vague feeling many have noticed that things are changing.\nI doubt that mechanical CO playing is ready for prime time just yet. Certainly the CC/CO binary results above need to be better understood. Mostly, I think the analytical framework presented here is quite powerful and worth continued development.","news_type":1},"isVote":1,"tweetType":1,"viewCount":140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186284050,"gmtCreate":1623501898270,"gmtModify":1704205201311,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Well well","listText":"Well well","text":"Well well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/186284050","repostId":"2142206100","repostType":4,"repost":{"id":"2142206100","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623470400,"share":"https://ttm.financial/m/news/2142206100?lang=&edition=fundamental","pubTime":"2021-06-12 12:00","market":"hk","language":"en","title":"15 momentum stocks expected to show the best sales growth over the next two years, including Carvana, Tesla and Palantir","url":"https://stock-news.laohu8.com/highlight/detail?id=2142206100","media":"Dow Jones","summary":"Several companies on a stock screen have estimated two-year revenue growth of over 100%.\nThere are m","content":"<p>Several companies on a stock screen have estimated two-year revenue growth of over 100%.</p>\n<p>There are many broad approaches to the stock market for selecting individual companies or groups for investments. Momentum investing -- trying to ride the wave of other investors' sentiment -- is popular for day-traders, especially during the current meme-stock craze. But it can also work over the long term.</p>\n<p>Below is a list of momentum stocks of companies expected to show the strongest sales growth over the next two years.</p>\n<p>Momentum ETF</p>\n<p>To begin with a large group of momentum stocks, we can look at the <a href=\"https://laohu8.com/S/MTUM\">iShares MSCI USA Momentum Factor</a> ETF (MTUM). This is the largest U.S. ETF that follows a momentum strategy, according to Mark Hulbert performance relative to its benchmark, the S&amp;P 500 Growth Index.</p>\n<p>For example, the largest holding of the ETF is Tesla Inc. <a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, which \"has experienced strong risk-adjusted performance related to the market over the past 12 months,\" according to <a href=\"https://laohu8.com/S/EEME\">iShares</a> (a subsidiary of BlackRock Inc. <a href=\"https://laohu8.com/S/BLK\">$(BLK)$</a>). But shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> are excluded from MTUM because even though <a href=\"https://laohu8.com/S/EGRW\">iShares</a> considered its 12-month return \"attractive,\" the stock's six-month risk-adjusted return underperformed the benchmark.</p>\n<p>So keeping in mind the weighting by price performance relative to the index, tempered by volatility (going back as much as three years), here are the top 10 holdings of the <a href=\"https://laohu8.com/S/IHPXF\">iShares MSCI</a> USA Momentum Factor ETF:</p>\n<table>\n <tbody>\n  <tr>\n   <td>Company</td>\n   <td>Ticker</td>\n   <td>Share of MTUM</td>\n  </tr>\n  <tr>\n   <td>Tesla Inc.</td>\n   <td>TSLA</td>\n   <td>5.00%</td>\n  </tr>\n  <tr>\n   <td>JPMorgan Chase &amp; Co.</td>\n   <td>JPM</td>\n   <td>4.76%</td>\n  </tr>\n  <tr>\n   <td>Berkshire Hathaway Inc. Class B</td>\n   <td>BRK.B</td>\n   <td>4.58%</td>\n  </tr>\n  <tr>\n   <td>Walt Disney Co.</td>\n   <td>DIS</td>\n   <td>4.48%</td>\n  </tr>\n  <tr>\n   <td>$Bank of America Corp(BAC-N)$.</td>\n   <td>BAC</td>\n   <td>4.29%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings Inc.</td>\n   <td>PYPL</td>\n   <td>3.66%</td>\n  </tr>\n  <tr>\n   <td>Wells Fargo &amp; Co.</td>\n   <td>WFC</td>\n   <td>3.11%</td>\n  </tr>\n  <tr>\n   <td>Applied Materials Inc.</td>\n   <td>AMAT</td>\n   <td>3.00%</td>\n  </tr>\n  <tr>\n   <td>Alphabet Inc. Class C</td>\n   <td>GOOG</td>\n   <td>2.67%</td>\n  </tr>\n  <tr>\n   <td>Alphabet Inc. Class A</td>\n   <td>GOOGL</td>\n   <td>2.45%</td>\n  </tr>\n  <tr>\n   <td>Goldman Sachs Group Inc.</td>\n   <td>GS</td>\n   <td>2.30%</td>\n  </tr>\n  <tr>\n   <td>(FactSet)</td>\n   <td></td>\n   <td></td>\n  </tr>\n </tbody>\n</table>\n<p>Actually, there are 11 stocks listed, as MTUM holds both share classes of Alphabet Inc. Banks and insurers make up half the list, which makes sense because financials have been the second-best performing sector in the S&amp;P 500 , after the materials sector.</p>\n<p>Momentum stock screen -- expected sales growth</p>\n<p>Thinking again about financials, they have had plenty of momentum as investors have gained confidence the U.S. economy will continue roaring back from the damage caused by the coronavirus pandemic.</p>\n<p>But revenue growth can be an important driver, especially for individual stock prices over the long term. From here, the financials might not be the best place to look for rapidly rising revenue over the next two years.</p>\n<p>Starting with the 125 momentum stocks held by MTUM, here are the 15 companies expected by analysts polled by FactSet to increase revenue the most over the next two calendar years, with 2021 as the baseline. The figures are in millions of dollars:</p>\n<p>Those are stellar sales-growth numbers -- if the analysts are close to being correct. Many of the stocks are also expensive relative to the expected 2023 sales numbers. In comparison, the <a href=\"https://laohu8.com/S/EMDI\">iShares</a> S&amp;P 500 Growth ETF <a href=\"https://laohu8.com/S/IVW\">$(IVW)$</a> (which tracks the entire S&amp;P 500 Growth Index) trades for 4.2 times estimated 2023 sales.</p>\n<p>Plug Power Inc. <a href=\"https://laohu8.com/S/PLUG\">$(PLUG)$</a> tops the list, with analysts expecting sales to increase to $1.1 billion in 2023. The company said on June 10 it would build a hydrogen-production plant in Camden County, Ga.</p>\n<p><a href=\"https://laohu8.com/S/SNAP\">Snap Inc</a>. (SNAP) CEO Evan Spiegal said recently the company had grown to 500 million active daily users and that almost half of U.S. smartphone users were using Snapchat.</p>\n<p>Novavax Inc. <a href=\"https://laohu8.com/S/NVAX\">$(NVAX)$</a> expects to apply for FDA approval of its coronavirus vaccine during the third quarter.</p>\n<p><a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> (CVNA) has been on a tear, with used-car demand spiking in the wake of component shortages for automobile production. The company's sales by units increased 76% in the first quarter from a year earlier.</p>\n<p>Uber Technologies Inc. <a href=\"https://laohu8.com/S/UBER\">$(UBER)$</a> and Lyft Inc <a href=\"https://laohu8.com/S/LYFT\">$(LYFT)$</a> are also expected to ride the economic recovery wave, although analysts expect Lyft to take longer to exceed its pre-pandemic revenue level .</p>\n<p><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> (PLTR) rounds out the list. The developer of software used by government defense and intelligence agencies was included in this analysis of meme stocks .</p>\n<p>Earnings</p>\n<p>Some of these companies are still in relatively early growth stages, and aren't expected to achieve full-year profitability until 2023. Here are consensus earnings-per-share estimates for three years:</p>\n<p>Those are very high price-to-earnings ratios based on current stock prices and consensus estimates for 2023. But for rapidly growing companies, earnings typically aren't a priority, which explains why Amazon.com Inc. <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a> always trades at a high P/E. In comparison, the the <a href=\"https://laohu8.com/S/EMEY\">iShares</a> S&amp;P 500 Growth ETF trades for 23.3 times its weighted aggregate consensus earnings estimate for 2023.</p>\n<p>Wall Street's opinion</p>\n<p>Here's a summary of opinion about the 15 companies held by MTUM that analysts expect to grow their revenue the most over the next two years:</p>\n<p>The 12-month price targets may not be useful -- for traders, this is an eternity; it may be a short period for long-term investors looking to profit for years as sales (and hopefully earnings, eventually) compound. It is important to do your own research and form your own opinion about a company's financial health and its ability to remain competitive.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>15 momentum stocks expected to show the best sales growth over the next two years, including Carvana, Tesla and Palantir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n15 momentum stocks expected to show the best sales growth over the next two years, including Carvana, Tesla and Palantir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-12 12:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Several companies on a stock screen have estimated two-year revenue growth of over 100%.</p>\n<p>There are many broad approaches to the stock market for selecting individual companies or groups for investments. Momentum investing -- trying to ride the wave of other investors' sentiment -- is popular for day-traders, especially during the current meme-stock craze. But it can also work over the long term.</p>\n<p>Below is a list of momentum stocks of companies expected to show the strongest sales growth over the next two years.</p>\n<p>Momentum ETF</p>\n<p>To begin with a large group of momentum stocks, we can look at the <a href=\"https://laohu8.com/S/MTUM\">iShares MSCI USA Momentum Factor</a> ETF (MTUM). This is the largest U.S. ETF that follows a momentum strategy, according to Mark Hulbert performance relative to its benchmark, the S&amp;P 500 Growth Index.</p>\n<p>For example, the largest holding of the ETF is Tesla Inc. <a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, which \"has experienced strong risk-adjusted performance related to the market over the past 12 months,\" according to <a href=\"https://laohu8.com/S/EEME\">iShares</a> (a subsidiary of BlackRock Inc. <a href=\"https://laohu8.com/S/BLK\">$(BLK)$</a>). But shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> are excluded from MTUM because even though <a href=\"https://laohu8.com/S/EGRW\">iShares</a> considered its 12-month return \"attractive,\" the stock's six-month risk-adjusted return underperformed the benchmark.</p>\n<p>So keeping in mind the weighting by price performance relative to the index, tempered by volatility (going back as much as three years), here are the top 10 holdings of the <a href=\"https://laohu8.com/S/IHPXF\">iShares MSCI</a> USA Momentum Factor ETF:</p>\n<table>\n <tbody>\n  <tr>\n   <td>Company</td>\n   <td>Ticker</td>\n   <td>Share of MTUM</td>\n  </tr>\n  <tr>\n   <td>Tesla Inc.</td>\n   <td>TSLA</td>\n   <td>5.00%</td>\n  </tr>\n  <tr>\n   <td>JPMorgan Chase &amp; Co.</td>\n   <td>JPM</td>\n   <td>4.76%</td>\n  </tr>\n  <tr>\n   <td>Berkshire Hathaway Inc. Class B</td>\n   <td>BRK.B</td>\n   <td>4.58%</td>\n  </tr>\n  <tr>\n   <td>Walt Disney Co.</td>\n   <td>DIS</td>\n   <td>4.48%</td>\n  </tr>\n  <tr>\n   <td>$Bank of America Corp(BAC-N)$.</td>\n   <td>BAC</td>\n   <td>4.29%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings Inc.</td>\n   <td>PYPL</td>\n   <td>3.66%</td>\n  </tr>\n  <tr>\n   <td>Wells Fargo &amp; Co.</td>\n   <td>WFC</td>\n   <td>3.11%</td>\n  </tr>\n  <tr>\n   <td>Applied Materials Inc.</td>\n   <td>AMAT</td>\n   <td>3.00%</td>\n  </tr>\n  <tr>\n   <td>Alphabet Inc. Class C</td>\n   <td>GOOG</td>\n   <td>2.67%</td>\n  </tr>\n  <tr>\n   <td>Alphabet Inc. Class A</td>\n   <td>GOOGL</td>\n   <td>2.45%</td>\n  </tr>\n  <tr>\n   <td>Goldman Sachs Group Inc.</td>\n   <td>GS</td>\n   <td>2.30%</td>\n  </tr>\n  <tr>\n   <td>(FactSet)</td>\n   <td></td>\n   <td></td>\n  </tr>\n </tbody>\n</table>\n<p>Actually, there are 11 stocks listed, as MTUM holds both share classes of Alphabet Inc. Banks and insurers make up half the list, which makes sense because financials have been the second-best performing sector in the S&amp;P 500 , after the materials sector.</p>\n<p>Momentum stock screen -- expected sales growth</p>\n<p>Thinking again about financials, they have had plenty of momentum as investors have gained confidence the U.S. economy will continue roaring back from the damage caused by the coronavirus pandemic.</p>\n<p>But revenue growth can be an important driver, especially for individual stock prices over the long term. From here, the financials might not be the best place to look for rapidly rising revenue over the next two years.</p>\n<p>Starting with the 125 momentum stocks held by MTUM, here are the 15 companies expected by analysts polled by FactSet to increase revenue the most over the next two calendar years, with 2021 as the baseline. The figures are in millions of dollars:</p>\n<p>Those are stellar sales-growth numbers -- if the analysts are close to being correct. Many of the stocks are also expensive relative to the expected 2023 sales numbers. In comparison, the <a href=\"https://laohu8.com/S/EMDI\">iShares</a> S&amp;P 500 Growth ETF <a href=\"https://laohu8.com/S/IVW\">$(IVW)$</a> (which tracks the entire S&amp;P 500 Growth Index) trades for 4.2 times estimated 2023 sales.</p>\n<p>Plug Power Inc. <a href=\"https://laohu8.com/S/PLUG\">$(PLUG)$</a> tops the list, with analysts expecting sales to increase to $1.1 billion in 2023. The company said on June 10 it would build a hydrogen-production plant in Camden County, Ga.</p>\n<p><a href=\"https://laohu8.com/S/SNAP\">Snap Inc</a>. (SNAP) CEO Evan Spiegal said recently the company had grown to 500 million active daily users and that almost half of U.S. smartphone users were using Snapchat.</p>\n<p>Novavax Inc. <a href=\"https://laohu8.com/S/NVAX\">$(NVAX)$</a> expects to apply for FDA approval of its coronavirus vaccine during the third quarter.</p>\n<p><a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> (CVNA) has been on a tear, with used-car demand spiking in the wake of component shortages for automobile production. The company's sales by units increased 76% in the first quarter from a year earlier.</p>\n<p>Uber Technologies Inc. <a href=\"https://laohu8.com/S/UBER\">$(UBER)$</a> and Lyft Inc <a href=\"https://laohu8.com/S/LYFT\">$(LYFT)$</a> are also expected to ride the economic recovery wave, although analysts expect Lyft to take longer to exceed its pre-pandemic revenue level .</p>\n<p><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> (PLTR) rounds out the list. The developer of software used by government defense and intelligence agencies was included in this analysis of meme stocks .</p>\n<p>Earnings</p>\n<p>Some of these companies are still in relatively early growth stages, and aren't expected to achieve full-year profitability until 2023. Here are consensus earnings-per-share estimates for three years:</p>\n<p>Those are very high price-to-earnings ratios based on current stock prices and consensus estimates for 2023. But for rapidly growing companies, earnings typically aren't a priority, which explains why Amazon.com Inc. <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a> always trades at a high P/E. In comparison, the the <a href=\"https://laohu8.com/S/EMEY\">iShares</a> S&amp;P 500 Growth ETF trades for 23.3 times its weighted aggregate consensus earnings estimate for 2023.</p>\n<p>Wall Street's opinion</p>\n<p>Here's a summary of opinion about the 15 companies held by MTUM that analysts expect to grow their revenue the most over the next two years:</p>\n<p>The 12-month price targets may not be useful -- for traders, this is an eternity; it may be a short period for long-term investors looking to profit for years as sales (and hopefully earnings, eventually) compound. It is important to do your own research and form your own opinion about a company's financial health and its ability to remain competitive.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc.","CVNA":"Carvana Co.","SNAP":"Snap Inc","PLUG":"普拉格能源","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142206100","content_text":"Several companies on a stock screen have estimated two-year revenue growth of over 100%.\nThere are many broad approaches to the stock market for selecting individual companies or groups for investments. Momentum investing -- trying to ride the wave of other investors' sentiment -- is popular for day-traders, especially during the current meme-stock craze. But it can also work over the long term.\nBelow is a list of momentum stocks of companies expected to show the strongest sales growth over the next two years.\nMomentum ETF\nTo begin with a large group of momentum stocks, we can look at the iShares MSCI USA Momentum Factor ETF (MTUM). This is the largest U.S. ETF that follows a momentum strategy, according to Mark Hulbert performance relative to its benchmark, the S&P 500 Growth Index.\nFor example, the largest holding of the ETF is Tesla Inc. $(TSLA)$, which \"has experienced strong risk-adjusted performance related to the market over the past 12 months,\" according to iShares (a subsidiary of BlackRock Inc. $(BLK)$). But shares of Merck & Co. Inc. $(MRK)$ are excluded from MTUM because even though iShares considered its 12-month return \"attractive,\" the stock's six-month risk-adjusted return underperformed the benchmark.\nSo keeping in mind the weighting by price performance relative to the index, tempered by volatility (going back as much as three years), here are the top 10 holdings of the iShares MSCI USA Momentum Factor ETF:\n\n\n\nCompany\nTicker\nShare of MTUM\n\n\nTesla Inc.\nTSLA\n5.00%\n\n\nJPMorgan Chase & Co.\nJPM\n4.76%\n\n\nBerkshire Hathaway Inc. Class B\nBRK.B\n4.58%\n\n\nWalt Disney Co.\nDIS\n4.48%\n\n\n$Bank of America Corp(BAC-N)$.\nBAC\n4.29%\n\n\nPayPal Holdings Inc.\nPYPL\n3.66%\n\n\nWells Fargo & Co.\nWFC\n3.11%\n\n\nApplied Materials Inc.\nAMAT\n3.00%\n\n\nAlphabet Inc. Class C\nGOOG\n2.67%\n\n\nAlphabet Inc. Class A\nGOOGL\n2.45%\n\n\nGoldman Sachs Group Inc.\nGS\n2.30%\n\n\n(FactSet)\n\n\n\n\n\nActually, there are 11 stocks listed, as MTUM holds both share classes of Alphabet Inc. Banks and insurers make up half the list, which makes sense because financials have been the second-best performing sector in the S&P 500 , after the materials sector.\nMomentum stock screen -- expected sales growth\nThinking again about financials, they have had plenty of momentum as investors have gained confidence the U.S. economy will continue roaring back from the damage caused by the coronavirus pandemic.\nBut revenue growth can be an important driver, especially for individual stock prices over the long term. From here, the financials might not be the best place to look for rapidly rising revenue over the next two years.\nStarting with the 125 momentum stocks held by MTUM, here are the 15 companies expected by analysts polled by FactSet to increase revenue the most over the next two calendar years, with 2021 as the baseline. The figures are in millions of dollars:\nThose are stellar sales-growth numbers -- if the analysts are close to being correct. Many of the stocks are also expensive relative to the expected 2023 sales numbers. In comparison, the iShares S&P 500 Growth ETF $(IVW)$ (which tracks the entire S&P 500 Growth Index) trades for 4.2 times estimated 2023 sales.\nPlug Power Inc. $(PLUG)$ tops the list, with analysts expecting sales to increase to $1.1 billion in 2023. The company said on June 10 it would build a hydrogen-production plant in Camden County, Ga.\nSnap Inc. (SNAP) CEO Evan Spiegal said recently the company had grown to 500 million active daily users and that almost half of U.S. smartphone users were using Snapchat.\nNovavax Inc. $(NVAX)$ expects to apply for FDA approval of its coronavirus vaccine during the third quarter.\nCarvana Co. (CVNA) has been on a tear, with used-car demand spiking in the wake of component shortages for automobile production. The company's sales by units increased 76% in the first quarter from a year earlier.\nUber Technologies Inc. $(UBER)$ and Lyft Inc $(LYFT)$ are also expected to ride the economic recovery wave, although analysts expect Lyft to take longer to exceed its pre-pandemic revenue level .\nPalantir Technologies Inc. (PLTR) rounds out the list. The developer of software used by government defense and intelligence agencies was included in this analysis of meme stocks .\nEarnings\nSome of these companies are still in relatively early growth stages, and aren't expected to achieve full-year profitability until 2023. Here are consensus earnings-per-share estimates for three years:\nThose are very high price-to-earnings ratios based on current stock prices and consensus estimates for 2023. But for rapidly growing companies, earnings typically aren't a priority, which explains why Amazon.com Inc. $(AMZN)$ always trades at a high P/E. In comparison, the the iShares S&P 500 Growth ETF trades for 23.3 times its weighted aggregate consensus earnings estimate for 2023.\nWall Street's opinion\nHere's a summary of opinion about the 15 companies held by MTUM that analysts expect to grow their revenue the most over the next two years:\nThe 12-month price targets may not be useful -- for traders, this is an eternity; it may be a short period for long-term investors looking to profit for years as sales (and hopefully earnings, eventually) compound. It is important to do your own research and form your own opinion about a company's financial health and its ability to remain competitive.","news_type":1},"isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":159944514,"gmtCreate":1624938589238,"gmtModify":1703848405619,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Like n comment&nbsp;","listText":"Like n comment&nbsp;","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/159944514","repostId":"2147837316","repostType":4,"repost":{"id":"2147837316","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624921533,"share":"https://ttm.financial/m/news/2147837316?lang=&edition=fundamental","pubTime":"2021-06-29 07:05","market":"us","language":"en","title":"Tech stock rally sends S&P and Nasdaq to record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2147837316","media":"Reuters","summary":" - The Nasdaq and S&P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.Big tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&P 500 and the Nasdaq.The S&P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.In contrast, cycl","content":"<p>(Reuters) - The Nasdaq and S&amp;P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.</p>\n<p>Big tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&amp;P 500 and the Nasdaq.</p>\n<p>The S&amp;P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.</p>\n<p>In contrast, cyclical sectors dropped sharply amid fears over a spike in COVID-19 cases across Asia. Financials and energy posted the biggest sectoral loss on S&amp;P 500, down by 0.81% and 3.33%, respectively.</p>\n<p>“It’s end of the quarter and investors may want to take some profits and rotate out of energy and stick with tech,” said Sam Stovall, chief investment strategist at CFRA Research in New York.</p>\n<p>Stovall expects stocks should continue their near-term climb as investors await the new earnings season, in which year-over-year earnings growth of S&amp;P 500 companies is expected to top 60%.</p>\n<p>The Dow Jones Industrial Average fell 150.57 points, or 0.44%, to close at 34,283.27. The S&amp;P 500 pared earlier losses and advanced from Friday’s record high by gaining 9.91 points, or 0.23%, to 4,290.61. The Nasdaq Composite added 140.12 points, or 0.98%, to 14,500.51.</p>\n<p>Both the S&amp;P 500 and the Nasdaq hit a series of record highs last week. the tech-heavy Nasdaq’s 5% gain in June is outpacing its peers as investors pile back in to tech-oriented growth stocks on diminishing worries about runaway inflation.</p>\n<p>“We believe with the Fed putting a realistic goal post, investors now have much more of a risk-on mentality going into the second half of the year. A lot of these tech names have underperformed, while fundamentals were very robust going into the June quarter,” said Wedbush Securities analyst Daniel Ives, who expects the Nasdaq to hit 16,000 by year-end.</p>\n<p>Facebook jumped over 4% as a U.S. judge granted the company’s motion to dismiss a Federal Trade Commission lawsuit. The social media giant finished Monday with over $1 trillion in market capitalization.</p>\n<p>On the Nasdaq 100, the largest gainer was Nvidia Corp, which rose 5.0% after major chip makers Broadcom Inc, Marvell and Taiwan-based MediaTek endorsed its $40 billion deal to buy UK chip designer Arm.</p>\n<p>With the S&amp;P 500 up almost 14% as the first half of 2021 draws to a close, activity in some areas of the market indicates concern over potential volatility, with some investors suggesting the market may be overdue for a significant pullback.</p>\n<p>On the economic front, investor attention will be focused on consumer confidence data, a private jobs report and a crucial monthly employment report due later this week. Quarterly results from Micron Technology Inc and Walgreens Boots Alliance are also slated for this week.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 36 new 52-week highs and no new lows; the Nasdaq Composite recorded 100 new highs and 31 new lows.</p>\n<p>Volume on U.S. exchanges was 9.55 billion shares, compared with the 11.17 billion average for the full session over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tech stock rally sends S&P and Nasdaq to record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTech stock rally sends S&P and Nasdaq to record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-29 07:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) - The Nasdaq and S&amp;P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.</p>\n<p>Big tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&amp;P 500 and the Nasdaq.</p>\n<p>The S&amp;P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.</p>\n<p>In contrast, cyclical sectors dropped sharply amid fears over a spike in COVID-19 cases across Asia. Financials and energy posted the biggest sectoral loss on S&amp;P 500, down by 0.81% and 3.33%, respectively.</p>\n<p>“It’s end of the quarter and investors may want to take some profits and rotate out of energy and stick with tech,” said Sam Stovall, chief investment strategist at CFRA Research in New York.</p>\n<p>Stovall expects stocks should continue their near-term climb as investors await the new earnings season, in which year-over-year earnings growth of S&amp;P 500 companies is expected to top 60%.</p>\n<p>The Dow Jones Industrial Average fell 150.57 points, or 0.44%, to close at 34,283.27. The S&amp;P 500 pared earlier losses and advanced from Friday’s record high by gaining 9.91 points, or 0.23%, to 4,290.61. The Nasdaq Composite added 140.12 points, or 0.98%, to 14,500.51.</p>\n<p>Both the S&amp;P 500 and the Nasdaq hit a series of record highs last week. the tech-heavy Nasdaq’s 5% gain in June is outpacing its peers as investors pile back in to tech-oriented growth stocks on diminishing worries about runaway inflation.</p>\n<p>“We believe with the Fed putting a realistic goal post, investors now have much more of a risk-on mentality going into the second half of the year. A lot of these tech names have underperformed, while fundamentals were very robust going into the June quarter,” said Wedbush Securities analyst Daniel Ives, who expects the Nasdaq to hit 16,000 by year-end.</p>\n<p>Facebook jumped over 4% as a U.S. judge granted the company’s motion to dismiss a Federal Trade Commission lawsuit. The social media giant finished Monday with over $1 trillion in market capitalization.</p>\n<p>On the Nasdaq 100, the largest gainer was Nvidia Corp, which rose 5.0% after major chip makers Broadcom Inc, Marvell and Taiwan-based MediaTek endorsed its $40 billion deal to buy UK chip designer Arm.</p>\n<p>With the S&amp;P 500 up almost 14% as the first half of 2021 draws to a close, activity in some areas of the market indicates concern over potential volatility, with some investors suggesting the market may be overdue for a significant pullback.</p>\n<p>On the economic front, investor attention will be focused on consumer confidence data, a private jobs report and a crucial monthly employment report due later this week. Quarterly results from Micron Technology Inc and Walgreens Boots Alliance are also slated for this week.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 36 new 52-week highs and no new lows; the Nasdaq Composite recorded 100 new highs and 31 new lows.</p>\n<p>Volume on U.S. exchanges was 9.55 billion shares, compared with the 11.17 billion average for the full session over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF",".SPX":"S&P 500 Index","PSQ":"纳指反向ETF","WBA":"沃尔格林联合博姿",".DJI":"道琼斯","QLD":"纳指两倍做多ETF","MU":"美光科技","TWTR":"Twitter","TQQQ":"纳指三倍做多ETF","NVDA":"英伟达","NFLX":"奈飞","SQQQ":"纳指三倍做空ETF","NDAQ":"纳斯达克OMX交易所"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147837316","content_text":"(Reuters) - The Nasdaq and S&P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.\nBig tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&P 500 and the Nasdaq.\nThe S&P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.\nIn contrast, cyclical sectors dropped sharply amid fears over a spike in COVID-19 cases across Asia. Financials and energy posted the biggest sectoral loss on S&P 500, down by 0.81% and 3.33%, respectively.\n“It’s end of the quarter and investors may want to take some profits and rotate out of energy and stick with tech,” said Sam Stovall, chief investment strategist at CFRA Research in New York.\nStovall expects stocks should continue their near-term climb as investors await the new earnings season, in which year-over-year earnings growth of S&P 500 companies is expected to top 60%.\nThe Dow Jones Industrial Average fell 150.57 points, or 0.44%, to close at 34,283.27. The S&P 500 pared earlier losses and advanced from Friday’s record high by gaining 9.91 points, or 0.23%, to 4,290.61. The Nasdaq Composite added 140.12 points, or 0.98%, to 14,500.51.\nBoth the S&P 500 and the Nasdaq hit a series of record highs last week. the tech-heavy Nasdaq’s 5% gain in June is outpacing its peers as investors pile back in to tech-oriented growth stocks on diminishing worries about runaway inflation.\n“We believe with the Fed putting a realistic goal post, investors now have much more of a risk-on mentality going into the second half of the year. A lot of these tech names have underperformed, while fundamentals were very robust going into the June quarter,” said Wedbush Securities analyst Daniel Ives, who expects the Nasdaq to hit 16,000 by year-end.\nFacebook jumped over 4% as a U.S. judge granted the company’s motion to dismiss a Federal Trade Commission lawsuit. The social media giant finished Monday with over $1 trillion in market capitalization.\nOn the Nasdaq 100, the largest gainer was Nvidia Corp, which rose 5.0% after major chip makers Broadcom Inc, Marvell and Taiwan-based MediaTek endorsed its $40 billion deal to buy UK chip designer Arm.\nWith the S&P 500 up almost 14% as the first half of 2021 draws to a close, activity in some areas of the market indicates concern over potential volatility, with some investors suggesting the market may be overdue for a significant pullback.\nOn the economic front, investor attention will be focused on consumer confidence data, a private jobs report and a crucial monthly employment report due later this week. Quarterly results from Micron Technology Inc and Walgreens Boots Alliance are also slated for this week.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored decliners.\nThe S&P 500 posted 36 new 52-week highs and no new lows; the Nasdaq Composite recorded 100 new highs and 31 new lows.\nVolume on U.S. exchanges was 9.55 billion shares, compared with the 11.17 billion average for the full session over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149284466,"gmtCreate":1625730748455,"gmtModify":1703747285868,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/149284466","repostId":"1140881081","repostType":4,"repost":{"id":"1140881081","kind":"news","pubTimestamp":1625714447,"share":"https://ttm.financial/m/news/1140881081?lang=&edition=fundamental","pubTime":"2021-07-08 11:20","market":"hk","language":"en","title":"Why Apple Stock Climbed to a New High Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1140881081","media":"The motley fool","summary":"Shares of $Apple$rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.JPMorgan analyst Samik Chatterjee reiterated his overweight rating on Apple's stock yesterday and boosted his share price forecast from $165 to $170. His new estimate implies potential gains to investors of roughly 18% in the coming year.Chatterjee noted that Apple underperformed theS&P 500and$Nasdaq$in the first half of 202","content":"<p>What happened</p>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/AAPL\">Apple</a></b>(NASDAQ:AAPL)rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.</p>\n<p>So what</p>\n<p>JPMorgan analyst Samik Chatterjee reiterated his overweight rating on Apple's stock yesterday and boosted his share price forecast from $165 to $170. His new estimate implies potential gains to investors of roughly 18% in the coming year.</p>\n<p>Chatterjee noted that Apple underperformed the<b>S&amp;P 500</b>and<b><a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a></b>in the first half of 2021. Yet he expects thetechtitan to post strong sales of both current and future models of the iPhone. Thus, Chatterjee posits that Apple's shares could generate strong gains for shareholders in the second half of the year ahead of the launch of the iPhone 13.</p>\n<p>Now what</p>\n<p>The recent rally in Apple's stock price suggests many investors agree with Chatterjee's bullish outlook. They're likely correct to do so. Robust iPhone volumes tend to also drive sales of Apple's high-margin services and fast-growing wearables revenue. So, if it does deliver blowout iPhone sales figures, Apple could enjoy an earnings bonanza later this year. This potential profit windfall, combined with Apple's bountiful share repurchases and steadily growing dividend, gives shareholders multiple ways to win.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Apple Stock Climbed to a New High Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Apple Stock Climbed to a New High Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/07/why-apple-stock-climbed-to-a-new-high-today/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Apple(NASDAQ:AAPL)rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/07/why-apple-stock-climbed-to-a-new-high-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","NGD":"New Gold","03086":"华夏纳指","AAPL":"苹果"},"source_url":"https://www.fool.com/investing/2021/07/07/why-apple-stock-climbed-to-a-new-high-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140881081","content_text":"What happened\nShares of Apple(NASDAQ:AAPL)rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.\nSo what\nJPMorgan analyst Samik Chatterjee reiterated his overweight rating on Apple's stock yesterday and boosted his share price forecast from $165 to $170. His new estimate implies potential gains to investors of roughly 18% in the coming year.\nChatterjee noted that Apple underperformed theS&P 500andNasdaqin the first half of 2021. Yet he expects thetechtitan to post strong sales of both current and future models of the iPhone. Thus, Chatterjee posits that Apple's shares could generate strong gains for shareholders in the second half of the year ahead of the launch of the iPhone 13.\nNow what\nThe recent rally in Apple's stock price suggests many investors agree with Chatterjee's bullish outlook. They're likely correct to do so. Robust iPhone volumes tend to also drive sales of Apple's high-margin services and fast-growing wearables revenue. So, if it does deliver blowout iPhone sales figures, Apple could enjoy an earnings bonanza later this year. This potential profit windfall, combined with Apple's bountiful share repurchases and steadily growing dividend, gives shareholders multiple ways to win.","news_type":1},"isVote":1,"tweetType":1,"viewCount":509,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186284050,"gmtCreate":1623501898270,"gmtModify":1704205201311,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Well well","listText":"Well well","text":"Well well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/186284050","repostId":"2142206100","repostType":4,"repost":{"id":"2142206100","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623470400,"share":"https://ttm.financial/m/news/2142206100?lang=&edition=fundamental","pubTime":"2021-06-12 12:00","market":"hk","language":"en","title":"15 momentum stocks expected to show the best sales growth over the next two years, including Carvana, Tesla and Palantir","url":"https://stock-news.laohu8.com/highlight/detail?id=2142206100","media":"Dow Jones","summary":"Several companies on a stock screen have estimated two-year revenue growth of over 100%.\nThere are m","content":"<p>Several companies on a stock screen have estimated two-year revenue growth of over 100%.</p>\n<p>There are many broad approaches to the stock market for selecting individual companies or groups for investments. Momentum investing -- trying to ride the wave of other investors' sentiment -- is popular for day-traders, especially during the current meme-stock craze. But it can also work over the long term.</p>\n<p>Below is a list of momentum stocks of companies expected to show the strongest sales growth over the next two years.</p>\n<p>Momentum ETF</p>\n<p>To begin with a large group of momentum stocks, we can look at the <a href=\"https://laohu8.com/S/MTUM\">iShares MSCI USA Momentum Factor</a> ETF (MTUM). This is the largest U.S. ETF that follows a momentum strategy, according to Mark Hulbert performance relative to its benchmark, the S&amp;P 500 Growth Index.</p>\n<p>For example, the largest holding of the ETF is Tesla Inc. <a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, which \"has experienced strong risk-adjusted performance related to the market over the past 12 months,\" according to <a href=\"https://laohu8.com/S/EEME\">iShares</a> (a subsidiary of BlackRock Inc. <a href=\"https://laohu8.com/S/BLK\">$(BLK)$</a>). But shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> are excluded from MTUM because even though <a href=\"https://laohu8.com/S/EGRW\">iShares</a> considered its 12-month return \"attractive,\" the stock's six-month risk-adjusted return underperformed the benchmark.</p>\n<p>So keeping in mind the weighting by price performance relative to the index, tempered by volatility (going back as much as three years), here are the top 10 holdings of the <a href=\"https://laohu8.com/S/IHPXF\">iShares MSCI</a> USA Momentum Factor ETF:</p>\n<table>\n <tbody>\n  <tr>\n   <td>Company</td>\n   <td>Ticker</td>\n   <td>Share of MTUM</td>\n  </tr>\n  <tr>\n   <td>Tesla Inc.</td>\n   <td>TSLA</td>\n   <td>5.00%</td>\n  </tr>\n  <tr>\n   <td>JPMorgan Chase &amp; Co.</td>\n   <td>JPM</td>\n   <td>4.76%</td>\n  </tr>\n  <tr>\n   <td>Berkshire Hathaway Inc. Class B</td>\n   <td>BRK.B</td>\n   <td>4.58%</td>\n  </tr>\n  <tr>\n   <td>Walt Disney Co.</td>\n   <td>DIS</td>\n   <td>4.48%</td>\n  </tr>\n  <tr>\n   <td>$Bank of America Corp(BAC-N)$.</td>\n   <td>BAC</td>\n   <td>4.29%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings Inc.</td>\n   <td>PYPL</td>\n   <td>3.66%</td>\n  </tr>\n  <tr>\n   <td>Wells Fargo &amp; Co.</td>\n   <td>WFC</td>\n   <td>3.11%</td>\n  </tr>\n  <tr>\n   <td>Applied Materials Inc.</td>\n   <td>AMAT</td>\n   <td>3.00%</td>\n  </tr>\n  <tr>\n   <td>Alphabet Inc. Class C</td>\n   <td>GOOG</td>\n   <td>2.67%</td>\n  </tr>\n  <tr>\n   <td>Alphabet Inc. Class A</td>\n   <td>GOOGL</td>\n   <td>2.45%</td>\n  </tr>\n  <tr>\n   <td>Goldman Sachs Group Inc.</td>\n   <td>GS</td>\n   <td>2.30%</td>\n  </tr>\n  <tr>\n   <td>(FactSet)</td>\n   <td></td>\n   <td></td>\n  </tr>\n </tbody>\n</table>\n<p>Actually, there are 11 stocks listed, as MTUM holds both share classes of Alphabet Inc. Banks and insurers make up half the list, which makes sense because financials have been the second-best performing sector in the S&amp;P 500 , after the materials sector.</p>\n<p>Momentum stock screen -- expected sales growth</p>\n<p>Thinking again about financials, they have had plenty of momentum as investors have gained confidence the U.S. economy will continue roaring back from the damage caused by the coronavirus pandemic.</p>\n<p>But revenue growth can be an important driver, especially for individual stock prices over the long term. From here, the financials might not be the best place to look for rapidly rising revenue over the next two years.</p>\n<p>Starting with the 125 momentum stocks held by MTUM, here are the 15 companies expected by analysts polled by FactSet to increase revenue the most over the next two calendar years, with 2021 as the baseline. The figures are in millions of dollars:</p>\n<p>Those are stellar sales-growth numbers -- if the analysts are close to being correct. Many of the stocks are also expensive relative to the expected 2023 sales numbers. In comparison, the <a href=\"https://laohu8.com/S/EMDI\">iShares</a> S&amp;P 500 Growth ETF <a href=\"https://laohu8.com/S/IVW\">$(IVW)$</a> (which tracks the entire S&amp;P 500 Growth Index) trades for 4.2 times estimated 2023 sales.</p>\n<p>Plug Power Inc. <a href=\"https://laohu8.com/S/PLUG\">$(PLUG)$</a> tops the list, with analysts expecting sales to increase to $1.1 billion in 2023. The company said on June 10 it would build a hydrogen-production plant in Camden County, Ga.</p>\n<p><a href=\"https://laohu8.com/S/SNAP\">Snap Inc</a>. (SNAP) CEO Evan Spiegal said recently the company had grown to 500 million active daily users and that almost half of U.S. smartphone users were using Snapchat.</p>\n<p>Novavax Inc. <a href=\"https://laohu8.com/S/NVAX\">$(NVAX)$</a> expects to apply for FDA approval of its coronavirus vaccine during the third quarter.</p>\n<p><a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> (CVNA) has been on a tear, with used-car demand spiking in the wake of component shortages for automobile production. The company's sales by units increased 76% in the first quarter from a year earlier.</p>\n<p>Uber Technologies Inc. <a href=\"https://laohu8.com/S/UBER\">$(UBER)$</a> and Lyft Inc <a href=\"https://laohu8.com/S/LYFT\">$(LYFT)$</a> are also expected to ride the economic recovery wave, although analysts expect Lyft to take longer to exceed its pre-pandemic revenue level .</p>\n<p><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> (PLTR) rounds out the list. The developer of software used by government defense and intelligence agencies was included in this analysis of meme stocks .</p>\n<p>Earnings</p>\n<p>Some of these companies are still in relatively early growth stages, and aren't expected to achieve full-year profitability until 2023. Here are consensus earnings-per-share estimates for three years:</p>\n<p>Those are very high price-to-earnings ratios based on current stock prices and consensus estimates for 2023. But for rapidly growing companies, earnings typically aren't a priority, which explains why Amazon.com Inc. <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a> always trades at a high P/E. In comparison, the the <a href=\"https://laohu8.com/S/EMEY\">iShares</a> S&amp;P 500 Growth ETF trades for 23.3 times its weighted aggregate consensus earnings estimate for 2023.</p>\n<p>Wall Street's opinion</p>\n<p>Here's a summary of opinion about the 15 companies held by MTUM that analysts expect to grow their revenue the most over the next two years:</p>\n<p>The 12-month price targets may not be useful -- for traders, this is an eternity; it may be a short period for long-term investors looking to profit for years as sales (and hopefully earnings, eventually) compound. It is important to do your own research and form your own opinion about a company's financial health and its ability to remain competitive.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>15 momentum stocks expected to show the best sales growth over the next two years, including Carvana, Tesla and Palantir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n15 momentum stocks expected to show the best sales growth over the next two years, including Carvana, Tesla and Palantir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-12 12:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Several companies on a stock screen have estimated two-year revenue growth of over 100%.</p>\n<p>There are many broad approaches to the stock market for selecting individual companies or groups for investments. Momentum investing -- trying to ride the wave of other investors' sentiment -- is popular for day-traders, especially during the current meme-stock craze. But it can also work over the long term.</p>\n<p>Below is a list of momentum stocks of companies expected to show the strongest sales growth over the next two years.</p>\n<p>Momentum ETF</p>\n<p>To begin with a large group of momentum stocks, we can look at the <a href=\"https://laohu8.com/S/MTUM\">iShares MSCI USA Momentum Factor</a> ETF (MTUM). This is the largest U.S. ETF that follows a momentum strategy, according to Mark Hulbert performance relative to its benchmark, the S&amp;P 500 Growth Index.</p>\n<p>For example, the largest holding of the ETF is Tesla Inc. <a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, which \"has experienced strong risk-adjusted performance related to the market over the past 12 months,\" according to <a href=\"https://laohu8.com/S/EEME\">iShares</a> (a subsidiary of BlackRock Inc. <a href=\"https://laohu8.com/S/BLK\">$(BLK)$</a>). But shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> are excluded from MTUM because even though <a href=\"https://laohu8.com/S/EGRW\">iShares</a> considered its 12-month return \"attractive,\" the stock's six-month risk-adjusted return underperformed the benchmark.</p>\n<p>So keeping in mind the weighting by price performance relative to the index, tempered by volatility (going back as much as three years), here are the top 10 holdings of the <a href=\"https://laohu8.com/S/IHPXF\">iShares MSCI</a> USA Momentum Factor ETF:</p>\n<table>\n <tbody>\n  <tr>\n   <td>Company</td>\n   <td>Ticker</td>\n   <td>Share of MTUM</td>\n  </tr>\n  <tr>\n   <td>Tesla Inc.</td>\n   <td>TSLA</td>\n   <td>5.00%</td>\n  </tr>\n  <tr>\n   <td>JPMorgan Chase &amp; Co.</td>\n   <td>JPM</td>\n   <td>4.76%</td>\n  </tr>\n  <tr>\n   <td>Berkshire Hathaway Inc. Class B</td>\n   <td>BRK.B</td>\n   <td>4.58%</td>\n  </tr>\n  <tr>\n   <td>Walt Disney Co.</td>\n   <td>DIS</td>\n   <td>4.48%</td>\n  </tr>\n  <tr>\n   <td>$Bank of America Corp(BAC-N)$.</td>\n   <td>BAC</td>\n   <td>4.29%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings Inc.</td>\n   <td>PYPL</td>\n   <td>3.66%</td>\n  </tr>\n  <tr>\n   <td>Wells Fargo &amp; Co.</td>\n   <td>WFC</td>\n   <td>3.11%</td>\n  </tr>\n  <tr>\n   <td>Applied Materials Inc.</td>\n   <td>AMAT</td>\n   <td>3.00%</td>\n  </tr>\n  <tr>\n   <td>Alphabet Inc. Class C</td>\n   <td>GOOG</td>\n   <td>2.67%</td>\n  </tr>\n  <tr>\n   <td>Alphabet Inc. Class A</td>\n   <td>GOOGL</td>\n   <td>2.45%</td>\n  </tr>\n  <tr>\n   <td>Goldman Sachs Group Inc.</td>\n   <td>GS</td>\n   <td>2.30%</td>\n  </tr>\n  <tr>\n   <td>(FactSet)</td>\n   <td></td>\n   <td></td>\n  </tr>\n </tbody>\n</table>\n<p>Actually, there are 11 stocks listed, as MTUM holds both share classes of Alphabet Inc. Banks and insurers make up half the list, which makes sense because financials have been the second-best performing sector in the S&amp;P 500 , after the materials sector.</p>\n<p>Momentum stock screen -- expected sales growth</p>\n<p>Thinking again about financials, they have had plenty of momentum as investors have gained confidence the U.S. economy will continue roaring back from the damage caused by the coronavirus pandemic.</p>\n<p>But revenue growth can be an important driver, especially for individual stock prices over the long term. From here, the financials might not be the best place to look for rapidly rising revenue over the next two years.</p>\n<p>Starting with the 125 momentum stocks held by MTUM, here are the 15 companies expected by analysts polled by FactSet to increase revenue the most over the next two calendar years, with 2021 as the baseline. The figures are in millions of dollars:</p>\n<p>Those are stellar sales-growth numbers -- if the analysts are close to being correct. Many of the stocks are also expensive relative to the expected 2023 sales numbers. In comparison, the <a href=\"https://laohu8.com/S/EMDI\">iShares</a> S&amp;P 500 Growth ETF <a href=\"https://laohu8.com/S/IVW\">$(IVW)$</a> (which tracks the entire S&amp;P 500 Growth Index) trades for 4.2 times estimated 2023 sales.</p>\n<p>Plug Power Inc. <a href=\"https://laohu8.com/S/PLUG\">$(PLUG)$</a> tops the list, with analysts expecting sales to increase to $1.1 billion in 2023. The company said on June 10 it would build a hydrogen-production plant in Camden County, Ga.</p>\n<p><a href=\"https://laohu8.com/S/SNAP\">Snap Inc</a>. (SNAP) CEO Evan Spiegal said recently the company had grown to 500 million active daily users and that almost half of U.S. smartphone users were using Snapchat.</p>\n<p>Novavax Inc. <a href=\"https://laohu8.com/S/NVAX\">$(NVAX)$</a> expects to apply for FDA approval of its coronavirus vaccine during the third quarter.</p>\n<p><a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> (CVNA) has been on a tear, with used-car demand spiking in the wake of component shortages for automobile production. The company's sales by units increased 76% in the first quarter from a year earlier.</p>\n<p>Uber Technologies Inc. <a href=\"https://laohu8.com/S/UBER\">$(UBER)$</a> and Lyft Inc <a href=\"https://laohu8.com/S/LYFT\">$(LYFT)$</a> are also expected to ride the economic recovery wave, although analysts expect Lyft to take longer to exceed its pre-pandemic revenue level .</p>\n<p><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> (PLTR) rounds out the list. The developer of software used by government defense and intelligence agencies was included in this analysis of meme stocks .</p>\n<p>Earnings</p>\n<p>Some of these companies are still in relatively early growth stages, and aren't expected to achieve full-year profitability until 2023. Here are consensus earnings-per-share estimates for three years:</p>\n<p>Those are very high price-to-earnings ratios based on current stock prices and consensus estimates for 2023. But for rapidly growing companies, earnings typically aren't a priority, which explains why Amazon.com Inc. <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a> always trades at a high P/E. In comparison, the the <a href=\"https://laohu8.com/S/EMEY\">iShares</a> S&amp;P 500 Growth ETF trades for 23.3 times its weighted aggregate consensus earnings estimate for 2023.</p>\n<p>Wall Street's opinion</p>\n<p>Here's a summary of opinion about the 15 companies held by MTUM that analysts expect to grow their revenue the most over the next two years:</p>\n<p>The 12-month price targets may not be useful -- for traders, this is an eternity; it may be a short period for long-term investors looking to profit for years as sales (and hopefully earnings, eventually) compound. It is important to do your own research and form your own opinion about a company's financial health and its ability to remain competitive.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc.","CVNA":"Carvana Co.","SNAP":"Snap Inc","PLUG":"普拉格能源","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142206100","content_text":"Several companies on a stock screen have estimated two-year revenue growth of over 100%.\nThere are many broad approaches to the stock market for selecting individual companies or groups for investments. Momentum investing -- trying to ride the wave of other investors' sentiment -- is popular for day-traders, especially during the current meme-stock craze. But it can also work over the long term.\nBelow is a list of momentum stocks of companies expected to show the strongest sales growth over the next two years.\nMomentum ETF\nTo begin with a large group of momentum stocks, we can look at the iShares MSCI USA Momentum Factor ETF (MTUM). This is the largest U.S. ETF that follows a momentum strategy, according to Mark Hulbert performance relative to its benchmark, the S&P 500 Growth Index.\nFor example, the largest holding of the ETF is Tesla Inc. $(TSLA)$, which \"has experienced strong risk-adjusted performance related to the market over the past 12 months,\" according to iShares (a subsidiary of BlackRock Inc. $(BLK)$). But shares of Merck & Co. Inc. $(MRK)$ are excluded from MTUM because even though iShares considered its 12-month return \"attractive,\" the stock's six-month risk-adjusted return underperformed the benchmark.\nSo keeping in mind the weighting by price performance relative to the index, tempered by volatility (going back as much as three years), here are the top 10 holdings of the iShares MSCI USA Momentum Factor ETF:\n\n\n\nCompany\nTicker\nShare of MTUM\n\n\nTesla Inc.\nTSLA\n5.00%\n\n\nJPMorgan Chase & Co.\nJPM\n4.76%\n\n\nBerkshire Hathaway Inc. Class B\nBRK.B\n4.58%\n\n\nWalt Disney Co.\nDIS\n4.48%\n\n\n$Bank of America Corp(BAC-N)$.\nBAC\n4.29%\n\n\nPayPal Holdings Inc.\nPYPL\n3.66%\n\n\nWells Fargo & Co.\nWFC\n3.11%\n\n\nApplied Materials Inc.\nAMAT\n3.00%\n\n\nAlphabet Inc. Class C\nGOOG\n2.67%\n\n\nAlphabet Inc. Class A\nGOOGL\n2.45%\n\n\nGoldman Sachs Group Inc.\nGS\n2.30%\n\n\n(FactSet)\n\n\n\n\n\nActually, there are 11 stocks listed, as MTUM holds both share classes of Alphabet Inc. Banks and insurers make up half the list, which makes sense because financials have been the second-best performing sector in the S&P 500 , after the materials sector.\nMomentum stock screen -- expected sales growth\nThinking again about financials, they have had plenty of momentum as investors have gained confidence the U.S. economy will continue roaring back from the damage caused by the coronavirus pandemic.\nBut revenue growth can be an important driver, especially for individual stock prices over the long term. From here, the financials might not be the best place to look for rapidly rising revenue over the next two years.\nStarting with the 125 momentum stocks held by MTUM, here are the 15 companies expected by analysts polled by FactSet to increase revenue the most over the next two calendar years, with 2021 as the baseline. The figures are in millions of dollars:\nThose are stellar sales-growth numbers -- if the analysts are close to being correct. Many of the stocks are also expensive relative to the expected 2023 sales numbers. In comparison, the iShares S&P 500 Growth ETF $(IVW)$ (which tracks the entire S&P 500 Growth Index) trades for 4.2 times estimated 2023 sales.\nPlug Power Inc. $(PLUG)$ tops the list, with analysts expecting sales to increase to $1.1 billion in 2023. The company said on June 10 it would build a hydrogen-production plant in Camden County, Ga.\nSnap Inc. (SNAP) CEO Evan Spiegal said recently the company had grown to 500 million active daily users and that almost half of U.S. smartphone users were using Snapchat.\nNovavax Inc. $(NVAX)$ expects to apply for FDA approval of its coronavirus vaccine during the third quarter.\nCarvana Co. (CVNA) has been on a tear, with used-car demand spiking in the wake of component shortages for automobile production. The company's sales by units increased 76% in the first quarter from a year earlier.\nUber Technologies Inc. $(UBER)$ and Lyft Inc $(LYFT)$ are also expected to ride the economic recovery wave, although analysts expect Lyft to take longer to exceed its pre-pandemic revenue level .\nPalantir Technologies Inc. (PLTR) rounds out the list. The developer of software used by government defense and intelligence agencies was included in this analysis of meme stocks .\nEarnings\nSome of these companies are still in relatively early growth stages, and aren't expected to achieve full-year profitability until 2023. Here are consensus earnings-per-share estimates for three years:\nThose are very high price-to-earnings ratios based on current stock prices and consensus estimates for 2023. But for rapidly growing companies, earnings typically aren't a priority, which explains why Amazon.com Inc. $(AMZN)$ always trades at a high P/E. In comparison, the the iShares S&P 500 Growth ETF trades for 23.3 times its weighted aggregate consensus earnings estimate for 2023.\nWall Street's opinion\nHere's a summary of opinion about the 15 companies held by MTUM that analysts expect to grow their revenue the most over the next two years:\nThe 12-month price targets may not be useful -- for traders, this is an eternity; it may be a short period for long-term investors looking to profit for years as sales (and hopefully earnings, eventually) compound. It is important to do your own research and form your own opinion about a company's financial health and its ability to remain competitive.","news_type":1},"isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149287632,"gmtCreate":1625730785426,"gmtModify":1703747287164,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149287632","repostId":"1100970955","repostType":4,"repost":{"id":"1100970955","kind":"news","pubTimestamp":1625730236,"share":"https://ttm.financial/m/news/1100970955?lang=&edition=fundamental","pubTime":"2021-07-08 15:43","market":"sh","language":"en","title":"Is China set to cut RRR soon? What are the implications?","url":"https://stock-news.laohu8.com/highlight/detail?id=1100970955","media":"Yahoo Finance","summary":"By Kevin Yao\nBEIJING, July 8 (Reuters) - The Chinese government on Wednesday pledged to use timely c","content":"<p>By Kevin Yao</p>\n<p>BEIJING, July 8 (Reuters) - The Chinese government on Wednesday pledged to use timely cuts in the amount of cash that banks must hold as reserves to support the slowing economy, raising expectations about an imminent move to ease policy.</p>\n<p>Such reductions in the reserve requirement ratio (RRR) will help underpin the economy, especially small firms, the cabinet said, taking investors by surprise as most had bet on a gradual tightening of policy.</p>\n<p>All eyes are now on the People's Bank of China (PBOC), which has been gradually scaling back pandemic-driven stimulus to curb debt risks, while maintaining targeted support for small firms.</p>\n<p>An RRR cut would be the first since April 2020 when the economy was jolted by the COVID-19 pandemic.</p>\n<p>IS AN RRR CUT COMING?</p>\n<p>Likely but not guaranteed.</p>\n<p>The PBOC usually follows guidance from the cabinet, which oversees the world's second-largest economy and charts the fundamental course of China's policies.</p>\n<p>In most cases in the past, the PBOC has followed the cabinet's calls for RRR cuts, but not every time. For example, there was no policy move after the cabinet flagged a cut in June 2020.</p>\n<p>Growth in China's economy is slowing, probably to 7-8% in April-June from a record 18.3% expansion in the first quarter, which was heavily skewed by the recoil effect from the sharp slump in activity in early 2020. The current slowdown could deepen due to rising commodity prices.</p>\n<p>Small firms in downstream industries could bear the brunt of rising raw material prices, as they struggle to pass on increased costs to consumers.</p>\n<p>WHEN AND IN WHAT FORM?</p>\n<p>Not certain.</p>\n<p>Most analysts expect a targeted RRR cut for small banks, given that the cabinet emphasised the need to support small firms, but a cut for all lenders cannot be ruled out.</p>\n<p>Analysts at Nomura expect a universal 50-basis point cut in the coming weeks.</p>\n<p>Wen Bin, an economist at Mingsheng Bank, expects a cut towards the end of September, if consumer inflation softens in the coming months.</p>\n<p>An RRR cut could inject permanent funds into the banking system, enabling banks to expand loan books and lower financing costs. Other policy channels such as the medium-term lending facility (MLF) will pump out short- to medium-term funds.</p>\n<p>The PBOC has used MLF loans more frequently in recent years than RRR cuts.</p>\n<p>Expected RRR cuts will help to ease liquidity pressure caused by the maturing of over 4 trillion yuan ($617.2 billion)in MLF loans and net government bond issuance totalling 4.5 trillion yuan in the second half of this year.</p>\n<p>HOW MUCH ROOM FOR FURTHER CUTS?</p>\n<p>There is still room but not as big as before.</p>\n<p>The RRR cut in April 2020 marked the tenth such reduction since early 2018, when the PBOC started an easing cycle, which accelerated significantly from early 2020 after the COVID-19 pandemic paralysed economic activity.</p>\n<p>In May 2020, the PBOC said the average RRR for Chinese financial institutions had fallen by a total of 520 basis points from early 2018 to 9.4%.</p>\n<p>WILL AN RRR CUT CHANGE POLICY COURSE?</p>\n<p>The central bank has been trying to cool credit growth to help rein in debt and financial risks, and that fundamental policy may not change.</p>\n<p>Chinese leaders have pledged to avoid sharp policy turns as the economic recovery is not yet broad-based and balanced.</p>\n<p>The PBOC has kept its benchmark lending rate, the loan prime rate (LPR), unchanged for 14 months.</p>\n<p>The economy is widely expected to grow more than 8% this year, against the government's modest growth target of over 6%, suggesting there is no big pressure to step up easing.</p>\n<p>On the fiscal front, local governments are likely to speed up bond issuance to channel more funds into key projects, helping to stimulate growth.</p>\n<p>An expected RRR cut, along with efforts to guide market interest rates lower, will likely be a policy fine-tuning operation to soothe downward pressure on the economy.</p>\n<p>A former central bank official said earlier this week that Beijing should also guide market interest rates lower to support economic growth and ease funding pressures on local governments, ($1 = 6.4808 Chinese yuan renminbi) (Reporting by Kevin Yao Editing by Shri Navaratnam)</p>","source":"yahoofinance_sg","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is China set to cut RRR soon? What are the implications?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs China set to cut RRR soon? What are the implications?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 15:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/explainer-china-set-cut-rrr-073327973.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Kevin Yao\nBEIJING, July 8 (Reuters) - The Chinese government on Wednesday pledged to use timely cuts in the amount of cash that banks must hold as reserves to support the slowing economy, raising ...</p>\n\n<a href=\"https://finance.yahoo.com/news/explainer-china-set-cut-rrr-073327973.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/explainer-china-set-cut-rrr-073327973.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100970955","content_text":"By Kevin Yao\nBEIJING, July 8 (Reuters) - The Chinese government on Wednesday pledged to use timely cuts in the amount of cash that banks must hold as reserves to support the slowing economy, raising expectations about an imminent move to ease policy.\nSuch reductions in the reserve requirement ratio (RRR) will help underpin the economy, especially small firms, the cabinet said, taking investors by surprise as most had bet on a gradual tightening of policy.\nAll eyes are now on the People's Bank of China (PBOC), which has been gradually scaling back pandemic-driven stimulus to curb debt risks, while maintaining targeted support for small firms.\nAn RRR cut would be the first since April 2020 when the economy was jolted by the COVID-19 pandemic.\nIS AN RRR CUT COMING?\nLikely but not guaranteed.\nThe PBOC usually follows guidance from the cabinet, which oversees the world's second-largest economy and charts the fundamental course of China's policies.\nIn most cases in the past, the PBOC has followed the cabinet's calls for RRR cuts, but not every time. For example, there was no policy move after the cabinet flagged a cut in June 2020.\nGrowth in China's economy is slowing, probably to 7-8% in April-June from a record 18.3% expansion in the first quarter, which was heavily skewed by the recoil effect from the sharp slump in activity in early 2020. The current slowdown could deepen due to rising commodity prices.\nSmall firms in downstream industries could bear the brunt of rising raw material prices, as they struggle to pass on increased costs to consumers.\nWHEN AND IN WHAT FORM?\nNot certain.\nMost analysts expect a targeted RRR cut for small banks, given that the cabinet emphasised the need to support small firms, but a cut for all lenders cannot be ruled out.\nAnalysts at Nomura expect a universal 50-basis point cut in the coming weeks.\nWen Bin, an economist at Mingsheng Bank, expects a cut towards the end of September, if consumer inflation softens in the coming months.\nAn RRR cut could inject permanent funds into the banking system, enabling banks to expand loan books and lower financing costs. Other policy channels such as the medium-term lending facility (MLF) will pump out short- to medium-term funds.\nThe PBOC has used MLF loans more frequently in recent years than RRR cuts.\nExpected RRR cuts will help to ease liquidity pressure caused by the maturing of over 4 trillion yuan ($617.2 billion)in MLF loans and net government bond issuance totalling 4.5 trillion yuan in the second half of this year.\nHOW MUCH ROOM FOR FURTHER CUTS?\nThere is still room but not as big as before.\nThe RRR cut in April 2020 marked the tenth such reduction since early 2018, when the PBOC started an easing cycle, which accelerated significantly from early 2020 after the COVID-19 pandemic paralysed economic activity.\nIn May 2020, the PBOC said the average RRR for Chinese financial institutions had fallen by a total of 520 basis points from early 2018 to 9.4%.\nWILL AN RRR CUT CHANGE POLICY COURSE?\nThe central bank has been trying to cool credit growth to help rein in debt and financial risks, and that fundamental policy may not change.\nChinese leaders have pledged to avoid sharp policy turns as the economic recovery is not yet broad-based and balanced.\nThe PBOC has kept its benchmark lending rate, the loan prime rate (LPR), unchanged for 14 months.\nThe economy is widely expected to grow more than 8% this year, against the government's modest growth target of over 6%, suggesting there is no big pressure to step up easing.\nOn the fiscal front, local governments are likely to speed up bond issuance to channel more funds into key projects, helping to stimulate growth.\nAn expected RRR cut, along with efforts to guide market interest rates lower, will likely be a policy fine-tuning operation to soothe downward pressure on the economy.\nA former central bank official said earlier this week that Beijing should also guide market interest rates lower to support economic growth and ease funding pressures on local governments, ($1 = 6.4808 Chinese yuan renminbi) (Reporting by Kevin Yao Editing by Shri Navaratnam)","news_type":1},"isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127791491,"gmtCreate":1624868018013,"gmtModify":1703846581916,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127791491","repostId":"2146854378","repostType":4,"repost":{"id":"2146854378","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624865895,"share":"https://ttm.financial/m/news/2146854378?lang=&edition=fundamental","pubTime":"2021-06-28 15:38","market":"us","language":"en","title":"With cloud and AI, IBM broadens 5G deals with Verizon and Telefonica","url":"https://stock-news.laohu8.com/highlight/detail?id=2146854378","media":"Reuters","summary":"BARCELONA, June 28 (Reuters) - IBM will offer telecom operators Verizon and Telefonica new services ","content":"<p>BARCELONA, June 28 (Reuters) - <a href=\"https://laohu8.com/S/IBM\">IBM</a> will offer telecom operators Verizon and Telefonica new services ranging from running 5G over a cloud platform to using artificial intelligence, the U.S. technology company said on Monday.</p>\n<p>Big technology players such as Microsoft and Amazon&nbsp;are vying for a share of 5G revenue by offering telecom operators next-generation software tools.</p>\n<p>IBM, using technology it obtained from buying software firm Red Hat, will offer the telecom operators cloud services to run their networks and assist them in selling products tailored to customers. No financial terms were disclosed about the tie-ups, which broadened IBM's existing partnerships with the two firms.</p>\n<p>A cloud platform uses software instead of physical equipment to perform network functions, helping telecom operators build 5G networks faster, reduce costs and sell customised services.</p>\n<p>\"It's a disruptive time in this particular market segment, telcos are trying to position themselves as the destination for services like augmented reality, machine learning and AI,\" Darell Jordan-Smith, vice president of Redhat, told Reuters.</p>\n<p>On the AI front, IBM and Spain's Telefonica have created a virtual assistant that they say will remove friction points, such as long wait times, by automating the handling of frequently asked questions and tasks like billing.</p>\n<p>\"We see this as an existential moment for telco operators with 5G: architecturally, they're looking to gain more control on their platforms and rethink their network as a digital world rather than a structured physical model,\" said Steve Canepa, IBM's general manager for communications business.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>With cloud and AI, IBM broadens 5G deals with Verizon and Telefonica</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWith cloud and AI, IBM broadens 5G deals with Verizon and Telefonica\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-28 15:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BARCELONA, June 28 (Reuters) - <a href=\"https://laohu8.com/S/IBM\">IBM</a> will offer telecom operators Verizon and Telefonica new services ranging from running 5G over a cloud platform to using artificial intelligence, the U.S. technology company said on Monday.</p>\n<p>Big technology players such as Microsoft and Amazon&nbsp;are vying for a share of 5G revenue by offering telecom operators next-generation software tools.</p>\n<p>IBM, using technology it obtained from buying software firm Red Hat, will offer the telecom operators cloud services to run their networks and assist them in selling products tailored to customers. No financial terms were disclosed about the tie-ups, which broadened IBM's existing partnerships with the two firms.</p>\n<p>A cloud platform uses software instead of physical equipment to perform network functions, helping telecom operators build 5G networks faster, reduce costs and sell customised services.</p>\n<p>\"It's a disruptive time in this particular market segment, telcos are trying to position themselves as the destination for services like augmented reality, machine learning and AI,\" Darell Jordan-Smith, vice president of Redhat, told Reuters.</p>\n<p>On the AI front, IBM and Spain's Telefonica have created a virtual assistant that they say will remove friction points, such as long wait times, by automating the handling of frequently asked questions and tasks like billing.</p>\n<p>\"We see this as an existential moment for telco operators with 5G: architecturally, they're looking to gain more control on their platforms and rethink their network as a digital world rather than a structured physical model,\" said Steve Canepa, IBM's general manager for communications business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VZ":"威瑞森","MSFT":"微软","AMZN":"亚马逊","IBM":"IBM"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146854378","content_text":"BARCELONA, June 28 (Reuters) - IBM will offer telecom operators Verizon and Telefonica new services ranging from running 5G over a cloud platform to using artificial intelligence, the U.S. technology company said on Monday.\nBig technology players such as Microsoft and Amazon are vying for a share of 5G revenue by offering telecom operators next-generation software tools.\nIBM, using technology it obtained from buying software firm Red Hat, will offer the telecom operators cloud services to run their networks and assist them in selling products tailored to customers. No financial terms were disclosed about the tie-ups, which broadened IBM's existing partnerships with the two firms.\nA cloud platform uses software instead of physical equipment to perform network functions, helping telecom operators build 5G networks faster, reduce costs and sell customised services.\n\"It's a disruptive time in this particular market segment, telcos are trying to position themselves as the destination for services like augmented reality, machine learning and AI,\" Darell Jordan-Smith, vice president of Redhat, told Reuters.\nOn the AI front, IBM and Spain's Telefonica have created a virtual assistant that they say will remove friction points, such as long wait times, by automating the handling of frequently asked questions and tasks like billing.\n\"We see this as an existential moment for telco operators with 5G: architecturally, they're looking to gain more control on their platforms and rethink their network as a digital world rather than a structured physical model,\" said Steve Canepa, IBM's general manager for communications business.","news_type":1},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127793510,"gmtCreate":1624867974030,"gmtModify":1703846582241,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127793510","repostId":"1142078063","repostType":4,"repost":{"id":"1142078063","kind":"news","pubTimestamp":1624866368,"share":"https://ttm.financial/m/news/1142078063?lang=&edition=fundamental","pubTime":"2021-06-28 15:46","market":"us","language":"en","title":"This Small-Cap Stock Can Pivot Between Old and New Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142078063","media":"Barrons","summary":"The energy transition is on its way, but for most companies the tangible results won’t show up for y","content":"<p>The energy transition is on its way, but for most companies the tangible results won’t show up for years. At Chart Industries, the action is happening now, and the company’s stock isn’t fully reflecting that yet.</p>\n<p>Chart (ticker: GTLS) makes cryogenic tanks and other equipment to freeze gases and make them easier to isolate and transport. Its products operate behind the scenes in a variety of industries, keeping soda bubbly and delivering oxygen to patients suffering from Covid-19. For now, Chart makes most of its money providing&nbsp;equipment to industrial-gas companies or fossil-fuel energy markets. But its stock offers a way to play both the rebound in traditional energy and the transition to new forms of it.</p>\n<p>“In the case of Big Oil, the energy transition will take 30 years,” says Raymond James analyst Pavel Molchanov. “For Chart, it’s happening in real time.” He has an Outperform rating on the shares and a $165 price target—18% above a recent price of $140.</p>\n<p>Chart is based in the small city of Ball Ground, Ga., but operates all over the globe. Its results have fluctuated with the fortunes of the natural-gas and chemical industries in recent years. Chart mostly persevered through the pandemic, growing earnings to $2.73 a share from $2.52 the previous year, on a slight decline in sales, to $1.2 billion. The company, however, has a record backlog of orders and is entering a much faster growth period, one that more than justifies its valuation of about 26 times next year’s expected earnings.</p>\n<p><img src=\"https://static.tigerbbs.com/333b9c8b2fde68b6acdb0557454fe1e7\" tg-width=\"950\" tg-height=\"625\"></p>\n<p>Chart specializes in taking volatile gases and processing them so they can be contained and transported. That can mean pumping them through heat exchangers, freezing and storing them in cryogenic tanks, and transporting them through insulated pipes. These technologies are used to turn natural gas into liquid form to be transported through pipes or overseas.</p>\n<p>The company has benefited as the shale-drilling revolution and new laws helped the U.S. become a major exporter of natural gas. But the technology that makes it possible to capture natural gas is also useful for capturing and taming other gases.</p>\n<p>“We’re molecule-agnostic,” Chart CEO Jillian Evanko tells&nbsp;<i>Barron’s</i>.</p>\n<p><img src=\"https://static.tigerbbs.com/6651e519519516c310bcc85214b99134\" tg-width=\"956\" tg-height=\"643\"></p>\n<p>Chart’s systems help pump nitrogen into pressurized containers to make nitro cold brew coffee, carbon dioxide into greenhouses to make cannabis plants grow faster, and ozone into water systems to keep them clean. Even more promising are its renewable-energy divisions, like hydrogen and carbon capture. Its specialty products division is the main reason that Chart is expected to grow earnings per share by 44% this year and 33% next year, with an expected long-term growth rate of 25%, according to FactSet. Specialty products now make up 20% of the company’s revenue, but analysts see them growing to nearly half of sales by 2025.</p>\n<p>Hydrogen, an alternative fuel that can produce electricity and power vehicles, is a big opportunity. Chart has been making equipment to process and transport hydrogen for decades, mostly for use in aerospace, but it is now becoming a key part of the supply chain for hydrogen use in alternative energy.</p>\n<p>Along with equipment for processing, storage, and transportation, Chart helps build the hydrogen fueling stations themselves, which are quickly spreading throughout Europe and starting to show up in the U.S. Its hydrogen orders grew to $71 million in the first quarter this year from $4 million in the first quarter of 2020, and it expects hydrogen and helium sales to rise to at least $99 million this year from $22 million in 2020. The company thinks the potential hydrogen market opportunity is worth $2.4 billion over the next three to five years.</p>\n<p>That pitch is drawing investors who are excited by hydrogen but wary of some companies in the sector that have potential but no profits.</p>\n<p>“If you play hydrogen through Chart, then you are already getting profits from those sales, because hydrogen is one of our most profitable elements as a business,” Evanko says.</p>\n<p>Steven Klopukh, a portfolio manager at Thornburg Investment Management, owns Chart in two funds he runs. “It’s a really good infrastructure play on the hydrogen economy,” he says. He sees a clear path for earnings to hit $8 a share a year and for the stock to reach $180 off the strength of its renewable energy products.</p>\n<p>Klopukh also sees promise in carbon capture and storage, a process that takes carbon emitted from drilling sites or factories and processes it for reuse or underground storage.</p>\n<p>Carbon capture is “the next big thing” in the energy transition businesses, predicts Evercore analyst James West. Among the companies betting big on carbon capture are&nbsp;Exxon Mobil(XOM), which is already one of Chart’s customers.</p>\n<p>Chart has projected that its slice of the carbon capture market is worth $800 million in the next three to five years. “It’s a year behind hydrogen, as far as what we’re seeing in the market,” CEO Evanko says.</p>\n<p>Government policies and investment could become another catalyst for Chart, particularly in areas like carbon capture. The company would almost certainly benefit from the infrastructure proposal just endorsed by President Joe Biden. “We still would expect to see significant growth without the infrastructure bill in the U.S., because there are multiple macro tailwinds in place,” Evanko says. “But it would definitely be an accelerant.”</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Small-Cap Stock Can Pivot Between Old and New Energy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Small-Cap Stock Can Pivot Between Old and New Energy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 15:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/chart-industries-stock-natural-gas-hydrogen-51624662014?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The energy transition is on its way, but for most companies the tangible results won’t show up for years. At Chart Industries, the action is happening now, and the company’s stock isn’t fully ...</p>\n\n<a href=\"https://www.barrons.com/articles/chart-industries-stock-natural-gas-hydrogen-51624662014?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GTLS":"查特工业"},"source_url":"https://www.barrons.com/articles/chart-industries-stock-natural-gas-hydrogen-51624662014?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142078063","content_text":"The energy transition is on its way, but for most companies the tangible results won’t show up for years. At Chart Industries, the action is happening now, and the company’s stock isn’t fully reflecting that yet.\nChart (ticker: GTLS) makes cryogenic tanks and other equipment to freeze gases and make them easier to isolate and transport. Its products operate behind the scenes in a variety of industries, keeping soda bubbly and delivering oxygen to patients suffering from Covid-19. For now, Chart makes most of its money providing equipment to industrial-gas companies or fossil-fuel energy markets. But its stock offers a way to play both the rebound in traditional energy and the transition to new forms of it.\n“In the case of Big Oil, the energy transition will take 30 years,” says Raymond James analyst Pavel Molchanov. “For Chart, it’s happening in real time.” He has an Outperform rating on the shares and a $165 price target—18% above a recent price of $140.\nChart is based in the small city of Ball Ground, Ga., but operates all over the globe. Its results have fluctuated with the fortunes of the natural-gas and chemical industries in recent years. Chart mostly persevered through the pandemic, growing earnings to $2.73 a share from $2.52 the previous year, on a slight decline in sales, to $1.2 billion. The company, however, has a record backlog of orders and is entering a much faster growth period, one that more than justifies its valuation of about 26 times next year’s expected earnings.\n\nChart specializes in taking volatile gases and processing them so they can be contained and transported. That can mean pumping them through heat exchangers, freezing and storing them in cryogenic tanks, and transporting them through insulated pipes. These technologies are used to turn natural gas into liquid form to be transported through pipes or overseas.\nThe company has benefited as the shale-drilling revolution and new laws helped the U.S. become a major exporter of natural gas. But the technology that makes it possible to capture natural gas is also useful for capturing and taming other gases.\n“We’re molecule-agnostic,” Chart CEO Jillian Evanko tells Barron’s.\n\nChart’s systems help pump nitrogen into pressurized containers to make nitro cold brew coffee, carbon dioxide into greenhouses to make cannabis plants grow faster, and ozone into water systems to keep them clean. Even more promising are its renewable-energy divisions, like hydrogen and carbon capture. Its specialty products division is the main reason that Chart is expected to grow earnings per share by 44% this year and 33% next year, with an expected long-term growth rate of 25%, according to FactSet. Specialty products now make up 20% of the company’s revenue, but analysts see them growing to nearly half of sales by 2025.\nHydrogen, an alternative fuel that can produce electricity and power vehicles, is a big opportunity. Chart has been making equipment to process and transport hydrogen for decades, mostly for use in aerospace, but it is now becoming a key part of the supply chain for hydrogen use in alternative energy.\nAlong with equipment for processing, storage, and transportation, Chart helps build the hydrogen fueling stations themselves, which are quickly spreading throughout Europe and starting to show up in the U.S. Its hydrogen orders grew to $71 million in the first quarter this year from $4 million in the first quarter of 2020, and it expects hydrogen and helium sales to rise to at least $99 million this year from $22 million in 2020. The company thinks the potential hydrogen market opportunity is worth $2.4 billion over the next three to five years.\nThat pitch is drawing investors who are excited by hydrogen but wary of some companies in the sector that have potential but no profits.\n“If you play hydrogen through Chart, then you are already getting profits from those sales, because hydrogen is one of our most profitable elements as a business,” Evanko says.\nSteven Klopukh, a portfolio manager at Thornburg Investment Management, owns Chart in two funds he runs. “It’s a really good infrastructure play on the hydrogen economy,” he says. He sees a clear path for earnings to hit $8 a share a year and for the stock to reach $180 off the strength of its renewable energy products.\nKlopukh also sees promise in carbon capture and storage, a process that takes carbon emitted from drilling sites or factories and processes it for reuse or underground storage.\nCarbon capture is “the next big thing” in the energy transition businesses, predicts Evercore analyst James West. Among the companies betting big on carbon capture are Exxon Mobil(XOM), which is already one of Chart’s customers.\nChart has projected that its slice of the carbon capture market is worth $800 million in the next three to five years. “It’s a year behind hydrogen, as far as what we’re seeing in the market,” CEO Evanko says.\nGovernment policies and investment could become another catalyst for Chart, particularly in areas like carbon capture. The company would almost certainly benefit from the infrastructure proposal just endorsed by President Joe Biden. “We still would expect to see significant growth without the infrastructure bill in the U.S., because there are multiple macro tailwinds in place,” Evanko says. “But it would definitely be an accelerant.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187041668,"gmtCreate":1623732067154,"gmtModify":1704209865887,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Like + comment","listText":"Like + comment","text":"Like + comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187041668","repostId":"1164323104","repostType":4,"repost":{"id":"1164323104","kind":"news","pubTimestamp":1623726988,"share":"https://ttm.financial/m/news/1164323104?lang=&edition=fundamental","pubTime":"2021-06-15 11:16","market":"us","language":"en","title":"ARK: Cathie Wood And The Exquisite Art Of Tail Gunning","url":"https://stock-news.laohu8.com/highlight/detail?id=1164323104","media":"seekingalpha","summary":"Summary\n\nARK Active ETFs are worth the management fee.\nStructured Lookback is introduced.\nTails are ","content":"<p><b>Summary</b></p>\n<ul>\n <li>ARK Active ETFs are worth the management fee.</li>\n <li>Structured Lookback is introduced.</li>\n <li>Tails are shown to have a logical structure and consistent patterns.</li>\n <li>The concepts of Simultaneity and Sequentiality are introduced.</li>\n <li>CO/OC directional differences are important indicators that are much more useful than two-dimensional measures like standard deviation.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b1271b2416859ceba7776d3cb65f490c\" tg-width=\"768\" tg-height=\"512\"><span>phongphan5922/iStock via Getty Images</span></p>\n<p><b>The Legend of Cathie Wood and Ark Active</b></p>\n<blockquote>\n Beatrix Kiddo: I am proficient in Tiger Crane style and more than proficient in the exquisite art of the samurai sword.\n</blockquote>\n<blockquote>\n <b>Kill Bill Vol 2 - The Cruel Tutelage of Pai Mei</b>\n</blockquote>\n<p>There is no question that Cathie Wood will be elected to the Stock Picker Hall of Fame on the first year of eligibility. The last person achieving that honor was Peter Lynch.</p>\n<p>Ark Active ETFs weren't really on my radar until after&nbsp;Trading Edge&nbsp;was published on June 1. At some point, I planned to make that article more about equity groups instead of ETFs, specifically biotech. Eventually the plan changed because that seemed premature.</p>\n<p>Another reason for my lack of attention is that I usually look for issues with at least 1500 days of price history and the four horsemen of Ark Active passed that milestone less than 200 trade days ago.</p>\n<p>Some commentators have mentioned recent negative return issues with&nbsp;ARKG, noting that the natives are getting restless. The first argument has some merit and touches on technical details that will affect the entire market. But, call me a romantic, I'm OK with cutting ARK a little slack here.</p>\n<p><b>Tail Gunning</b></p>\n<p><b>Tail</b>&nbsp;is a statistical term related to&nbsp;<b>data distribution</b>. When data points are plotted, a&nbsp;<b>bell shaped curve</b>&nbsp;forms and the unusual results on either side of the curve are the tails. If the distribution is consistent with the ideal bell pattern, it is considered normal. Results of many coin flips produce a<b>normal distribution</b>, stock returns do not.</p>\n<p>This implies that&nbsp;<b>probabilities</b>&nbsp;based on normal distributions are accurate while non-normal distribution probabilities are not. This is a serious problem for the academic discipline of Finance as not understanding probabilities suggests that it cannot offer a practical methodology to mitigate&nbsp;<b>risk</b>.</p>\n<p>In this article, I will try to show that Ark Active returns are highly dependent on exploiting extreme tail activity. Hence the term&nbsp;<b>tail gunning</b>. Surprisingly, tail activity is more structured than one might initially think, so this may have some theoretical importance.</p>\n<p>ARK Active has been quite good over many years at staying on the wild side.</p>\n<p><b>The Legend of Data Manipulation</b></p>\n<p>Modern stock exchanges and casinos both appeared in the first part of the 17th century, not long after the modern rules of chess were established. Academic disciplines relevant to understanding these innovations such as calculus, linear algebra, statistics, quantum mechanics etc. slowly developed over the next 400 years.</p>\n<p>The revolutionary implications of data science have not yet been fully appreciated. Practical skill in data manipulation more than compensates for lack of formal academic knowledge in any of the other disciplines. A goal of my work is to demonstrate the soundness of this view.</p>\n<p>A trained practitioner of statistical finance won't approach the stock return problem through data manipulation. No doubt, data manipulation is my hammer, so everything else looks like a nail.</p>\n<p>Major weaknesses in the academic understanding of stuff in general include:</p>\n<ul>\n <li>Time</li>\n <li>High dimensionality</li>\n</ul>\n<p>Volatility is a function of time, claims by some financial sages that they understand volatility are prima facie absurd. Academic deficiencies can be exploited by competent users of computer power.</p>\n<p>In this article, I'll discuss how to set up and analyze market data, with attention given to the superb performance of the ARK Active ETFs.</p>\n<p><b>Price History Data</b></p>\n<p><img src=\"https://static.tigerbbs.com/d90c98591d40fa964b5d072099898d37\" tg-width=\"466\" tg-height=\"296\" referrerpolicy=\"no-referrer\"></p>\n<p>The analysis presented here, only considers the date, open and close. Financial statisticians generally consider daily open, high, and low numbers to be noise. Essentially, that is an admission of the limitations of their analytical framework.</p>\n<p>Looking at one stock at a time is wrong on many different levels. It is absolutely critical to examine groups of stocks.</p>\n<p>A mechanism is needed to produce historical daily prices for many different stocks. Prices must be adjusted for dividends and splits. The data should be stored in Excel csv workbooks where the workbook and worksheet names are the stock symbol.</p>\n<p>Databases are inappropriate for historical price analysis. Rebuilding the data at least daily from scratch is quick and eliminates many possible points of failure.</p>\n<p>It is best to solve the data problem by paying for a reliable delivery method like Norgate. Everyone who does this type of work, initially spends a lot of time figuring out how to get prices for free. I did that for about 15 years. It is good to build up the skill and understanding, but eventually the cost of inefficient use of time is substantial.</p>\n<p><b>Data Transformation - Natural Log Returns</b></p>\n<p><img src=\"https://static.tigerbbs.com/fe2b70f7a667237e2fde7818ec22248f\" tg-width=\"515\" tg-height=\"239\" referrerpolicy=\"no-referrer\"></p>\n<p>The per share price of a stock has absolutely no rational analytical relevance, assuming the investor has at least enough money to buy one share.</p>\n<p>The human mind can deal with a limited number of things at once, and with stock groups, price is too much detail. Data transformation is a methodology to remove that complexity. Here, daily prices are transformed to a return stream. That makes it easy to analyze even large groups of equities.</p>\n<p>Natural logs are the correct way to store a return stream, unless you are in a contest to find an inferior solution.</p>\n<p>The simple calculations below need to be done for each date for each stock in the group being analyzed. It only takes a few minutes on an 8th generation i7 Windows PC to do this for hundreds of stocks containing thousands of days of price history.</p>\n<p>Using 3/16 in the table above as an example:</p>\n<ul>\n <li><b>CC</b>(Close to Close) = natural log of 3/16 Close / 3/15 Close = nl(394.62/395.12) = -0.0013.</li>\n <li><b>CO</b>(Close to Open) = natural log of 3/16 Open / 3/15 Close = nl(395.77/395.12) = 0.0017.</li>\n <li><b>OC</b>(Open to Close) = natural log of 3/16 Close / 3/16 Open = nl(394.62/395.77) = -0.0029.</li>\n</ul>\n<p>The bCC/bCO/bOC columns are binary answers to the question of whether the excursion was positive (1 = positive 0 = not positive). It is quite useful to answer questions before they are asked. This same technique is used to encode strategies into a return stream.</p>\n<p>I specialize in low level stuff. For example, with the binary codes:</p>\n<ul>\n <li>If bCO = 1 and bOC = 1 Then bCC = 1</li>\n <li>If bCO = 0 and bOC = 0 Then bCC = 0</li>\n <li>otherwise, you have to check bCC.</li>\n</ul>\n<p>Probably, most people wouldn't spend months analyzing the implications of that. I'm making good progress but still not finished. xSig, discussed below is related to that analysis. The issue is that if bCC = 4, bCO = 2, and bOC = 1 to create an Octal number; 3 and 4 can't happen.</p>\n<p><b>1,400-Day Structured Lookback</b></p>\n<p><img src=\"https://static.tigerbbs.com/6a9152d4c32880ea9b67cfcfba92a528\" tg-width=\"640\" tg-height=\"451\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/816a4f84749432ed63cad49e9629fea1\" tg-width=\"640\" tg-height=\"440\" referrerpolicy=\"no-referrer\"><b>CC1400 = CO1400 + OC1400</b></p>\n<p><b>$CC1400 = $CO1400 * $OC1400</b></p>\n<p>In my&nbsp;Trading Edge article, CC1400 was called tCC.</p>\n<p><b>CO/OC Imbalance</b></p>\n<p>The CO state is clearly dominant over OC. Trading Edge even suggested this may be a permanent market feature. It is somewhat heretical to even whisper of such things. If someone refutes that, I promise not to get mad.</p>\n<p>Trading Edge considered the 3x Bulls to be the most obvious way to exploit the CO edge. ARK Active smokes the leveraged financially engineered abominations.</p>\n<p><b>Structured Lookback Design</b></p>\n<p><img src=\"https://static.tigerbbs.com/3619120948d5766322b4336d698d190f\" tg-width=\"428\" tg-height=\"275\" referrerpolicy=\"no-referrer\"></p>\n<p>I introduced date yrmolation as a concept in my&nbsp;Kabbalah articlein January. Perhaps structured lookback is a better term, if only because it has more vowels. The idea is to provide a logical methodology for creating segments of sequential time.</p>\n<p>The day is the standard market unit of time. The traditional day/week/month/year construct does not get us closer to a suitable lookback solution, and mostly just confuses the issue. Generally, one doesn't solve a problem by adding needless complexity.</p>\n<p>Every total time frame of&nbsp;<b>n days</b>, is broken into 3 consecutive periods. The first period is 1/7 the total period, the second 2/7, and the third 4/7. I worked on this backwards of course, so:</p>\n<ul>\n <li>x[1] = 200</li>\n <li>x[2] = x[1] * 2 = 400</li>\n <li>x[3] = x[1] * 4 = 800</li>\n <li>x[0] = Total days = 200 + 400 + 800 = 1400</li>\n</ul>\n<p>Another time concept is iteration. The study is labeled 200i0. i0 means iteration 0. An i1 study implies the 1400 days before 11/13/15.</p>\n<p><b>xSig logic.</b>There are three hex codes after the x. The bit values go:</p>\n<ul>\n <li>8 = xx1400</li>\n <li>4 = xx200</li>\n <li>2 = xx400</li>\n <li>1 = xx800</li>\n</ul>\n<p>xFF2 appears most often in the table. This means:</p>\n<ul>\n <li>First/F - All structured CC periods have positive returns.</li>\n <li>Second/F - All Structured CO periods have positive returns.</li>\n <li>Third/2 - All OC periods except OC400 have losses.</li>\n</ul>\n<p><b>Win Rate</b></p>\n<p>This is another critically important metric that virtually nobody looks at. In the table, the differences between CO and OC win rates are stunning.</p>\n<p><b>400-Day Segment Detail</b></p>\n<p><img src=\"https://static.tigerbbs.com/7299f454e25cd1b7c76e9270ba0d7555\" tg-width=\"640\" tg-height=\"318\" referrerpolicy=\"no-referrer\"></p>\n<p>The 400-day segment showed the best numbers for OC so it is worth looking at. All four of the time segments display simultaneously on an HD monitor; the challenge writing about them is mostly how to cut up the information for the article format. The win percentages for OC are notably higher than those seen on the 1400 day study. ARKW performs respectably here, both CO and OC, but even in the best OC environment, with the most favorable ETF, CO is not worse.</p>\n<p><b>ARKG</b></p>\n<p>ARKG performs better CO than any of the 3x Bulls CC or CO. ARK win rates are all at least 62% CO, much better than the bulls. Win rates OC are much worse. Obviously, with the strategy of playing CO, ideally we want to see all positive returns during CO and all the negative returns during OC.</p>\n<p><b>Performance Graphs</b></p>\n<blockquote>\n <img src=\"https://static.tigerbbs.com/62164faed041f049e43de95eae97d7f8\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\">Sam: I never walk into a place I don't know how to walk out of.\n</blockquote>\n<blockquote>\n <b>Ronin</b>\n</blockquote>\n<p>I can see how the recent sharp excursion down to about the 38.2 fib line might freak out some of the CC players, especially those who bought near the top. Personally, I'm afraid of parabolic heights, so it is difficult for me to visualize the thought process of the players who were buying at triple digits. Guess that is why I'll never be rich.</p>\n<p>After detailed poring over the entrails and consulting entities whose names are best left unspoken, I think holding any of the ARK Active puppies CO is worth serious consideration.</p>\n<p>I was really impressed by ARK's stock selection results and watched a recent interview of Cathie, where she was confident of the funds performing at the historical pace. Needless to say, I've been curious if she knows about the CO/OC imbalance where a CO player could theoretically beat buy and hold by about a factor of 10.</p>\n<p><b>Finding Biotech Tail</b></p>\n<p>Virtually all Biotechs are part of the tail when considered with the stock universe, so all one needs is a list of suitable candidates.</p>\n<p>Biotech and Semiconductors are the two industries with the most favorable positive CO vs OC characteristics based on my research. Energy is also quite good, but I haven't looked at that sector closely. Small caps are also consistently favorable.</p>\n<p>Biotech is a bit more persistent and obvious. An ETF performs at some sort of median to the characteristics of the group it is composed of, but ETF numbers pretty much precisely reflect the characteristics of the entire group.</p>\n<p>81 biotech stocks with average daily volume greater than 300K, and current price greater than $10 were assembled. The top stocks in CC, CO, and OC will be shown below:</p>\n<p><b>Top Biotech CC</b><img src=\"https://static.tigerbbs.com/d841bf3f146ef20a3b33e5907560506f\" tg-width=\"640\" tg-height=\"398\" referrerpolicy=\"no-referrer\"><b>Top BioTech CO</b><img src=\"https://static.tigerbbs.com/75d42024dd22967d2389f0bff6f5051b\" tg-width=\"640\" tg-height=\"359\" referrerpolicy=\"no-referrer\"><b>Top Biotech OC and Median</b></p>\n<p><img src=\"https://static.tigerbbs.com/71d670bb51438ece3d1e0ea1af330418\" tg-width=\"640\" tg-height=\"339\" referrerpolicy=\"no-referrer\"></p>\n<p>These are just overwhelming numbers arguing for CO. A random pick in this universe is much more likely to be profitable CO than anywhere else and that profit is much more likely to exceed CC. The win rates are lower than seen in most sectors. In general, this type of analysis is a fertile avenue for research.</p>\n<p><b>CO/OC or Standard Deviation</b></p>\n<p>The tendency of stocks to move in opposite directions CO and OC can be measured as has been shown here. These movements appear to be quite persistent and consistent in direction over time. The investor gains important and usable information by studying these structures, as opposed to standard deviation.</p>\n<p>Standard deviation only measures CC and ignores violent movements during the day. A year is usually considered the proper standard deviation sample, mostly because any other length is equally worthless.</p>\n<p><b>Recent Action</b></p>\n<p>CO has not been a great performer lately. I've been noting that on my website since at least March I think. The more interesting thing is watching things unfold with a decent toolset and trying to figure out what is happening.</p>\n<p><b>252-Day Structured Lookback</b></p>\n<p><img src=\"https://static.tigerbbs.com/8d0b19158fd2c03a403a0b4e050337e5\" tg-width=\"640\" tg-height=\"277\" referrerpolicy=\"no-referrer\"></p>\n<p>I'll stick with natural log results only in this pass. A natural log of 0.69 is doubling your money. 0.72 for ARKG is CV$1 2.06. All of the puppies at least tripled CO except for ARKW. Not bad for a year. Note the CO win rate.</p>\n<p>xSig is weaker than long term as xFF is no longer showing. As time ranges get longer, xFF gets more common.</p>\n<p><img src=\"https://static.tigerbbs.com/56d55c932d2bf44bdbc6453973b0deca\" tg-width=\"640\" tg-height=\"259\" referrerpolicy=\"no-referrer\"></p>\n<p>I guess the CC players got annoyed that things were better at this end point than 6/11/21. CO win rates are about the best I've ever seen.</p>\n<p><img src=\"https://static.tigerbbs.com/8545852036c8982dbfe9b43f7a5cbadb\" tg-width=\"640\" tg-height=\"259\" referrerpolicy=\"no-referrer\"></p>\n<p>Win rates seriously dropped from the 144 day segment. The Biotech correction started February 9th.</p>\n<p><img src=\"https://static.tigerbbs.com/b8a78565860d28888443a05446a954fc\" tg-width=\"640\" tg-height=\"282\" referrerpolicy=\"no-referrer\"></p>\n<p>The ARKG pattern starts with a double top. LABU and XBI made a single top, with a nice dark cloud cover candle that worked out for a change. In some parallel universes, they always work.</p>\n<p><img src=\"https://static.tigerbbs.com/05104399c4fdd23a584cf50f2b0c17f1\" tg-width=\"640\" tg-height=\"282\" referrerpolicy=\"no-referrer\"></p>\n<p>The black candles show the day traders getting slapped. No big deal for CO players. I'm happy I wasn't playing these guys during this period; no question I would have botched things up.</p>\n<p><img src=\"https://static.tigerbbs.com/6ae737de17a78652910a1d3026bcb38c\" tg-width=\"640\" tg-height=\"259\" referrerpolicy=\"no-referrer\"></p>\n<p>The 36-day shows weakness coming into CO and a little strength in OC at least for ARKG. Note the two winning percentages are the same. This is less trivial than it appears as that situation also exists in the Biotechs.</p>\n<p><img src=\"https://static.tigerbbs.com/149ae96de3fe3e9bae8c62f9d00080d3\" tg-width=\"640\" tg-height=\"432\" referrerpolicy=\"no-referrer\"></p>\n<p><img src=\"https://static.tigerbbs.com/0dcc46d54a59d3ac1078bb04cdefaac4\" tg-width=\"640\" tg-height=\"282\" referrerpolicy=\"no-referrer\"></p>\n<p>The recent low at 72.87 was not only the important ludicrously long term 38.2 fib line but the 52 week moving average, and on the other side of the chasm there is obvious support around 72. I don't see how that can be arranged to spell sell. Note the pop we are seeing off the low is coming on OC strength.</p>\n<p>The plain meaning of the weekly chart is bullish: Heat sensitive longs from the congestion period, put stops in below the 52 week SMA that were triggered during the week of May 10. That is shown by the head fake and bottoming tail. Even a retest of the low would probably not be too bad, but hopefully that won't part of the near term conversation. The poke above the 13-week SMA is encouraging, a move above 93 doesn't seem excessively optimistic.</p>\n<p>Is The 252-Day Structured Lookback Kosher?</p>\n<p>252 market days is as close to an exact calendar year as you can get. 252 / 7 = 36. Therefore we can say that a market year is divided into 7 periods of 36 days. In this scheme, every day is the end of a year.</p>\n<p>With<b>Gematria</b>, the number 36 is 2 * 18. 18 = Life. 36 is comprised of the letters Lamed Vav, which correspond to the<b>TzadikimNistarim</b>, the 36 hidden righteous ones who support the world in every generation.</p>\n<p>Somehow, that gives me a little confidence that the structured lookback solution isn't completely ridiculous. It is definitely kosher.</p>\n<p>Simultaneity and Sequentiality</p>\n<blockquote>\n Adm Mark Turso USN Ret: You were given a Ferrari and your people treated it like a lawnmower.\n</blockquote>\n<blockquote>\n <b>The Bourne Legacy</b>\n</blockquote>\n<p>Earlier, I mentioned the binary codes bCC, bCO, and bOC. These probably have to be understood to understand the CO/OC imbalance. They are useful in understanding the forces of simultaneity and sequentiality which propel stock prices.</p>\n<p><img src=\"https://static.tigerbbs.com/6c17ed7424c6e637ad896c0fbaed4baf\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\"></p>\n<p>The ARK Ferraris are included with the lawn mowers.</p>\n<p>XBI and IBB are weird with their different returns, which is not easily exploitable.</p>\n<p>Buy The Dip Or Pop - CCn1 or CCp1<img src=\"https://static.tigerbbs.com/6ca6dcb7e38682509246a811e20b4b50\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\">The Specter Clock</p>\n<p>CCn1 means CC negative returns of the Specter stock from the previous day are analyzed. The Specter stock is SPY. The specter functions something like a clock and provides high dimensional order to the group.</p>\n<p>This happened 105 times in the last 252 days - note end of top line. The bulk of CC profits occurred after this happened. The CC median win rate is 60 instead of 55. Note that this state accounts for more than 100% of OC profits.</p>\n<p><b>CCp1</b></p>\n<p><img src=\"https://static.tigerbbs.com/7c139fe7edf8287f22fb4902d489ee01\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\">CC is usually positive of course and it was for 147 of the 252 days. It has been best to buy the pop CO and then get out OC.</p>\n<p>These might be good examples of sequentiality, or not.</p>\n<p>SPY is Positive or Negative CO Today - COp0 or COn0</p>\n<p><img src=\"https://static.tigerbbs.com/2e4b10f70d9011fe586ed6d10f3dff28\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\"></p>\n<p>This is an example of simultaneity. If SPY is up OC 90% of the sector ETFs will go up.</p>\n<p>Simultaneity has weakened during the last segment and probably a little before that as well.</p>\n<p><img src=\"https://static.tigerbbs.com/49fd6dcb993413dabcf4039ed0937c37\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\">There definitely isn't the same kind of breadth as in the good old days. That seems at least mildly negative.</p>\n<p><b>COn0</b></p>\n<p><img src=\"https://static.tigerbbs.com/a1da4b68139194cb3c20cbdddbfcddd5\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\">This shows that COn0 weakness in SPY is less of a factor than COp0. Note that if CO is negative, there are better chances for OC to be positive.</p>\n<p><img src=\"https://static.tigerbbs.com/14ca38d49389a36c6f2b1c69036409fa\" tg-width=\"640\" tg-height=\"469\" referrerpolicy=\"no-referrer\"></p>\n<p>The 36-day view shows the sectors having consensus on SPY down moves rather than up moves lately. There has been no lack of buyers OC.</p>\n<p>Essentially, this type of analysis adds a concrete framework that shows a pretty subtle picture of market state. It confirms a vague feeling many have noticed that things are changing.</p>\n<p>I doubt that mechanical CO playing is ready for prime time just yet. Certainly the CC/CO binary results above need to be better understood. Mostly, I think the analytical framework presented here is quite powerful and worth continued development.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARK: Cathie Wood And The Exquisite Art Of Tail Gunning</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARK: Cathie Wood And The Exquisite Art Of Tail Gunning\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 11:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4434708-ark-cathie-wood-and-tail-gunning><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nARK Active ETFs are worth the management fee.\nStructured Lookback is introduced.\nTails are shown to have a logical structure and consistent patterns.\nThe concepts of Simultaneity and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4434708-ark-cathie-wood-and-tail-gunning\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKR":"Ark Restaurants Corp","ARKQ":"ARK Autonomous Technology & Robotics ETF","ARKF":"ARK Fintech Innovation ETF","ARKG":"ARK Genomic Revolution ETF","ARKO":"ARKO Corp","ARKK":"ARK Innovation ETF"},"source_url":"https://seekingalpha.com/article/4434708-ark-cathie-wood-and-tail-gunning","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164323104","content_text":"Summary\n\nARK Active ETFs are worth the management fee.\nStructured Lookback is introduced.\nTails are shown to have a logical structure and consistent patterns.\nThe concepts of Simultaneity and Sequentiality are introduced.\nCO/OC directional differences are important indicators that are much more useful than two-dimensional measures like standard deviation.\n\nphongphan5922/iStock via Getty Images\nThe Legend of Cathie Wood and Ark Active\n\n Beatrix Kiddo: I am proficient in Tiger Crane style and more than proficient in the exquisite art of the samurai sword.\n\n\nKill Bill Vol 2 - The Cruel Tutelage of Pai Mei\n\nThere is no question that Cathie Wood will be elected to the Stock Picker Hall of Fame on the first year of eligibility. The last person achieving that honor was Peter Lynch.\nArk Active ETFs weren't really on my radar until after Trading Edge was published on June 1. At some point, I planned to make that article more about equity groups instead of ETFs, specifically biotech. Eventually the plan changed because that seemed premature.\nAnother reason for my lack of attention is that I usually look for issues with at least 1500 days of price history and the four horsemen of Ark Active passed that milestone less than 200 trade days ago.\nSome commentators have mentioned recent negative return issues with ARKG, noting that the natives are getting restless. The first argument has some merit and touches on technical details that will affect the entire market. But, call me a romantic, I'm OK with cutting ARK a little slack here.\nTail Gunning\nTail is a statistical term related to data distribution. When data points are plotted, a bell shaped curve forms and the unusual results on either side of the curve are the tails. If the distribution is consistent with the ideal bell pattern, it is considered normal. Results of many coin flips produce anormal distribution, stock returns do not.\nThis implies that probabilities based on normal distributions are accurate while non-normal distribution probabilities are not. This is a serious problem for the academic discipline of Finance as not understanding probabilities suggests that it cannot offer a practical methodology to mitigate risk.\nIn this article, I will try to show that Ark Active returns are highly dependent on exploiting extreme tail activity. Hence the term tail gunning. Surprisingly, tail activity is more structured than one might initially think, so this may have some theoretical importance.\nARK Active has been quite good over many years at staying on the wild side.\nThe Legend of Data Manipulation\nModern stock exchanges and casinos both appeared in the first part of the 17th century, not long after the modern rules of chess were established. Academic disciplines relevant to understanding these innovations such as calculus, linear algebra, statistics, quantum mechanics etc. slowly developed over the next 400 years.\nThe revolutionary implications of data science have not yet been fully appreciated. Practical skill in data manipulation more than compensates for lack of formal academic knowledge in any of the other disciplines. A goal of my work is to demonstrate the soundness of this view.\nA trained practitioner of statistical finance won't approach the stock return problem through data manipulation. No doubt, data manipulation is my hammer, so everything else looks like a nail.\nMajor weaknesses in the academic understanding of stuff in general include:\n\nTime\nHigh dimensionality\n\nVolatility is a function of time, claims by some financial sages that they understand volatility are prima facie absurd. Academic deficiencies can be exploited by competent users of computer power.\nIn this article, I'll discuss how to set up and analyze market data, with attention given to the superb performance of the ARK Active ETFs.\nPrice History Data\n\nThe analysis presented here, only considers the date, open and close. Financial statisticians generally consider daily open, high, and low numbers to be noise. Essentially, that is an admission of the limitations of their analytical framework.\nLooking at one stock at a time is wrong on many different levels. It is absolutely critical to examine groups of stocks.\nA mechanism is needed to produce historical daily prices for many different stocks. Prices must be adjusted for dividends and splits. The data should be stored in Excel csv workbooks where the workbook and worksheet names are the stock symbol.\nDatabases are inappropriate for historical price analysis. Rebuilding the data at least daily from scratch is quick and eliminates many possible points of failure.\nIt is best to solve the data problem by paying for a reliable delivery method like Norgate. Everyone who does this type of work, initially spends a lot of time figuring out how to get prices for free. I did that for about 15 years. It is good to build up the skill and understanding, but eventually the cost of inefficient use of time is substantial.\nData Transformation - Natural Log Returns\n\nThe per share price of a stock has absolutely no rational analytical relevance, assuming the investor has at least enough money to buy one share.\nThe human mind can deal with a limited number of things at once, and with stock groups, price is too much detail. Data transformation is a methodology to remove that complexity. Here, daily prices are transformed to a return stream. That makes it easy to analyze even large groups of equities.\nNatural logs are the correct way to store a return stream, unless you are in a contest to find an inferior solution.\nThe simple calculations below need to be done for each date for each stock in the group being analyzed. It only takes a few minutes on an 8th generation i7 Windows PC to do this for hundreds of stocks containing thousands of days of price history.\nUsing 3/16 in the table above as an example:\n\nCC(Close to Close) = natural log of 3/16 Close / 3/15 Close = nl(394.62/395.12) = -0.0013.\nCO(Close to Open) = natural log of 3/16 Open / 3/15 Close = nl(395.77/395.12) = 0.0017.\nOC(Open to Close) = natural log of 3/16 Close / 3/16 Open = nl(394.62/395.77) = -0.0029.\n\nThe bCC/bCO/bOC columns are binary answers to the question of whether the excursion was positive (1 = positive 0 = not positive). It is quite useful to answer questions before they are asked. This same technique is used to encode strategies into a return stream.\nI specialize in low level stuff. For example, with the binary codes:\n\nIf bCO = 1 and bOC = 1 Then bCC = 1\nIf bCO = 0 and bOC = 0 Then bCC = 0\notherwise, you have to check bCC.\n\nProbably, most people wouldn't spend months analyzing the implications of that. I'm making good progress but still not finished. xSig, discussed below is related to that analysis. The issue is that if bCC = 4, bCO = 2, and bOC = 1 to create an Octal number; 3 and 4 can't happen.\n1,400-Day Structured Lookback\nCC1400 = CO1400 + OC1400\n$CC1400 = $CO1400 * $OC1400\nIn my Trading Edge article, CC1400 was called tCC.\nCO/OC Imbalance\nThe CO state is clearly dominant over OC. Trading Edge even suggested this may be a permanent market feature. It is somewhat heretical to even whisper of such things. If someone refutes that, I promise not to get mad.\nTrading Edge considered the 3x Bulls to be the most obvious way to exploit the CO edge. ARK Active smokes the leveraged financially engineered abominations.\nStructured Lookback Design\n\nI introduced date yrmolation as a concept in my Kabbalah articlein January. Perhaps structured lookback is a better term, if only because it has more vowels. The idea is to provide a logical methodology for creating segments of sequential time.\nThe day is the standard market unit of time. The traditional day/week/month/year construct does not get us closer to a suitable lookback solution, and mostly just confuses the issue. Generally, one doesn't solve a problem by adding needless complexity.\nEvery total time frame of n days, is broken into 3 consecutive periods. The first period is 1/7 the total period, the second 2/7, and the third 4/7. I worked on this backwards of course, so:\n\nx[1] = 200\nx[2] = x[1] * 2 = 400\nx[3] = x[1] * 4 = 800\nx[0] = Total days = 200 + 400 + 800 = 1400\n\nAnother time concept is iteration. The study is labeled 200i0. i0 means iteration 0. An i1 study implies the 1400 days before 11/13/15.\nxSig logic.There are three hex codes after the x. The bit values go:\n\n8 = xx1400\n4 = xx200\n2 = xx400\n1 = xx800\n\nxFF2 appears most often in the table. This means:\n\nFirst/F - All structured CC periods have positive returns.\nSecond/F - All Structured CO periods have positive returns.\nThird/2 - All OC periods except OC400 have losses.\n\nWin Rate\nThis is another critically important metric that virtually nobody looks at. In the table, the differences between CO and OC win rates are stunning.\n400-Day Segment Detail\n\nThe 400-day segment showed the best numbers for OC so it is worth looking at. All four of the time segments display simultaneously on an HD monitor; the challenge writing about them is mostly how to cut up the information for the article format. The win percentages for OC are notably higher than those seen on the 1400 day study. ARKW performs respectably here, both CO and OC, but even in the best OC environment, with the most favorable ETF, CO is not worse.\nARKG\nARKG performs better CO than any of the 3x Bulls CC or CO. ARK win rates are all at least 62% CO, much better than the bulls. Win rates OC are much worse. Obviously, with the strategy of playing CO, ideally we want to see all positive returns during CO and all the negative returns during OC.\nPerformance Graphs\n\nSam: I never walk into a place I don't know how to walk out of.\n\n\nRonin\n\nI can see how the recent sharp excursion down to about the 38.2 fib line might freak out some of the CC players, especially those who bought near the top. Personally, I'm afraid of parabolic heights, so it is difficult for me to visualize the thought process of the players who were buying at triple digits. Guess that is why I'll never be rich.\nAfter detailed poring over the entrails and consulting entities whose names are best left unspoken, I think holding any of the ARK Active puppies CO is worth serious consideration.\nI was really impressed by ARK's stock selection results and watched a recent interview of Cathie, where she was confident of the funds performing at the historical pace. Needless to say, I've been curious if she knows about the CO/OC imbalance where a CO player could theoretically beat buy and hold by about a factor of 10.\nFinding Biotech Tail\nVirtually all Biotechs are part of the tail when considered with the stock universe, so all one needs is a list of suitable candidates.\nBiotech and Semiconductors are the two industries with the most favorable positive CO vs OC characteristics based on my research. Energy is also quite good, but I haven't looked at that sector closely. Small caps are also consistently favorable.\nBiotech is a bit more persistent and obvious. An ETF performs at some sort of median to the characteristics of the group it is composed of, but ETF numbers pretty much precisely reflect the characteristics of the entire group.\n81 biotech stocks with average daily volume greater than 300K, and current price greater than $10 were assembled. The top stocks in CC, CO, and OC will be shown below:\nTop Biotech CCTop BioTech COTop Biotech OC and Median\n\nThese are just overwhelming numbers arguing for CO. A random pick in this universe is much more likely to be profitable CO than anywhere else and that profit is much more likely to exceed CC. The win rates are lower than seen in most sectors. In general, this type of analysis is a fertile avenue for research.\nCO/OC or Standard Deviation\nThe tendency of stocks to move in opposite directions CO and OC can be measured as has been shown here. These movements appear to be quite persistent and consistent in direction over time. The investor gains important and usable information by studying these structures, as opposed to standard deviation.\nStandard deviation only measures CC and ignores violent movements during the day. A year is usually considered the proper standard deviation sample, mostly because any other length is equally worthless.\nRecent Action\nCO has not been a great performer lately. I've been noting that on my website since at least March I think. The more interesting thing is watching things unfold with a decent toolset and trying to figure out what is happening.\n252-Day Structured Lookback\n\nI'll stick with natural log results only in this pass. A natural log of 0.69 is doubling your money. 0.72 for ARKG is CV$1 2.06. All of the puppies at least tripled CO except for ARKW. Not bad for a year. Note the CO win rate.\nxSig is weaker than long term as xFF is no longer showing. As time ranges get longer, xFF gets more common.\n\nI guess the CC players got annoyed that things were better at this end point than 6/11/21. CO win rates are about the best I've ever seen.\n\nWin rates seriously dropped from the 144 day segment. The Biotech correction started February 9th.\n\nThe ARKG pattern starts with a double top. LABU and XBI made a single top, with a nice dark cloud cover candle that worked out for a change. In some parallel universes, they always work.\n\nThe black candles show the day traders getting slapped. No big deal for CO players. I'm happy I wasn't playing these guys during this period; no question I would have botched things up.\n\nThe 36-day shows weakness coming into CO and a little strength in OC at least for ARKG. Note the two winning percentages are the same. This is less trivial than it appears as that situation also exists in the Biotechs.\n\n\nThe recent low at 72.87 was not only the important ludicrously long term 38.2 fib line but the 52 week moving average, and on the other side of the chasm there is obvious support around 72. I don't see how that can be arranged to spell sell. Note the pop we are seeing off the low is coming on OC strength.\nThe plain meaning of the weekly chart is bullish: Heat sensitive longs from the congestion period, put stops in below the 52 week SMA that were triggered during the week of May 10. That is shown by the head fake and bottoming tail. Even a retest of the low would probably not be too bad, but hopefully that won't part of the near term conversation. The poke above the 13-week SMA is encouraging, a move above 93 doesn't seem excessively optimistic.\nIs The 252-Day Structured Lookback Kosher?\n252 market days is as close to an exact calendar year as you can get. 252 / 7 = 36. Therefore we can say that a market year is divided into 7 periods of 36 days. In this scheme, every day is the end of a year.\nWithGematria, the number 36 is 2 * 18. 18 = Life. 36 is comprised of the letters Lamed Vav, which correspond to theTzadikimNistarim, the 36 hidden righteous ones who support the world in every generation.\nSomehow, that gives me a little confidence that the structured lookback solution isn't completely ridiculous. It is definitely kosher.\nSimultaneity and Sequentiality\n\n Adm Mark Turso USN Ret: You were given a Ferrari and your people treated it like a lawnmower.\n\n\nThe Bourne Legacy\n\nEarlier, I mentioned the binary codes bCC, bCO, and bOC. These probably have to be understood to understand the CO/OC imbalance. They are useful in understanding the forces of simultaneity and sequentiality which propel stock prices.\n\nThe ARK Ferraris are included with the lawn mowers.\nXBI and IBB are weird with their different returns, which is not easily exploitable.\nBuy The Dip Or Pop - CCn1 or CCp1The Specter Clock\nCCn1 means CC negative returns of the Specter stock from the previous day are analyzed. The Specter stock is SPY. The specter functions something like a clock and provides high dimensional order to the group.\nThis happened 105 times in the last 252 days - note end of top line. The bulk of CC profits occurred after this happened. The CC median win rate is 60 instead of 55. Note that this state accounts for more than 100% of OC profits.\nCCp1\nCC is usually positive of course and it was for 147 of the 252 days. It has been best to buy the pop CO and then get out OC.\nThese might be good examples of sequentiality, or not.\nSPY is Positive or Negative CO Today - COp0 or COn0\n\nThis is an example of simultaneity. If SPY is up OC 90% of the sector ETFs will go up.\nSimultaneity has weakened during the last segment and probably a little before that as well.\nThere definitely isn't the same kind of breadth as in the good old days. That seems at least mildly negative.\nCOn0\nThis shows that COn0 weakness in SPY is less of a factor than COp0. Note that if CO is negative, there are better chances for OC to be positive.\n\nThe 36-day view shows the sectors having consensus on SPY down moves rather than up moves lately. There has been no lack of buyers OC.\nEssentially, this type of analysis adds a concrete framework that shows a pretty subtle picture of market state. It confirms a vague feeling many have noticed that things are changing.\nI doubt that mechanical CO playing is ready for prime time just yet. Certainly the CC/CO binary results above need to be better understood. Mostly, I think the analytical framework presented here is quite powerful and worth continued development.","news_type":1},"isVote":1,"tweetType":1,"viewCount":140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9090777410,"gmtCreate":1643274632493,"gmtModify":1676533793807,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Huat ah","listText":"Huat ah","text":"Huat ah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090777410","isVote":1,"tweetType":1,"viewCount":339,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9090772831,"gmtCreate":1643274454927,"gmtModify":1676533793736,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090772831","repostId":"9004448317","repostType":1,"repost":{"id":9004448317,"gmtCreate":1642676525258,"gmtModify":1676533734534,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"Join Tiger Ski Championship, Win a Bonus of Up to USD 2022","htmlText":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: <a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/happy-new-year/#/\" target=\"_blank\">Click to Join the Game</a>","listText":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: <a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/happy-new-year/#/\" target=\"_blank\">Click to Join the Game</a>","text":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: Click to Join the Game","images":[{"img":"https://static.tigerbbs.com/a7b44fa056439fb4010fa55e163d27c3","width":"750","height":"1726"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004448317","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149287253,"gmtCreate":1625730806872,"gmtModify":1703747287326,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149287253","repostId":"2149154533","repostType":4,"repost":{"id":"2149154533","kind":"news","pubTimestamp":1625727047,"share":"https://ttm.financial/m/news/2149154533?lang=&edition=fundamental","pubTime":"2021-07-08 14:50","market":"us","language":"en","title":"Gold prices steamrolling toward $2,000: Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2149154533","media":"Yahoo Finance","summary":"Gold prices are finally catching a long-awaited bid as inflation fears have subsided, and Goldman Sa","content":"<p>Gold prices are finally catching a long-awaited bid as inflation fears have subsided, and Goldman Sachs analyst Mikhail Sprogis said the upside move is only just beginning.</p>\n<p>Sprogis reiterated his $2,000 an ounce price target on gold prices in a new research note this week, voicing optimism amid the backup in Treasury yields and easing inflation concerns.</p>\n<p>\"As a result of the liquidation, gold is now again pricing a Goldilocks scenario of moderate inflation and continued global recovery and is thus trading at a large discount to the current real rate. We estimate that the current gold price is consistent with a real rate of 0.1% vs. the -0.87% that is currently priced by the market. In our base case that the global recovery continues uninterrupted and inflation remains subdued, we expect this discount to persist and see just modest upside to gold, driven by only a small increase in real rates and a continued improvement in EM wealth,\" Sprogis contends.</p>\n<p>Sprogis' price target assumes an 11% gain in gold prices from current levels.</p>\n<p>To say the gold trade has been dead in the water may be an understatement, as investors have rotated into value stocks in a bid to drive returns during a sharp economic recovery. More recently, gold has fallen by the wayside as traders buy up big-cap tech stocks such as Apple and Amazon.</p>\n<p>While gold prices have tacked on 2% in the past week, they remain 11% lower from the July 2020 record high of more than $2,036 an ounce. Silver prices have remained mostly steady during the same timespan. Copper prices have rallied nearly 50% due to the metal's role in rebuilding the industrial economy post-pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://s.yimg.com/os/creatr-uploaded-images/2021-07/f717e2c0-df44-11eb-bd79-77f05c0df7f7\" tg-width=\"3000\" tg-height=\"2021\" referrerpolicy=\"no-referrer\"><span>A worker scoops gold shots at Japanese jewellery brand, Ginza Tanaka's original equipment manufacturer (OEM) factory in the Chiba prefecture, east of Tokyo. REUTERS/Yuriko Nakao (JAPAN BUSINESS IMAGES OF THE DAY)Yuriko Nakao / reuters</span></p>\n<p>\"Over the past several months, gold has been strongly correlated with the \"inflation fear factor. Prices therefore corrected sharply after the hawkish Fed surprise which our economists interpret as the Fed taking a more backward-looking interpretation of average inflation targeting,\" said Sprogis. \"This not only reversed the inflation trade but also removed the market's pricing of inflation tail risks.\"</p>\n<p>Now it looks to be game (at least in the short-term) on for not only gold prices, but for correlated equities.</p>\n<p>Shares of gold miner Barrick Gold are up 1.5% in the last week, slightly outperforming the S&amp;P 500. The SPDR Gold Shares ET is up about 1.8%.</p>\n<p>\"In a scenario where the global economic recovery does not play out as expected or inflation begins to move materially above expectations, we see material upside to gold given its undervaluation and low allocation from the investment community. Therefore, we think that gold may be a good strategic purchase here for portfolio managers looking to hedge against tail risks of macro volatility,\" added Sprogis.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gold prices steamrolling toward $2,000: Goldman Sachs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGold prices steamrolling toward $2,000: Goldman Sachs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 14:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gold-prices-steamrolling-toward-2000-goldman-sachs-170547546.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gold prices are finally catching a long-awaited bid as inflation fears have subsided, and Goldman Sachs analyst Mikhail Sprogis said the upside move is only just beginning.\nSprogis reiterated his $2,...</p>\n\n<a href=\"https://finance.yahoo.com/news/gold-prices-steamrolling-toward-2000-goldman-sachs-170547546.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FCX":"麦克莫兰铜金","GS":"高盛","GOLD":"巴里克黄金","GSD.SI":"GLD SG$"},"source_url":"https://finance.yahoo.com/news/gold-prices-steamrolling-toward-2000-goldman-sachs-170547546.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149154533","content_text":"Gold prices are finally catching a long-awaited bid as inflation fears have subsided, and Goldman Sachs analyst Mikhail Sprogis said the upside move is only just beginning.\nSprogis reiterated his $2,000 an ounce price target on gold prices in a new research note this week, voicing optimism amid the backup in Treasury yields and easing inflation concerns.\n\"As a result of the liquidation, gold is now again pricing a Goldilocks scenario of moderate inflation and continued global recovery and is thus trading at a large discount to the current real rate. We estimate that the current gold price is consistent with a real rate of 0.1% vs. the -0.87% that is currently priced by the market. In our base case that the global recovery continues uninterrupted and inflation remains subdued, we expect this discount to persist and see just modest upside to gold, driven by only a small increase in real rates and a continued improvement in EM wealth,\" Sprogis contends.\nSprogis' price target assumes an 11% gain in gold prices from current levels.\nTo say the gold trade has been dead in the water may be an understatement, as investors have rotated into value stocks in a bid to drive returns during a sharp economic recovery. More recently, gold has fallen by the wayside as traders buy up big-cap tech stocks such as Apple and Amazon.\nWhile gold prices have tacked on 2% in the past week, they remain 11% lower from the July 2020 record high of more than $2,036 an ounce. Silver prices have remained mostly steady during the same timespan. Copper prices have rallied nearly 50% due to the metal's role in rebuilding the industrial economy post-pandemic.\nA worker scoops gold shots at Japanese jewellery brand, Ginza Tanaka's original equipment manufacturer (OEM) factory in the Chiba prefecture, east of Tokyo. REUTERS/Yuriko Nakao (JAPAN BUSINESS IMAGES OF THE DAY)Yuriko Nakao / reuters\n\"Over the past several months, gold has been strongly correlated with the \"inflation fear factor. Prices therefore corrected sharply after the hawkish Fed surprise which our economists interpret as the Fed taking a more backward-looking interpretation of average inflation targeting,\" said Sprogis. \"This not only reversed the inflation trade but also removed the market's pricing of inflation tail risks.\"\nNow it looks to be game (at least in the short-term) on for not only gold prices, but for correlated equities.\nShares of gold miner Barrick Gold are up 1.5% in the last week, slightly outperforming the S&P 500. The SPDR Gold Shares ET is up about 1.8%.\n\"In a scenario where the global economic recovery does not play out as expected or inflation begins to move materially above expectations, we see material upside to gold given its undervaluation and low allocation from the investment community. Therefore, we think that gold may be a good strategic purchase here for portfolio managers looking to hedge against tail risks of macro volatility,\" added Sprogis.","news_type":1},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159979095,"gmtCreate":1624938744317,"gmtModify":1703848408211,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Well","listText":"Well","text":"Well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159979095","repostId":"1124906464","repostType":4,"repost":{"id":"1124906464","kind":"news","pubTimestamp":1624936236,"share":"https://ttm.financial/m/news/1124906464?lang=&edition=fundamental","pubTime":"2021-06-29 11:10","market":"us","language":"en","title":"CVRx Pursues $100 Million U.S. IPO Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1124906464","media":"seekingalpha","summary":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commerc","content":"<p>Summary</p>\n<ul>\n <li>CVRx has filed to raise $100 million in a U.S. IPO of its common stock.</li>\n <li>The firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.</li>\n <li>CVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.</li>\n <li>Looking for more investing ideas like this one? Get them exclusively at IPO Edge.</li>\n</ul>\n<p>CVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.</p>\n<p>The firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.</p>\n<p>CVRX was negatively affected by the COVID-19 pandemic but has rebounded.</p>\n<p>However, the IPO appears pricey, so I'll watch it from the sidelines.</p>\n<p><b>Company and Technology</b></p>\n<p>Minneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.</p>\n<p>Management is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.</p>\n<p>CVRx has received at least $330 million in equity investment from investors including Johnson &amp; Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.</p>\n<p><b>Customer Acquisition and Market</b></p>\n<p>The firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.</p>\n<p>The firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>155.9%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>160.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>97.6%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>0.3</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.0</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>According to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.</p>\n<p>This represents a forecast CAGR of 13.1% from 2016 to 2022.</p>\n<p>The main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.</p>\n<p>Also, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.</p>\n<p><b>Financial Performance</b></p>\n<p>CVRx’s recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Rebounding topline revenue growth</p></li>\n <li><p>Increasing gross profit but uneven gross margin</p></li>\n <li><p>Growing operating losses</p></li>\n <li><p>Increasing cash used in operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Total Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Total Revenue</p></td>\n   <td><p>% Variance vs. Prior</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ 2,860,000</p></td>\n   <td><p>66.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ 6,053,000</p></td>\n   <td><p>-3.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ 6,257,000</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Gross Profit (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Gross Profit (Loss)</p></td>\n   <td><p>% Variance vs. Prior</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ 1,993,000</p></td>\n   <td><p>55.0%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ 4,613,000</p></td>\n   <td><p>0.9%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ 4,574,000</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Gross Margin</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Gross Margin</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>69.69%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>76.21%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>73.10%</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Operating Profit (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Operating Profit (Loss)</p></td>\n   <td><p>Operating Margin</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (4,217,000)</p></td>\n   <td><p>-147.4%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (11,514,000)</p></td>\n   <td><p>-190.2%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (10,194,000)</p></td>\n   <td><p>-162.9%</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Net Income (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Net Income (Loss)</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (8,627,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (14,109,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (14,633,000)</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Cash Flow From Operations</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Cash Flow From Operations</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (5,038,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (16,096,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (12,785,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>(Glossary Of Terms)</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>As of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).</p>\n<p><b>IPO Details</b></p>\n<p>CVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.</p>\n<p>No existing shareholders have indicated an interest to purchase shares at the IPO price.</p>\n<p>Assuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.</p>\n<p>Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.</p>\n<p>Management says it will use the net proceeds from the IPO as follows:</p>\n<blockquote>\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n</blockquote>\n<p>Management’s presentation of the company roadshow isavailable here.</p>\n<p>Listed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Measure [TTM]</b></p></td>\n   <td><p><b>Amount</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Market Capitalization at IPO</p></td>\n   <td><p>$296,717,728</p></td>\n  </tr>\n  <tr>\n   <td><p>Enterprise Value</p></td>\n   <td><p>$170,592,728</p></td>\n  </tr>\n  <tr>\n   <td><p>Price / Sales</p></td>\n   <td><p>41.24</p></td>\n  </tr>\n  <tr>\n   <td><p>EV / Revenue</p></td>\n   <td><p>23.71</p></td>\n  </tr>\n  <tr>\n   <td><p>EV / EBITDA</p></td>\n   <td><p>-13.70</p></td>\n  </tr>\n  <tr>\n   <td><p>Earnings Per Share</p></td>\n   <td><p>-$0.97</p></td>\n  </tr>\n  <tr>\n   <td><p>Float To Outstanding Shares Ratio</p></td>\n   <td><p>33.70%</p></td>\n  </tr>\n  <tr>\n   <td><p>Proposed IPO Midpoint Price per Share</p></td>\n   <td><p>$16.00</p></td>\n  </tr>\n  <tr>\n   <td><p>Net Free Cash Flow</p></td>\n   <td><p>-$16,946,000</p></td>\n  </tr>\n  <tr>\n   <td><p>Free Cash Flow Yield Per Share</p></td>\n   <td><p>-5.71%</p></td>\n  </tr>\n  <tr>\n   <td><p>Revenue Growth Rate</p></td>\n   <td><p>66.47%</p></td>\n  </tr>\n  <tr>\n   <td><p>(Glossary Of Terms)</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p><b>Commentary</b></p>\n<p>CVRx is seeking public investment capital for its continued commercialization efforts.</p>\n<p>The company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.</p>\n<p>Revenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.</p>\n<p>Free cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&amp;A efficiency rate has since increased to 0.3x in Q1 2021.</p>\n<p>The market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.</p>\n<p>JPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.</p>\n<p>As for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.</p>\n<p>While CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.</p>\n<p>Expected IPO Pricing Date: June 29, 2021</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVRx Pursues $100 Million U.S. IPO Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVRx Pursues $100 Million U.S. IPO Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 11:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVRX":"CVRx, Inc."},"source_url":"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1124906464","content_text":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.\nLooking for more investing ideas like this one? Get them exclusively at IPO Edge.\n\nCVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.\nThe firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.\nCVRX was negatively affected by the COVID-19 pandemic but has rebounded.\nHowever, the IPO appears pricey, so I'll watch it from the sidelines.\nCompany and Technology\nMinneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.\nManagement is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.\nCVRx has received at least $330 million in equity investment from investors including Johnson & Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.\nCustomer Acquisition and Market\nThe firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.\nThe firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.\nSelling, G&A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nThree Mos. Ended March 31, 2021\n155.9%\n\n\n2020\n160.5%\n\n\n2019\n97.6%\n\n\n\n(Source)\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nThree Mos. Ended March 31, 2021\n0.3\n\n\n2020\n0.0\n\n\n\n(Source)\nAccording to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.\nThis represents a forecast CAGR of 13.1% from 2016 to 2022.\nThe main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.\nAlso, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.\nFinancial Performance\nCVRx’s recent financial results can be summarized as follows:\n\nRebounding topline revenue growth\nIncreasing gross profit but uneven gross margin\nGrowing operating losses\nIncreasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 2,860,000\n66.5%\n\n\n2020\n$ 6,053,000\n-3.3%\n\n\n2019\n$ 6,257,000\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 1,993,000\n55.0%\n\n\n2020\n$ 4,613,000\n0.9%\n\n\n2019\n$ 4,574,000\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nThree Mos. Ended March 31, 2021\n69.69%\n\n\n2020\n76.21%\n\n\n2019\n73.10%\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nThree Mos. Ended March 31, 2021\n$ (4,217,000)\n-147.4%\n\n\n2020\n$ (11,514,000)\n-190.2%\n\n\n2019\n$ (10,194,000)\n-162.9%\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nThree Mos. Ended March 31, 2021\n$ (8,627,000)\n\n\n2020\n$ (14,109,000)\n\n\n2019\n$ (14,633,000)\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nThree Mos. Ended March 31, 2021\n$ (5,038,000)\n\n\n2020\n$ (16,096,000)\n\n\n2019\n$ (12,785,000)\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nAs of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.\nFree cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).\nIPO Details\nCVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.\nNo existing shareholders have indicated an interest to purchase shares at the IPO price.\nAssuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.\nExcluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.\nManagement says it will use the net proceeds from the IPO as follows:\n\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n\nManagement’s presentation of the company roadshow isavailable here.\nListed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$296,717,728\n\n\nEnterprise Value\n$170,592,728\n\n\nPrice / Sales\n41.24\n\n\nEV / Revenue\n23.71\n\n\nEV / EBITDA\n-13.70\n\n\nEarnings Per Share\n-$0.97\n\n\nFloat To Outstanding Shares Ratio\n33.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$16,946,000\n\n\nFree Cash Flow Yield Per Share\n-5.71%\n\n\nRevenue Growth Rate\n66.47%\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nCommentary\nCVRx is seeking public investment capital for its continued commercialization efforts.\nThe company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.\nRevenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.\nFree cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).\nSelling, G&A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&A efficiency rate has since increased to 0.3x in Q1 2021.\nThe market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.\nJPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.\nAs for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.\nWhile CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.\nExpected IPO Pricing Date: June 29, 2021","news_type":1},"isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159947813,"gmtCreate":1624938641132,"gmtModify":1703848406268,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159947813","repostId":"1124906464","repostType":4,"repost":{"id":"1124906464","kind":"news","pubTimestamp":1624936236,"share":"https://ttm.financial/m/news/1124906464?lang=&edition=fundamental","pubTime":"2021-06-29 11:10","market":"us","language":"en","title":"CVRx Pursues $100 Million U.S. IPO Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1124906464","media":"seekingalpha","summary":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commerc","content":"<p>Summary</p>\n<ul>\n <li>CVRx has filed to raise $100 million in a U.S. IPO of its common stock.</li>\n <li>The firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.</li>\n <li>CVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.</li>\n <li>Looking for more investing ideas like this one? Get them exclusively at IPO Edge.</li>\n</ul>\n<p>CVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.</p>\n<p>The firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.</p>\n<p>CVRX was negatively affected by the COVID-19 pandemic but has rebounded.</p>\n<p>However, the IPO appears pricey, so I'll watch it from the sidelines.</p>\n<p><b>Company and Technology</b></p>\n<p>Minneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.</p>\n<p>Management is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.</p>\n<p>CVRx has received at least $330 million in equity investment from investors including Johnson &amp; Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.</p>\n<p><b>Customer Acquisition and Market</b></p>\n<p>The firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.</p>\n<p>The firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>155.9%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>160.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>97.6%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>0.3</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.0</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>According to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.</p>\n<p>This represents a forecast CAGR of 13.1% from 2016 to 2022.</p>\n<p>The main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.</p>\n<p>Also, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.</p>\n<p><b>Financial Performance</b></p>\n<p>CVRx’s recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Rebounding topline revenue growth</p></li>\n <li><p>Increasing gross profit but uneven gross margin</p></li>\n <li><p>Growing operating losses</p></li>\n <li><p>Increasing cash used in operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Total Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Total Revenue</p></td>\n   <td><p>% Variance vs. Prior</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ 2,860,000</p></td>\n   <td><p>66.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ 6,053,000</p></td>\n   <td><p>-3.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ 6,257,000</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Gross Profit (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Gross Profit (Loss)</p></td>\n   <td><p>% Variance vs. Prior</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ 1,993,000</p></td>\n   <td><p>55.0%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ 4,613,000</p></td>\n   <td><p>0.9%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ 4,574,000</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Gross Margin</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Gross Margin</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>69.69%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>76.21%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>73.10%</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Operating Profit (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Operating Profit (Loss)</p></td>\n   <td><p>Operating Margin</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (4,217,000)</p></td>\n   <td><p>-147.4%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (11,514,000)</p></td>\n   <td><p>-190.2%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (10,194,000)</p></td>\n   <td><p>-162.9%</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Net Income (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Net Income (Loss)</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (8,627,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (14,109,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (14,633,000)</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Cash Flow From Operations</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Cash Flow From Operations</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (5,038,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (16,096,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (12,785,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>(Glossary Of Terms)</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>As of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).</p>\n<p><b>IPO Details</b></p>\n<p>CVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.</p>\n<p>No existing shareholders have indicated an interest to purchase shares at the IPO price.</p>\n<p>Assuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.</p>\n<p>Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.</p>\n<p>Management says it will use the net proceeds from the IPO as follows:</p>\n<blockquote>\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n</blockquote>\n<p>Management’s presentation of the company roadshow isavailable here.</p>\n<p>Listed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Measure [TTM]</b></p></td>\n   <td><p><b>Amount</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Market Capitalization at IPO</p></td>\n   <td><p>$296,717,728</p></td>\n  </tr>\n  <tr>\n   <td><p>Enterprise Value</p></td>\n   <td><p>$170,592,728</p></td>\n  </tr>\n  <tr>\n   <td><p>Price / Sales</p></td>\n   <td><p>41.24</p></td>\n  </tr>\n  <tr>\n   <td><p>EV / Revenue</p></td>\n   <td><p>23.71</p></td>\n  </tr>\n  <tr>\n   <td><p>EV / EBITDA</p></td>\n   <td><p>-13.70</p></td>\n  </tr>\n  <tr>\n   <td><p>Earnings Per Share</p></td>\n   <td><p>-$0.97</p></td>\n  </tr>\n  <tr>\n   <td><p>Float To Outstanding Shares Ratio</p></td>\n   <td><p>33.70%</p></td>\n  </tr>\n  <tr>\n   <td><p>Proposed IPO Midpoint Price per Share</p></td>\n   <td><p>$16.00</p></td>\n  </tr>\n  <tr>\n   <td><p>Net Free Cash Flow</p></td>\n   <td><p>-$16,946,000</p></td>\n  </tr>\n  <tr>\n   <td><p>Free Cash Flow Yield Per Share</p></td>\n   <td><p>-5.71%</p></td>\n  </tr>\n  <tr>\n   <td><p>Revenue Growth Rate</p></td>\n   <td><p>66.47%</p></td>\n  </tr>\n  <tr>\n   <td><p>(Glossary Of Terms)</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p><b>Commentary</b></p>\n<p>CVRx is seeking public investment capital for its continued commercialization efforts.</p>\n<p>The company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.</p>\n<p>Revenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.</p>\n<p>Free cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&amp;A efficiency rate has since increased to 0.3x in Q1 2021.</p>\n<p>The market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.</p>\n<p>JPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.</p>\n<p>As for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.</p>\n<p>While CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.</p>\n<p>Expected IPO Pricing Date: June 29, 2021</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVRx Pursues $100 Million U.S. IPO Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVRx Pursues $100 Million U.S. IPO Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 11:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVRX":"CVRx, Inc."},"source_url":"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1124906464","content_text":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.\nLooking for more investing ideas like this one? Get them exclusively at IPO Edge.\n\nCVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.\nThe firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.\nCVRX was negatively affected by the COVID-19 pandemic but has rebounded.\nHowever, the IPO appears pricey, so I'll watch it from the sidelines.\nCompany and Technology\nMinneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.\nManagement is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.\nCVRx has received at least $330 million in equity investment from investors including Johnson & Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.\nCustomer Acquisition and Market\nThe firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.\nThe firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.\nSelling, G&A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nThree Mos. Ended March 31, 2021\n155.9%\n\n\n2020\n160.5%\n\n\n2019\n97.6%\n\n\n\n(Source)\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nThree Mos. Ended March 31, 2021\n0.3\n\n\n2020\n0.0\n\n\n\n(Source)\nAccording to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.\nThis represents a forecast CAGR of 13.1% from 2016 to 2022.\nThe main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.\nAlso, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.\nFinancial Performance\nCVRx’s recent financial results can be summarized as follows:\n\nRebounding topline revenue growth\nIncreasing gross profit but uneven gross margin\nGrowing operating losses\nIncreasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 2,860,000\n66.5%\n\n\n2020\n$ 6,053,000\n-3.3%\n\n\n2019\n$ 6,257,000\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 1,993,000\n55.0%\n\n\n2020\n$ 4,613,000\n0.9%\n\n\n2019\n$ 4,574,000\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nThree Mos. Ended March 31, 2021\n69.69%\n\n\n2020\n76.21%\n\n\n2019\n73.10%\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nThree Mos. Ended March 31, 2021\n$ (4,217,000)\n-147.4%\n\n\n2020\n$ (11,514,000)\n-190.2%\n\n\n2019\n$ (10,194,000)\n-162.9%\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nThree Mos. Ended March 31, 2021\n$ (8,627,000)\n\n\n2020\n$ (14,109,000)\n\n\n2019\n$ (14,633,000)\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nThree Mos. Ended March 31, 2021\n$ (5,038,000)\n\n\n2020\n$ (16,096,000)\n\n\n2019\n$ (12,785,000)\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nAs of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.\nFree cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).\nIPO Details\nCVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.\nNo existing shareholders have indicated an interest to purchase shares at the IPO price.\nAssuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.\nExcluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.\nManagement says it will use the net proceeds from the IPO as follows:\n\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n\nManagement’s presentation of the company roadshow isavailable here.\nListed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$296,717,728\n\n\nEnterprise Value\n$170,592,728\n\n\nPrice / Sales\n41.24\n\n\nEV / Revenue\n23.71\n\n\nEV / EBITDA\n-13.70\n\n\nEarnings Per Share\n-$0.97\n\n\nFloat To Outstanding Shares Ratio\n33.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$16,946,000\n\n\nFree Cash Flow Yield Per Share\n-5.71%\n\n\nRevenue Growth Rate\n66.47%\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nCommentary\nCVRx is seeking public investment capital for its continued commercialization efforts.\nThe company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.\nRevenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.\nFree cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).\nSelling, G&A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&A efficiency rate has since increased to 0.3x in Q1 2021.\nThe market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.\nJPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.\nAs for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.\nWhile CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.\nExpected IPO Pricing Date: June 29, 2021","news_type":1},"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187046338,"gmtCreate":1623732173124,"gmtModify":1704209868307,"author":{"id":"3582021834657737","authorId":"3582021834657737","name":"Jaywj","avatar":"https://static.tigerbbs.com/aae92f267285945c71f56c6d201bd7d8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582021834657737","authorIdStr":"3582021834657737"},"themes":[],"htmlText":"Huats&nbsp;","listText":"Huats&nbsp;","text":"Huats","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187046338","repostId":"1109511555","repostType":4,"repost":{"id":"1109511555","kind":"news","pubTimestamp":1623727571,"share":"https://ttm.financial/m/news/1109511555?lang=&edition=fundamental","pubTime":"2021-06-15 11:26","market":"us","language":"en","title":"Apple Plans Faster Watch, Future Temperature and Glucose Sensors","url":"https://stock-news.laohu8.com/highlight/detail?id=1109511555","media":"Bloomberg","summary":"Updated screens and performance this year, new functions later. New entry-level and extreme sports models planned for 2022. A customer tries on an Apple watch at a store in Palo Alto, California. Photographer: Nina Riggio/Bloomberg. Apple Inc. is working on new Apple Watch models and health features, spanning display and speed upgrades, an extreme sports edition and body temperature and blood sugar sensors.The Cupertino, California-based tech giant is planning to refresh the line this year -- wi","content":"<ul>\n <li>Updated screens and performance this year, new functions later</li>\n <li>New entry-level and extreme sports models planned for 2022</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e86dd58655f96500dda750d2b1350121\" tg-width=\"2000\" tg-height=\"1333\"><span>A customer tries on an Apple watch at a store in Palo Alto, California. Photographer: Nina Riggio/Bloomberg</span></p>\n<p>Apple Inc.&nbsp;is working on new Apple Watch models and health features, spanning display and speed upgrades, an extreme sports edition and body temperature and blood sugar sensors.</p>\n<p>The Cupertino, California-based tech giant is planning to refresh the line this year -- with a model likely dubbed the Apple Watch Series 7 -- by adding a faster processor, improved wireless connectivity and an updated screen, according to people with knowledge of the plans. Next year the company plans to update the main Apple Watch alongside a successor for the lower-end Apple Watch SE and a new version targeting extreme sports athletes.</p>\n<p>Apple had previously aimed to put a body temperature sensor in this year’s model, but that is now more likely to be included in the 2022 update. The blood-sugar sensor, which would help diabetics monitor their glucose levels, is unlikely to be ready for commercial launch for several more years.</p>\n<p>For this year’s model, Apple has tested thinner display borders and a new lamination technique that brings the display closer to the front cover. The new Watch is likely to be slightly thicker overall, but not in a way that’s noticeable to the user.</p>\n<p>The model will include updated ultra-wideband functionality, the same underlying technology in the Apple AirTag item finder. At its developer conference in early June, Apple previewed the upcoming watchOS 8 software update that will let the device unlock door and hotel rooms.</p>\n<p>The extreme sports model, described by some inside Apple as either an “explorer” or “adventure” edition, was in development for release as early as this year, but it is now more likely to launch in 2022. That new model would help Apple compete with rugged offerings from players like&nbsp;Garmin Ltd.&nbsp;and&nbsp;Casio Computer Co.</p>\n<p>An Apple spokeswoman declined to comment. The company’s plans remain fluid and could change, the people said.</p>\n<p>Luxshare Precision Industry Co.&nbsp;is the primary assembler for the main Apple Watch, while&nbsp;Hon Hai Precision Industry Co., or Foxconn, shares some of those orders in addition to splitting assembly of the Apple Watch SE with Taiwan’s&nbsp;Compal Electronics Inc.</p>\n<p>Measuring body temperature became an essential part of Covid-19 detection, prompting a&nbsp;surge&nbsp;in demand for gadgets such as the&nbsp;Withings Thermo. Some companies offer small digital thermometers that plug into a smartphone’s charging port. Adding the functionality into its watch would help Apple match other smartwatches and fitness bands, including products from&nbsp;Alphabet Inc.-owned&nbsp;Fitbit.</p>\n<p>Blood sugar monitoring has been long in the works at Apple and would be a feature thus far unrivaled by competitors. Apple and others currently rely on apps that let users input their glucose levels manually, while medical device companies like&nbsp;Dexcom Inc.&nbsp;offer blood sugar monitors that share data with the Apple Watch. Users typically need to prick their finger to draw blood for an accurate glucose test, but Apple is aiming for a non-invasive solution that can analyze blood through the skin.</p>\n<p>Since going on sale in 2015, the Apple Watch has grown into a key part of Apple’s product portfolio. Along with the iPhone and iPad, it fills out the company’s hardware ecosystem and helped Apple’s broader wearables, home and accessories category generate more than $30 billion last fiscal year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Plans Faster Watch, Future Temperature and Glucose Sensors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Plans Faster Watch, Future Temperature and Glucose Sensors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 11:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-14/apple-plans-faster-watch-future-temperature-and-glucose-sensors><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Updated screens and performance this year, new functions later\nNew entry-level and extreme sports models planned for 2022\n\nA customer tries on an Apple watch at a store in Palo Alto, California. ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-14/apple-plans-faster-watch-future-temperature-and-glucose-sensors\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-14/apple-plans-faster-watch-future-temperature-and-glucose-sensors","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109511555","content_text":"Updated screens and performance this year, new functions later\nNew entry-level and extreme sports models planned for 2022\n\nA customer tries on an Apple watch at a store in Palo Alto, California. Photographer: Nina Riggio/Bloomberg\nApple Inc. is working on new Apple Watch models and health features, spanning display and speed upgrades, an extreme sports edition and body temperature and blood sugar sensors.\nThe Cupertino, California-based tech giant is planning to refresh the line this year -- with a model likely dubbed the Apple Watch Series 7 -- by adding a faster processor, improved wireless connectivity and an updated screen, according to people with knowledge of the plans. Next year the company plans to update the main Apple Watch alongside a successor for the lower-end Apple Watch SE and a new version targeting extreme sports athletes.\nApple had previously aimed to put a body temperature sensor in this year’s model, but that is now more likely to be included in the 2022 update. The blood-sugar sensor, which would help diabetics monitor their glucose levels, is unlikely to be ready for commercial launch for several more years.\nFor this year’s model, Apple has tested thinner display borders and a new lamination technique that brings the display closer to the front cover. The new Watch is likely to be slightly thicker overall, but not in a way that’s noticeable to the user.\nThe model will include updated ultra-wideband functionality, the same underlying technology in the Apple AirTag item finder. At its developer conference in early June, Apple previewed the upcoming watchOS 8 software update that will let the device unlock door and hotel rooms.\nThe extreme sports model, described by some inside Apple as either an “explorer” or “adventure” edition, was in development for release as early as this year, but it is now more likely to launch in 2022. That new model would help Apple compete with rugged offerings from players like Garmin Ltd. and Casio Computer Co.\nAn Apple spokeswoman declined to comment. The company’s plans remain fluid and could change, the people said.\nLuxshare Precision Industry Co. is the primary assembler for the main Apple Watch, while Hon Hai Precision Industry Co., or Foxconn, shares some of those orders in addition to splitting assembly of the Apple Watch SE with Taiwan’s Compal Electronics Inc.\nMeasuring body temperature became an essential part of Covid-19 detection, prompting a surge in demand for gadgets such as the Withings Thermo. Some companies offer small digital thermometers that plug into a smartphone’s charging port. Adding the functionality into its watch would help Apple match other smartwatches and fitness bands, including products from Alphabet Inc.-owned Fitbit.\nBlood sugar monitoring has been long in the works at Apple and would be a feature thus far unrivaled by competitors. Apple and others currently rely on apps that let users input their glucose levels manually, while medical device companies like Dexcom Inc. offer blood sugar monitors that share data with the Apple Watch. Users typically need to prick their finger to draw blood for an accurate glucose test, but Apple is aiming for a non-invasive solution that can analyze blood through the skin.\nSince going on sale in 2015, the Apple Watch has grown into a key part of Apple’s product portfolio. Along with the iPhone and iPad, it fills out the company’s hardware ecosystem and helped Apple’s broader wearables, home and accessories category generate more than $30 billion last fiscal year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}